Continuous renal replacement therapy (CRRT) in critically ill patients with acute renal failure (ARF) by TAN HAN KHIM
 i 
CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) IN 
CRITICALLY ILL PATIENTS WITH 










  TAN HAN KHIM 









A THESIS SUBMITTED 
FOR THE DEGREE OF DOCTOR OF MEDICINE (MD) 
DEPARTMENT OF MEDICINE 
NATIONAL UNIVERSITY OF SINGAPORE 
2003 
           ii 
 2 
Acknowledgements  
 This thesis would not have been completed without the advice and assistance from 
numerous individuals.  
 I am deeply grateful to Dr Rinaldo Bellomo, Professor of Medicine, University of 
Melbourne and Director of Intensive Care Research, Department of Intensive Care, Austin 
and Repatriation Medical Centre (A&RMC), Heidelberg, Melbourne, Victoria, Australia, and 
Professor Woo Keng Thye, Emeritus Consultant, Department of Renal Medicine, Singapore 
General Hospital (SGH). They have inspired me to undertake medical research through their 
own academic and scientific accomplishments.  
I would like to thank Professor Evan Lee Jon Choon, Head of Division of Nephrology, 
Department of Medicine, National University Hospital (NUH), who gave me much invaluable 
advice on the preparation of this thesis.  
I would also like to thank my critical care colleagues at the Department of Intensive 
Care, Austin and Repatriation Medical Centre (A&RMC) where I spent a one year Fellowship 
in Critical Care Nephrology, sponsored by the Singapore Ministry of Health (MOH) under the 
Health Manpower Development Plan (HMDP) from October 1998 to October 1999. They 
taught me about the principles and practice of critical care medicine and were as follows: 
Drs Geoff Gutteridge, Graeme Hart, Jonathan Buckmaster, Laurie Doolan, William Silvester, 
Louise Cole and, last but not least Ian Baldwin.  
This thesis would also not have been possible without the generous help of the 
nursing, laboratory, paramedical and auxiliary staff of Monash Medical Centre (MMC), 
Clayton, and those of the Austin and Repatriation Medical Centre (A&RMC), Heidelberg, 
both centres in Victoria, Australia. 
Funding for the studies was generously supported by the following sources, with 
corresponding studies enumerated next to the funding sources: 
(1) Austin and Repatriation Medical Centre Intensive Care Research Fund: This fund 
supported the study in Chapter 3.1.  
 3 
(2) Austin Hospital Anaesthesia and Intensive Care Trust Fund: This fund supported the 
study in Chapters 3.3.  
(3) Austin and Repatriation Medical Centre Anaesthesia and Intensive Care Trust Fund: 
This fund supported the studes in Chapter 3.5 and 4.2. 
Locally, I wish to thank all my nephrology teachers and senior nephrology 
colleagues: Drs Lina Choong Hui Lin, Vathsala Anantharaman, Wong Kok Seng and Grace 
Lee. It is from them that I learnt about clinical nephrology.     
Finally, I am especially grateful to my parents for my upbringing, my wife for her kind 
understanding at home and my children for their patience and unconditional affection for 
me.  A special thanks also goes to Ms Irene Ow who provided excellent secretarial 


















       iv 
Table of Contents 
          Page 
Preface 
Title Page         i 
Acknowledgements       ii 
Table of contents       iv 
Summary        vii 
List of Abbreviations       x 
List of Figures        xiv 
List of Tables        xix 
Publications arising from material in the thesis   xxii 
 
Chapter 1 Introduction         
1.1 Acute renal failure (ARF) in critically ill patients     1 
1.1.1 Acute renal failure (ARF)-related clinical syndromes 
1.1.2 Pathophysiology of acute renal failure (ARF) 
1.1.3 The immune system in multi-organ 
failure (MOF)/acute renal failure (ARF) 
1.1.4 Vasoactive molecules 
1.1.5 Oxidant injury 
1.2.  Medical management of acute renal failure    5 
1.2.1 Volume replacement 
1.2.2 Vasopressor agents 
1.2.3 Diuretics 
1.2.4 Atrial natriuretic peptide (ANP) 
1.2.5 Low dose theophylline 
 5 
1.2.6 N-acetylcysteine (NAC) 
1.2.7 Growth factors 
1.2.8 Fenoldopam 
1.3 Acute renal replacement therapy     4 
1.3.1 Acute peritoneal dialysis 
1.3.2 Acute intermittent haemodialysis (IHD) versus Continuous 
renal replacement therapy (CRRT) 
(1) Patient survival 
(2) Physiological parameters 
(3) Biochemical parameters 
(4) Haemodynamic status 
(5) Dialytic adequacy  
(6) Membrane biocompatibility 
(7) ARRT modality choice 
1.3.3 Isolated ultrafiltration (UF), slow continuous ultrafiltration  
(SCUF) and slow, low-efficiency dialysis (SLED) 
1.3.4 Molecular Adsorbent Recirculating System (MARS) 
 
Chapter 2 Continuous Renal Replacement Therapy (CRRT):  
2.1 CRRT in severe renal failure 
2.1.1 Background 
2.1.2 Technique 
2.1.3 Machines and Solutions 
2.1.4 CRRT circuit surveillance 
2.1.5 Circuit patency I: Anticoagulatory factors 
2.1.6 Circuit patency II: Physico-mechanical factors 
2.1.7 Other metabolic effects of CRRT 
 6 
2.1.8 Clinical impact 
2.2 CRRT-derived Blood Purification Techniques 
2.2.1 High-Volume Haemofiltration (HVHF) 
2.2.2 Membrane plasma filtration (PF) 
2.2.3 Coupled plasma filtration-adsorption (CPFA) 
2.3 Aims of CRRT Thesis 
 
Chapter 3 Biochemical Effects of CRRT  
3.1 Ionised serum calcium and phosphate concentrations during acute  
renal failure (ARF): intermittent haemodialysis (IHD) versus continuous  
haemodiafiltration (HDF) 
 3.2 The acid-base effects of continuous haemofiltration  
with lactate or bicarbonate buffered replacement fluids   
3.3 Electrolyte mass balance during CVVH: lactate versus  
bicarbonate buffered replacement fluids 
 3.4  High protein intake during continuous haemodiafiltration:  
Impact on amino acids and nitrogen balance    
 
Chapter 4 CRRT Technique I: Physico-mechanical Factors 
4.1 Possible strategies to prolong filter life during  
haemofiltration: Three controlled studies 
 4.2 Ex-vivo evaluation of vascular catheters for 
continuous haemofiltration 




Chapter 5 CRRT Technique II: Anticoagulation    
5.1 Continuous veno-venous haemofiltration without  
anticoagulation in high-risk patients     
5.2 A prospective study of thromboelastography (TEG) and filter life during 
continuous veno-venous haemofiltration (CVVH)  
 
Chapter 6 Clinical Impact of CRRT 
6.1 Early and intensive continuous haemofiltration for  
severe renal failure after cardiac surgery    
 
































           vii 
 8 
Summary  
 Acute renal failure (ARF) is a common complication in critically ill patients. Severe 
ARF is associated with high mortality. Different pathogenetic factors contribute to its 
development. Precipitating factors include severe sepsis, hypotension, drug nephrotoxicity 
and hypovolaemia. To prevent ARF and to promote recovery, standard ICU care has a 
central role. To this end, ensuring adequate circulatory volume and systemic and organ 
perfusion pressures are vital. Given that there are hitherto no renal-specific, disease-
modifying pharmacological agent capable of “curing” ARF, much of the progress in the 
clinical management of ARF has been in the area of acute renal replacement therapy 
(ARRT). This includes intermittent haemodialysis (IHD), slow, low efficiency dialysis (SLED), 
continuous renal replacement therapy (CRRT) and Molecular Adsorbent Recirculating 
System (MARS). MARS has been used for both liver and renal dialysis.  
 
However, CRRT remains an important treatment modality in critically ill patients, 
especially haemodynamically unstable ones. Central to its optimal use is an understanding 
of its clinical effects in critically ill ICU patients. Such information complements knowledge of 
the course and characteristics of major critical illnesses and would make the interpretation 
of clinical and laboratory data more meaningful. Moreover, technical factors affecting the 
optimal operation of CRRT systems are also pertinent. Frequent system “downtimes” 
potentially reduce the overall dialytic dose delivered. This thesis is therefore focussed on 
three main aspects of CRRT: (1) Biochemical effects in terms of electrolyte and acid-base 
regulation, (2) Technique in terms of understanding both the anticoagulatory and non-
anticoagulatory or physico-mechanical factors affecting CRRT operational integrity, and (3) 
the clinical impact of CRRT utilisation in terms of the effects of timing of initiation and dialytic 
intensity on patient outcome in a group of critically ill post-cardiosurgical patients.  
To this end, we performed a study to understand the relative effects of IHD and 
continuous venovenous haemodiafiltration (CVVHDF) on serum ionised calcium and 
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phosphate concentrations in critically ill patients (Chapter 3.1). In addition, a prospective, 
randomised, double cross-over comparative study of the effects of continuous venovenous 
haemofiltration (CVVH) on acid-base status using proprietary lactate- and bicarbonate-
buffered haemofiltration (HF) replacement fluids was also conducted (Chapter 3.2). Another 
study looked at the kinetics of electrolyte elimination from the blood compartment during 
CVVH and whether blood-to-effluent movement of electrolytes is influenced by the nature of 
the buffer (lactate- versus bicarbonate) used in the HF replacement fluid (Chapter 3.3). 
Given that many critically ill patients are catabolic, intensive nutritional support may be 
indicated. However, such regimens may exacerbate the uraemic milieu in ARF. A study was 
performed to determine if CRRT could ameliorate the uraemic effects of a high protein 
nutritional regimen and also to delineate the specific effects of CRRT on individual amino 
acid losses in the ultrafiltrate and their corresponding serum concentrations (Chapter 3.4).  
 
CRRT technique is concerned with the factors that contribute to a patent 
extracorporeal blood circuit, the natural tendency of which is to clot spontaneously in the 
absence of adequate antithrombotic factors/agents. Such clotting, if frequent, compromises 
dialytic adequacy of the treatment. These technical factors can be divided into two main 
categories: (1) Non-anticoagulatory or physico-mechanical factors, and (2) Anticoagulatory 
strategies. Individual studies addressing specific aspects of these two broad categories are 
detailed in Chapter 4 – CRRT Technique I and Chapter 5 – CRRT Technqiue II, 
respectively.  
Three different physical strategies were studied: haemofilter geometry, site of 
heparin anticoagulation in the extracorporeal circuit (EC), and surface area of haemofilter 
(Chapter 4.1). Larger surface area and flat-plate haemofilters were studied to see if they 
were associated with longer circuit lifespans. Similarly, exclusive administration of heparin 
anticoagulant pre-filter was compared with simultaneous pre-filter and direct air-bubble 
chamber heparin administration to determine if there was any significant prolongation of 
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CVVH circuit lifespan with the latter intervention. Another critical component of the EC is the 
central venous, dual-lumen dialysis catheter. An ex-vivo experiment was conducted using 
different proprietary dialysis catheters under standard conditions to determine blood flow 
resistivities (Chapter 4.2). This may provide objective data about catheter performance and 
guide their selection for use. Given that blood is in contact with the artificial plastic surface of 
the EC during its passage through the circuit, blood-circuit interactions can occur. These 
may result in quantitative and qualitative changes of leucocytes, erythrocytes and platelets, 
which can also be deranged by the critical illness complex per se. A study of the quantitative 
effect of the AN69 haemofilter on platelets was therefore performed (Chapter 4.3). Changes 
in platelet counts in such patients can then be interpreted more accurately in terms of 
whether it is due to underlying disease and/or filter membrane per se.  
 
Anticoagulation is the mainstay of ensuring EC patency in clinical practice. 
Accordingly, different anticoagulants, modes of administration, and various anticoagulation 
protocols have evolved for clinical use in CRRT. All are associated with some degree of 
bleeding risk which would be greatly increased in patients who are already at high bleeding 
risk. On the other hand, omitting anticoagulant was considered impractical since this was 
thought to result in frequent circuit clotting. Our study of CVVH without standard heparin 
anticoagulation observed that such an approach is compatible with circuit lifespans 
comparable to those of anticoagulated circuits (Chapter 5.1). Another aspect of 
anticoagulation relates to monitoring of its intensity. It is recognised that standard laboratory 
indices of anticoagulation do not accurately correlate with circuit lifespan. Circuits can still 
clot despite an adequate level of anticoagulation. Measurements of the actual process of 
clot formation using thromboelastography (TEG) was explored to see if TEG-derived 
variables of physical clot formation provided more accurate correlation with circuit 
patency/clotting (Chapter 5.2).  
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Last but not least, the timing of initiation and intensity of CVVH treatment in severe 
renal failure were studied to see if these factors had any effect on the clinical outcome of 
critically ill cardiosurgical patients. Such data would guide the use and titration of CVVH 
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CVVHDF  Continuous veno-venous haemodiafiltration  
CVVHD  Continuous veno-venous haemodialysis 
DA   Dopamine 
DAH   Diffuse alveolar haemorrhage 
DIVC   Disseminated intravascular coagulation 
DM   Diabetes mellitus 
DNA   Deoxyribonucleic acid  
DVT   Deep venous thrombosis 
EC   Extracorporeal blood circuit 
E/P ratio  Ratio of solute concentration in the effluent to that in plasma water 
EPO   Erythropoietin  
ESHF   End-stage heart failure 
ESRD   End-stage renal disease 
ESLD   End-stage liver disease 
ESRF   End-stage renal failure 
ET (A)   Endothelin A 
ET (B)   Endothelin B 
F1+2   Prothrombin fragment 1 + 2 
FeNa   Fractional excretion of sodium 
FFP   Fresh frozen plasma 
FHF   Fulminant hepatic failure 
GFR   Glomerular filtration rate in ml/min 
GIT   Gastrointestinal tract 
HD   Haemodialysis   
HDF   Haemodiafiltration  
HF    Haemofiltration  
HITS   Heparin-induced thrombocytopaenic syndrome 
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HMG Co-A   Hydroxymethylglutaryl Co-A reductase inhibitors or “statins” 
HVHF   High-volume haemofiltration (also termed “sepsis” dose  
   “pulsed” haemofiltration) 
ICAM-1  Intercellular adhesion molecule-1 
ICP   Intracranial pressure 
ICU   Intensive care unit 
IGF-1   Insulin-like growth factor I 
IHD   Intermittent haemodialysis 
IRI   Ischaemia-reperfusion injury (an animal model of ARF) 
IL-6   Interleukin-6 
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effect) 
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LMWH   Low molecular weight heparin 
LPS   Lipopolysaccharide 
LTx Liver transplantation 
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PCO2i  Intramucosal partial pressure of carbon dioxide in mmHg 
PD   Peritoneal dialysis 
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pHi   intramucosal pH 
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PMMA   Polymethylmethacrylate (synthetic) membrane 
PRA   Plasma renin activity 
PS   Polysulphone membrane  
PRA   Plasma renin activity 
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PF   Plasma filtration method of therapeutic plasma exchange 
Pre-dilution   HF replacement fluid enters the EC pre-filter during CVVH 
Post-dilution  HF replacement fluid enters the EC post-filter during CVVH 
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ROS   Reactive oxygen species 
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RTx   Renal transplant 
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SEM   Standard error of the mean 
SIRS   Systemic inflammatory response syndrome 
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Chapter 1  
Introduction 
 This chapter focusses on acute renal failure (ARF) in critically ill patients. ARF can 
occur either in isolation or as part of a larger clinical syndrome. In addition, the biological 
mechanisms of ARF will also be examined. Both these aspects of ARF will be reviewed in 
Chapter 1.1. The nondialytic, medical management of ARF will next be discussed, including 
that of important basic parameters such as circulatory volume and systemic/perfusion 
pressure. Specific pharmacological agents to prevent or treat ARF will also be detailed in 
the same chapter, Chapter 1.2. Finally, the dialytic management of severe renal failure, 
collectively termed “acute renal replacement therapy” or “ARRT”, is further discussed in 
Chapter 1.3. It encompasses conventional modalities such as acute peritoneal dialysis (PD), 
acute intermittent haemodialysis (IHD), isolated ultrafiltration (UF), slow continuous 
ultrafiltration (SCUF), slow, low-efficiency dialysis (SLED), and Molecular Adsorbent 
Recirculating System (MARS). The relative dialytic efficacy and clinical outcomes associated 
with the use of IHD versus continuous renal replacement therapy (CRRT) will be analysed in 













Chapter 1.1  
Acute Renal Failure (ARF) in Critically Ill patients 
1. 1. 1. Acute Renal Failure (ARF)-Related Clinical Syndromes 
 Critically ill patients who develop acute renal failure (ARF) are known to have a high 
mortality rate.1, 2 There are known precipitating factors frequently associated with its 
development. Hypotension, hypovolaemia, severe sepsis, nephrotoxic drug exposure, 
obstructive uropathy and other nephrological causes are the main ones.3 Identifying and 
reversing these pathophysiological factors are important in the early phase of ARF to 
prevent its establishment. Moreover, this approach helps to ensure eventual ARF recovery 
even after acute tubular necrosis (ATN) has developed. To this end, establishing adequate 
circulatory volume and systemic perfusion pressure are of fundamental importance clinically 
and is relevant to medical and surgical intensive care patients.3, 4 Avoidance or minimisation 
of exposure to nephrotoxic drugs to prevent or avoid aggravation of established ARF is 
basic but may be unavoidable in the treatment of serious infections. Examples of such drugs 
are vancomycin, aminoglycosides, amphotericin and non-steroidal anti-inflammatory drugs.4-
8
 Electrolyte abnormalities arising from ARF may also potentiate the nephrotoxic potential of 
certain drugs, such as those used to treat patients with human immunodeficiency virus (HIV) 
infections.9  
 
In addition to the key principles of ARF management outlined above, it is also 
important to recognise certain clinical syndromes of which ARF may be a feature or 
complication (Figure 1). Appropriate management of the clinical syndrome together with 
renal-specific measures are crucial in ensuring a favourable outcome. Obstetric patients 
with severe pre-eclampsia/eclampsia may develop the HELLP (Hypertension, Elevated Liver 
Enzymes and Low Platelets [thrombocytopaenia]) syndrome in which ARF may 
complicate.10, 11 Early delivery of the foetus and optimal maternal ICU management are 
critical steps.12, 13 Thrombotic thrombocytopaenic purpura (TTP) is another condition in 
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which ARF may be a prominent feature. It is characterised by thrombocytopaenia, platelet 
aggregation in the capillaries, microangiopathic haemolytic anaemia (MAHA) and secondary 
end-organ ischaemia with predilection for the central nervous system (CNS) and the 
kidneys, the latter resulting in ARF. Specific measures that have been used, albeit with 
mixed results, include intravenous immunoglobulin and therapeutic plasma exchange 
(TPE).14, 15 Hypotension causes organ hypoperfusion, including that in the renal vasculature. 
The resultant renal ischaemia eventually leads to acute tubular necrosis (ATN). A specific 
example of this is cardiogenic shock following acute myocardial infarction (AMI). This has 
been shown to lead to ARF, a poor prognostic indicator in such patients. Post-AMI patients 
with no ARF had a hospital mortality of 53% compared with those with ARF of 87% 
(p<0.001).16 ARF can also develop in oncological patients with tumour lysis syndrome (TLS). 
The mechanisms for ARF in this clinical syndrome is multifactorial and include 
hypovolaemia, urinary precipitation of calcium, phosphate and nucleic acid metabolites and 
other malignancy-associated nephrotoxins. Rehydration, alkalinisation and the use of 
allopurinol may attenuate the severity of this condition.17 ARF can develop in severe hepatic 
dysfunction and fulminant hepatic failure (FHF). ARF and severe liver failure may be a 
concomitant occurrence arising from a single insult such as drugs or circulatory shock. ARF 
can also be secondary to FHF.18-20 Mortality in FHF patients with ARF approaches 90%.19-21 
Atheroembolic ARF is an entity that may be seen in patients with atheromatous disease 
undergoing invasive vascular investigations such as coronary angiography. This form of 
ARF may be severe enough to warrant dialytic support. In one series of dialysis-dependent, 
atheroembolic ARF patients, diagnosis was made on the basis of clinical presentation and 
renal histological findings. This group of patients was also more likely to have pre-existing 
hypertension and chronic renal dysfunction.22 Contrast media is routinely used for 
angiography. This has been linked to contrast-induced nephropathy.23 Medical measures 
that have been used include hydration, dopamine, diuretics, mannitol, calcium channel 
antagonists and haemodialysis. More recently, N-acetylcystine (NAC) was shown to be 
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useful in preventing this complication.24 However, NAC has not been shown to be useful in 
critically ill patients in either preventing or facilitating recovery from ARF. Among surgical 
patients, cardiosurgical ones are especially susceptible to ARF. In this subset of critically ill 
patients, valvular surgery is consistently associated with post-operative ARF.25, 26 Transplant 
recipients can also develop ARF. An example is bone marrow transplantation (BMT). Post-
BMT ARF is multifactorial. The use of multiple nephrotoxic drugs is one reason. Another is 
cyclosporin- and foscarnet-related acute veno-occlusive disease. The latter can in turn lead 
to ARF.27  
 
Among infectious diseases associated with ARF, malaria is a prominent example. 
Fluid and electrolyte disorders, hypercatabolism and direct nephrotoxicity of malarial 
parasites all contribute to its pathogenesis in falciparum malaria.28, 29 Leptospirosis is 
another example of an infectious aetiology associated with ARF. Antimicrobial and 
supportive management are central to its management.30 In the ICU, severe sepsis is one of 
the most important causes of critical illness, ARF and multi-organ failure (MOF). Standard 
treatment for sepsis comprises the use of broad-spectrum antimicrobials, achieving and 
maintaining optimal haemodynamic status with respect to circulatory volume and systemic 
pressure, surgery to drain abscesses and remove devitalised tissue or organs, and other 
symptomatic organ-specific support such as mechanical ventilation and nutritional support. 
However, mortality of septic ICU patients with ARF remains very high.31, 32 In one series of 
surgical patients with sepsis and ARF, it was found that serum creatinine > 88 umol/L  
(> 1 mg/dl) at baseline and metabolic acidosis with pH < 7.3 on day one of sepsis, was each 
independently associated with the subsequent development of ARF. Mortality in these 
patients was correlated with patient age, need for vasopressor support, mechanical 
ventilation and renal replacement therapy (RRT).31 Another study of polytraumatic 
earthquake victims observed that crush injuries and sepsis increased mortality in dialysis-
dependent ARF patients.32 Severe sepsis triggers a systemic inflammatory response 
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syndrome (SIRS) which is characterised not only by increased levels of cytokines and 
haemostatic factors early in the course of sepsis. Examples of such haemostatic factors are: 
thrombomodulin, tissue-type plasminogen activator (t-PA antigen), prothrombin fragment 1 
+ 2 (F1 + 2), thrombin-antithrombin complexes (TAT), D-dimer and plasminogen activity 
inhibitor type 1 (PAI-1) antigen. Preliminary data suggest that raised PAI-1 antigen and 
F1+2 variables are found in patients with severe sepsis and SIRS and may be included in 
future prediction models to calculate patient mortality in this condition.33 Pro-inflammatory 
cytokines such as tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) are 
produced in increased quantities in severe sepsis. In a study of 537 patients with sepsis and 
septic shock, ARF was found in 20% of this population. The concentrations of TNF-alpha 
and IL-6 were comparable in patients with and without ARF. However, the concentrations of 
soluble TNF-alpha receptors I and II (S-TNF-RI 25 ± 16 vs 18 ± 13 ng/ml; p=0.00006, and 
S-TNF-RII 25 ± 21 vs 18 ± 17 ng/ml; p=0.0007) were elevated and were strongly correlated 
with the development of ARF. Elevated S-TNF-R was also shown to be an independent 
predictor of mortality in these patients.34 Given that cytokines play a central role in the 
pathogenesis of sepsis, ARF and multi-organ failure (MOF), workers have proposed that 
their removal from the body through various techniques may ameliorate the septic process. 
Such techniques will be discussed in Chapter 2.2 and are collectively known as “blood 
purification”. The hypothesis is that by removing cytokines at a rate that is close to or 
matches that at which it is being produced in a patient with severe sepsis, it may be possible 
to attenuate the disease and improve patient outcome.35 Auto-immune diseases may cause 
severe critical illness and ARF. Examples include Goodpasture’s syndrome and systemic 
lupus erythematosus (SLE).36, 37 Diffuse alveolar haemorrhage (DAH) can develop in SLE 
patients. A Taiwanese series documented the need for aggressive immunosuppressive 
therapy, ICU care and different modalities of extracorporeal organ support such as 
therapeutic plasma exchange (TPE) and CRRT. Overall mortality for this condition in this 
series was 50%.38 Goodpasture’s syndrome is another specific aetiological cause for acute 
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pulmonary-renal syndrome. Intensive immunosuppression using corticosteroids, 
cyclophosphamide and TPE are some of the therapeutic options needed, including ICU 



























ARF-related complications and clinical syndromes
ARF in ICU patients
Complications (examples):
Increased bleeding risk, cardiac depression, fluid overload, electrolyte and
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1. 1. 2. Pathophysiology of Acute Renal Failure (ARF) 
 Besides recognising the pathophysiological factors underpinning ARF in patients and 
possible associated clinical syndromes, complications arising from ARF per se need to be 
recognised as well (Figure 1). Many of these features of ARF are subclinical. For example, 
acute uraemic encephalopathy may be difficult to diagnose given that many critically ill 
patients have concomitant sepsis, septic encephalopathy and are likely to be sedated. 
However, there is a higher incidence of infections following surgery when there is 
concomitant ARF. In one series, candidaemia developed more frequently in dialysis-
dependent ARF patients. However, this was due neither to dialysis nor ARF per se. 
Candidaemia in that series was more directly related to the use of central venous dialysis 
access catheters, multiple antibiotic usage, concomitant corticosteroid therapy and co-
morbid diseases such as systemic lupus erythematosus (SLE). Management included the 
prompt removal of dialysis catheters and the institution of anti-fungal therapy.41 Open-heart 
surgery complicated by pre-operative renal dysfunction has also been shown to be 
associated with higher incidence of infections. Increased post-operative infections in those 
with post-operative ARF was found to be independent of pre-operative renal function.42 
Increased bleeding tendency is also noted in patients with ARF. There was a higher 
incidence of acute gastrointestinal tract (GIT) bleeding in patients with ARF. Such bleeding 
was in turn associated with greatly increased mortality and length of hospital stay.43  
 
 
1. 1. 3. The Immune System in Multi-Organ Failure (MOF)/Acute Renal Failure (ARF) 
 The pathophysiological mechanisms of, the clinical syndromes associated with and 
clinical sequelae of ARF have been discussed above. Further advances in its clinical 
management must evolve from a better understanding of the biology of ARF. Laboratory 
and animal studies on the pathogenesis of ARF have focussed on 2 main mechanisms: (1) 
cell-mediated and (2) non-cell mediated (Figure 2). An animal model of cardiac arrest and 
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circulatory shut-down was used to study murine ischaemia-reperfusion injury (IRI). 
Increased expression of pro-inflammatory cytokines such as interleukin-6 (IL-6) was noted. 
T-cell deficient knock-out mice were compared with T-cell replete or wild-type mice. Both 
groups of mice were subject to the same whole body insult. T-cell deficient mice had a 
significantly decreased rise in serum creatinine (SeCr) and decreased tubular injury 
compared with the wild-type controls. This suggests an important pathogenetic role of T-
lymphocytes in ARF in this model.44 In order for inflammatory cells to cause renal damage in 
ARF, they need to migrate into renal tissue first. Monocyte-chemoattractant peptide-1 (MCP-
1) was studied in an IRI model in Sprague-Dawley rats. It was noted that areas in the rat 
kidneys with increased monocytic infiltration also had a concomitant increase in MCP-1 
expression. While the pathophysiological significance of this is uncertain, MCP-1 is either 
directly pathogenic or is a biomarker of mononuclear cell infiltrate in the area of renal 
injury.45 Another study examined the effect of T-cell depletion in a murine IRI model using 
three different T-cell depleting monoclonal antibodies targeted at: (1) CD4, (2) CD8 and (3) 
Pan-T cells. While antibodies targeted at CD4 and CD8 caused considerable depletion of 
these two T-cell subtypes, it did not attenuate a rise in SeCr in the mice following IRI. 
However, when all three types of antibodies were administered together, CD4 T-cell 
depletion was augmented and this led to a significantly improved preservation of renal 
function and structure.46 In addition to migration of T-cells into the renal tissue, it has been 
shown that T-lymphocytes and neutrophils aggregate in extrarenal organs such as the liver, 
spleen and the unclamped contralateral kidney following the development of ischaemic ARF 
in a murine model (C57BL/6 and C3H/He mice). There was also concomitant liver 
dysfunction. This suggests that a systemic cellular inflammatory response is triggered in 
ischaemic ARF and may potentially explain the progressive evolution of multi-organ failure 
(MOF) in critically ill patients.47 For the cell-mediated mechanisms of renal injury to work, 
inflammatory cells need to come into contact with and adhere to the target renal cells. The 
substances mediating this are collectively termed “adhesion molecules”.48 Ventura et al 
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studied the effect of an immunosuppressant mycophenolate mofetil (MMF) on renal IRI in 
male Wistar rats. MMF pre-treated rats were found to have decreased immunostaining for 
intercellular adhesion molecule-1 (ICAM-1) following induction of IRI compared to control 
rats that also received MMF but not the renal ischaemic insult. The pre-treated IRI rats also 
demonstrated an earlier decrease in the numbers of infiltrating macrophages/lymphocytes 
as well as decreased proliferation of these inflammatory cells. Thus, adhesion molecules 
such as ICAM-1 play an important part in cell-mediated ARF injury.49  
 
Injury in ischaemic ARF is fundamentally an inflammatory process. Its pathogenesis 
may be thought of as a complex inflammatory cascade involving not only inflammatory cells, 
but also cytokines, vasoactive substances and also complement.50 Thurman et al studied the 
role of complement in murine IRI. Control wild-type mice which were factor-B replete were 
compared with factor-B deficient knock-out mice after induction of IRI in both groups. Factor 
B is an important component of the alternate complement pathway. Deficiency in factor-B 
protected these knock-out mice against functional and structural renal injury, suggesting 
that the alternate complement pathway has a role to play in the inflammatory cascade 
alluded to earlier.51 Certain cytokines also appear to play a role in the pathogenesis of ARF. 
Hydroxymethylglutaryl Co-A (HMG-CoA) reductase inhibitors or “statins” have recently been 
shown to have an anti-inflammatory function which is distinct from its cholesterol-lowering 
effect. Cerivastatin was administered to a murine IRI model compared to saline treated 
murine controls. Both groups of mice then underwent IRI. Neutrophil and macrophage 
infiltration into renal tissue were comparable in both groups. However, IL-6 was significantly 
upregulated in the statin-pretreated group compared with the saline-pretreated controls. In 
addition, rise in SeCr was blunted in the statin-treated group compared with controls. Thus, 
statin-induction of IL-6 synthesis may be a potentially protective mechanism, at least in a 
murine IRI model of ARF.52 Gueler et al randomised male Sprague-Dawley rats for pre-
treatment with either cerivastatin or vehicle in the control arm. IRI was induced through a 
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combination of right total nephrectomy and left renal artery clamping in this 
uninephrectomised IRI model. Statin-pretreated rats had a 40% reduction in SeCr rise 
compared with vehicle-pretreated controls (p<0.005). The collective data seems to suggest 
that statins have an anti-inflammatory effect in that there is almost complete prevention of 
monocyte-macrophage infiltration into renal tissue, significant reduction in ICAM-1 
upregulation and attenuation of inducible nitric oxide synthase expression.53  
 
 
1. 1. 4. Vasoactive Molecules 
Restoration of renal perfusion is important to prevent aggravation of ischaemia 
following IRI. Renal vascular biology studies have focussed on vasoactive compounds and 
their vascular cell receptors. Stimulating these receptors causes vasoconstriction thereby 
inducing or worsening local renal ischaemia. In contrast, blocking these receptors prevents 
renal vasoconstriction and may even lead to relative vasodilatation thereby improving renal 
perfusion. An example of such a substance is adenosine and the adenosine A3 receptor. A3 
adenosine receptor activation and inhibition worsens and improves renal function, 
respectively. A3 knock-out mice were compared with wild-type controls. Following either IRI 
or myoglobinuric renal injury, SeCr was found to be significantly lower in the A3 knock-out 
mice compared with controls, suggesting a possible role of adenosine in acute vascular 
renal injury. Pre-treatment of wild-type controls with A3 adenosine receptor (A3 AR) 
antagonists also conferred significant renal protection in ischaemic and myoglobinuric renal 
insults.54  
 
Another target for intervention to restore compromised renal perfusion in renal IRI is 
the dopamine D-1 receptor. Halpenny et al in a study of a canine model of acute 
hypovolaemic ARF examined renal blood flow (RBF) and renal tubular function (RTF) by 
comparing fenoldopam versus saline infusion during four phases of the experiment: (1) at 
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baseline, (2) during infusion of study drug and saline, (3) during a period of hypovolaemia 
induced by acute partial exsanguination, and (4) after retransfusing the dogs.  RBF and 
urine output (UO) decreased significantly from baseline during the period of hypovolaemia in 
the placebo control group (72 ± 20 to 47 ± 6 ml/min and 0.26 ± 0.15 to 0.08 ± 0.05 ml/min, 
respectively; both p<0.01). This was not observed in the fenoldopam-treated group in terms 
of the same variables RBF and UO (75 ± 14 to 73 ± 17 ml/min and 0.3 ± 0.19 to 0.14 ± 0.05 
ml/min, respectively; both NS). Creatinine clearance (CCT) and fractional excretion of 
sodium (FeNa) also decreased significantly in the control group during hypovolaemia 
compared to baseline (3.0 ± 0.4 to 1.8 ± 0.8 ml/kg/min and 1.7 ± 0.9% to 0.4 ± 0.2%, 
respectively; both p<0.01). In contrast, fenoldopam-treated dogs preserved their CCT and 
FeNa during hypovolaemia (3.0 ± 1.0 to 2.9 ± 0.5 ml/kg/min and 1.9 ± 1.1% to 1.7 ± 2.7%, 
respectively; both NS). Thus, fenoldopam appeared to have a reno-protective effect in this 
model.55  
 
Endothelins have also been studied in IRI models. Released in response to 
hypoperfusion and anoxic insult, they may have a role in causing ARF. Huang et al studied 
the effects of a non-selective endothelin ET(A)/endothelin ET(B) (SB209670) and an 
endothelin-A (ET-A)-selective (UK-350,926) endothelin receptor antagonist in ameliorating 
IRI in uninephrectomised rats. It was observed that ET(A)/ET(B) non-selective and ET(A) 
selective receptor antagonists ameliorated IRI when given during the peri-ischaemic period 
but not when ET(A)-receptor antagonist was administered 60 min after the ischaemic period 
at 100 mcg/kg/min.56  
 
 
1. 1. 5. Oxidant Injury 
Oxidant injury has been noted to play a role in ARF pathogenesis. Anti-oxidant 
therapy is a potential complementary strategy to prevent and/or treat ARF. Inflammatory 
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injury sustained during reperfusion is thought to be due to oxidative stress. In-vitro 
investigations have found that reactive oxygen species (ROS) induce the formation of 
oxidised phospholipids with platelet-activating factor (PAF)-like activity. These are termed 
PAF-like lipids. During warm renal ischaemia in rabbits, there was an increase in the release 
of PAF and PAF-like lipids. The release of these phospholipids was associated with intense 
DNA oxidation and increase in myeloperoxidase activity. Administration of vitamin C reduced 
these post-ischaemic oxidative changes, decreased PAF and PAF-like lipids and reduced 
myeloperoxidase activity.57  
  
Further discussion of the biology and pathophysiology of ARF is beyond the scope of 
this thesis. The aforementioned is nevertheless an overview of some of the key 

















Chapter 1.2  
Medical Management of Acute Renal Failure  
1. 2. 1. Volume Replacement 
 Despite the increased understanding of the pathogenesis and biological mechanisms 
and pathways of ARF development, clinical management of the critically ill patient with ARF 
remains a major challenge. Therapy of ARF can be broadly divided into two main areas: (1) 
medical management, and (2) acute renal replacement therapy (ARRT), the latter the 
subject of Chapter 1.3. Medical management refers to non-dialytic measures to correct 
pathophysiological derangements such as hypovolaemia and hypotension, and specific 
pharmacological agents. Such drugs may be used either for ARF prophylaxis or in 
facilitating recovery from established ARF. Most of the drugs tested in ARF therapy belong 
to the former category.  
  
An adequate circulatory volume is of fundamental importance in preventing ARF, 
especially in pre-renal ARF.58 This applies to most sub-populations of critically ill patients, 
including critically ill obstetric patients with oliguria and renal failure.59 In the absence of 
disease-modifying, ARF-specific drugs or “magic bullets”, good intensive care unit (ICU) 
care remains of utmost importance.60 In a retrospective study on the prevention of acute 
rhabdomyolytic ARF, acute rhabdomyolysis was diagnosed on the basis of creatine kinase 
(CK) level > 500 IU/L. A total of 15 patients were treated with a combination of saline, 
mannitol and sodium bicarbonate infusions. This was compared with another group of 9 
patients treated with saline alone. Baseline SeCr between the combination therapy group 
and the saline infusion group was comparable. SeCr decrements were similar in both 
groups and all patients reached normal levels by 2-3 days. Notwithstanding the retrospective 
nature of this study, simple saline infusion alone appeared to be as effective as combination 
therapy with mannitol and sodium bicarbonate in the prophylaxis of acute rhabdomyolytic 
ARF.61 What is less certain is the choice of fluids for resuscitation: crystalloids versus 
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colloids. This controversy persists despite multiple meta-analyses. There is some data 
suggesting that albumin may increase mortality. In addition, starch solutions may adversely 
affect renal function while crystalloids are favoured in trauma patients. These views, 
however, need to be further substantiated.62, 63 Moreover, the tonicity of crystalloids used for 
fluid resuscitation is also an important consideration, the hypothesis being that a 
comparable degree of circulatory volume repletion may be achieved with a smaller volume 
of fluid when hypertonic solutions are used compared with isotonic ones. This was however 
refuted in a study of critically ill patients with major burns. They were randomised to receive 
either hypertonic saline (sodium concentration 290 mEq/L) or lactated Ringer’s solution 
(sodium concentration 130 mEq/L). Although baseline clinical characteristics of patients in 
both groups such as total burn size and presence of inhalational lung injury were 
comparable, the use of hypertonic saline failed to significantly reduce the volume of fluids 
needed for resuscitation. Moreover, it increased the incidence of renal failure and death.64  
 
 
1. 2. 2. Vasopressor Agents 
Vasopressor agents are commonly used in conventional ICU care in patients who 
have an adequate circulatory volume yet remain hypotensive due to peripheral 
vasodilatation. This can occur in severe sepsis and septic shock. One such pressor agent is 
norepinephrine (NE) or noradrenaline (NA). Although NA is now commonly used, early data 
on NA in experimental models suggested that it was injurious to kidneys. Direct intra-renal 
infusion of NA into renal artery of dogs produced a reversible ischaemic model of ARF at a 
dose of 0.75 mg/kg/min. ATN developed but its pattern and distribution differed from that 
seen in “renal artery clamping (RAC)” model of ischaemic ARF.65, 66 These observations are 
consistent with the vasoconstrictive effects of NA on organ vasculature. However, clinical 
use of NA in critically ill patients with hypotension secondary to peripheral vasodilatation and 
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normal or increased cardiac output in sepsis, has nevertheless demonstrated its positive 
effects on glomerular filtration rate (GFR) and urine output.67, 68   
 
Using fluids to restore and maintain an adequate intra-vascular volume and pressor 
agents such as NA in distributive septic shock to counteract peripheral vasodilatation may 
not be sufficient to prevent or ameliorate renal function in ICU patients with severe renal 
failure. Specific pharmacological agents may have to be used. Low dose or “renal-dose” 
dopamine (DA) has been advocated for a long time as one such drug. There have been as 
many studies in support of as there are against the use of dopamine for reno-protection. A 
randomised, double-blind, placebo-controlled trial of low-dose dopamine (3 mcg/kg/min) was 
performed in patients undergoing elective repair of either abdominal aortic aneurysm (AAA) 
or aortofemoral bypass grafting. Eighteen patients were in the low-dose dopamine arm and 
19 were in the placebo arm. Measured 24 h urine creatinine clearance (CCT) increased by 
9.89 ml/min in dopamine group versus 11.98 ml/min in the placebo group (p>0.2). Urine 
volumes were slightly higher in the dopamine group compared with the placebo group (NS). 
Although this study showed no benefit for low-dose dopamine, it was hampered by the small 
study sample and by the exclusion of acute oliguric renal failure patients.69 Other workers 
have combined dopamine with diltiazem to improve the renoprotective effects of DA. Yavuz 
et al prospectively randomised sixty patients with normal pre-operative renal function 
undergoing coronary artery bypass grafting (CABG) to four treatment groups: (1) control 
(n=15), (2) DA only (n=15), (3) diltiazem only (n=15) and (4) DA + diltiazem (n=15). CCT 
was significantly higher in the DA + diltiazem group compared with the other three groups 
24 h after surgery.70 Another prospective, randomised, double-blind study also noted positive 
findings with DA to reduce renal tubular injury following cardiopulmonary bypass (CPB). A 
total of forty-eight patients were randomised to receive either intravenous DA or saline from 
the start of induction of anaesthesia until 48 h post-surgery. Baseline pre-operative renal 
function, mean age and duration of CPB were comparable in both groups. 51Cr-EDTA GFR 
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(ml/min/1.73 m2) was measured pre-operatively and on the fifth post-operative day. Urinary 
markers of tubular injury such as albumin, N-acetylglucosaminidase (NAG) and retinol-
binding protein (RBP) were also measured pre- and post-operatively. Although GFR was 
comparable in both groups, urinary markers of tubular injury were significantly lower in the 
DA-treated group compared with control.71  
 
Another approach was to combine the diuretic agent frusemide and DA. A 
prospective, randomised, controlled, double-blind trial was conducted in 126 patients with 
normal baseline pre-operative renal function who then underwent elective cardiac surgery. 
They were randomised to receive continuous infusion of either frusemide, renal-dose DA or 
isotonic sodium chloride as control at the start of surgery and continuing for 48 h or until 
discharge from ICU, whichever came first. The mean volume of infused fluids and blood 
products was comparable in all groups. The study noted that continuous infusion of DA was 
no better than control in preventing post-operative renal dysfunction. Moreover, frusemide 
infusion was even associated with a higher rate of renal failure than the other two groups.72 
A meta-analysis of the use of DA by Kellum and Decker reviewed all literature on the subject 
published between 1966 – 2000 involving 2149 subjects in 58 studies. Of these, only 17 
studies involving 854 patients were randomised clinical trials. The overall data did not 
support the role of DA in preventing patient mortality, onset of ARF or need for dialysis. It 




1. 2. 3. Diuretics 
Another drug that is frequently used is the loop diuretics such as frusemide and 
bumetanide. While these drugs facilitate fluid management by improving urine output in 
some oligo-anuric patients, they have not been shown to change the natural history of ARF 
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of critical illness. Kallskog et al studied an ischaemic model of ARF in Sprague-Dawley rats. 
They were randomised to receive either intravenous frusemide or saline as control before 
and after the onset of renal ischaemia. After one month, GFR of frusemide-treated rats 
compared with control rats was 0.5 ± 0.08 ml/min and 0.8 ± 0.14 ml/min, respectively (NS). 
Frusemide therefore did not improve the long-term outcome of ischaemic rat kidneys.74 In 
addition, clinical data also do not support the use of diuretics as an ARF-specific, disease-
modifying drug. Shilliday et al conducted a prospective, randomised, double-blind study to 
investigate the effects of diuretics on renal recovery, need for dialysis and patient mortality. 
A total of 92 patients with ARF were enrolled. All of them received a standardised regime of 
intravenous low-dose DA (2 mcg/kg/min) throughout the study period and 20% mannitol 
(100 ml 6 hourly) for the first 3 days. They were then randomised to receive either 
torasemide, frusemide or placebo in a double-blind manner at 3 mg/kg BW every 6 hours for 
21 days, until renal recovery or death. Patients given a loop diuretic had a significantly 
higher urine flow rate in the first 24 h compared to placebo (p=0.02). In addition, non-oliguric 
patients (urine flow rate  50 ml/h) were found to have a significantly lower mortality rate 
than oliguric ones (urine flow rate < 50 ml/min) (43% vs. 69%, p=0.01). However, non-
oliguric patients were less severely ill compared with their oliguric counterparts (APACHE II 
score 17.2 vs. 20.6, p=0.008) and had less severe baseline renal failure at entry into the 
study (CCT 14 vs. 4 ml/min, p<0.0001). Thus, while diuresis can be promoted with loop 
diuretics, they do not influence patient outcome.75  
 
Sirivella partly addressed the question of whether the mode of diuretic administration 
had any impact on renal outcome in cardiac surgery patients with post-operative ARF. A 
total of 100 patients with severe olio-anuric ARF were studied. At entry into the study, all of 
them had adequate post-operative cardiac output and haemodynamic function. Forty 
patients (Group A) were randomised to receive intermittent doses of diuretics (frusemide, 
bumetanide and ethacrynic acid) and fluids. Another sixty patients (Group B) received 
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continuous infusion of a solution of mannitol, frusemide and dopamine. Those in Group B 
who received their infusion within 6 h of onset of renal failure were subgrouped as Group B1 
(n=30) while the others who received the infusion 6 h after onset of renal failure were 
designated Group B2 (n=30). Diuresis occurred in 93.3% in Group B compared with 10% in 
Group A. Dialysis requirement was observed in 90% of Group A patients and 6.7% of Group 
B patients. Renal function (serum creatinine) was restored to normal pre-operative levels or 
baseline abnormal values after the first post-operative week in Group B1 and third post-
operative week in Group B2.76 It would appear in this study that infusion of a diuretic solution 
(comprising mannitol, dopamine and frusemide) promoted superior diuresis (Group B) 
compared to those who only received intermittent doses of diuretics (comprising frusemide, 
bumetanide and ethacrynic acid) (Group A). Eventual requirement for dialysis was also 
higher in group A compared to group B. It is, however, uncertain how the use of diuretics 
and its mode of administration impacts the morbidity and mortality in those who ended up 
requiring dialytic support.76 Finally, Mehta et al observed in a Californian cohort study of 552 
ICU patients with ARF in four academic medical centres that diuretic use tended to be in 
patients with serious co-morbidity such as advanced age, congestive cardiac failure, 
nephrotoxic ARF, acute respiratory failure and lower serum urea nitrogen concentrations. 
Further analysis showed that the use of diuretics was associated with a greater mortality 
rate and higher risk of nonrecovery of renal failure. One possible explanation for this 
observation could be that the use of diuretics was a surrogate indicator for delayed initiation 
of renal replacement therapy (RRT). Such delay could partly explain why diuretic-treated 
patients had a relatively worse outcome in the Mehta report. Overall, this and other studies 






1. 2. 4. Atrial Natriuretic Peptide (ANP) 
Atrial natriuretic peptide (ANP) is another drug that has been investigated for 
possible use in ARF prophylaxis. Radiocontrast nephropathy (RCN) was a specific form of 
ARF studied. A multi-centre, prospective, randomised, double-blind, placebo-controlled trial 
was performed to evaluate the efficacy of intravenous ANP (anaritide). All patients were 
given 0.45% saline for 12 h before and 12 h after radiocontrast administration. Both ionic 
and non-ionic radiocontrast were used in the study. Patients in the study had stable baseline 
chronic renal dysfunction. They were randomised to receive either placebo or one of three 
doses of ANP. Of the 247 patients who completed the study, 50% had concomitant diabetes 
mellitus. RCN was defined as an absolute increase in serum creatinine (SeCr) of  44 
umol/L ( 0.5 mg/dl) or a percent increase of  25% over baseline values. The results 
showed that ANP did not reduce the incidence of RCN following radiocontrast study in 
patients with pre-existing renal impairment with or without diabetes mellitus.78 Another study 
using ANP involved 222 patients with oliguric ARF in a multi-centre, randomised, double-
blind, placebo-controlled trial. Subjects were randomised to receive either a 24 h infusion of 
ANP or placebo. Dialysis-free survival rate was 21% in the ANP group compared with 15% 
in the placebo group (p=0.22). By day 14 of the study, 64% of the ANP group compared with 
77% of the placebo group had undergone dialysis (p=0.054). Mortality rates through to day 
60 of the trial was 60% in ANP-treated versus 56% in placebo-treated patients (p=0.541).79  
 
 
1. 2. 5. Low Dose Theophylline 
Adenosine is a vasoconstrictor. Administration of an adenosine receptor antagonist 
theophylline may attenuate ischaemia by counteracting the vasoconstrictive effects of 
adenosine. A prospective, randomised, placebo-controlled study investigated the effect of 
theophyline or saline infusion prior to radiocontrast administration. It found that theophylline 
prevented a significant reduction in GFR following exposure to radiocontrast compared with 
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the placebo-treated group. Theophylline-treated patients also had relative preservation of 
their endocrine functions in terms of plasma erythropoietin (EPO) and plasma renin activity 
(PRA) concentrations.80 Erley et al also studied the effects of theophylline in RCN. A total of 
39 patients undergoing radiocontrast study were recruited. Forty-five minutes before the 
administration of radiocontrast, the patients were randomised to receive either theophylline 
(5 mg/kg BW) or vehicle + placebo (saline) in a double-blind manner. Theophylline was 
within the therapeutic range during and 4 h after contrast exposure. GFR declined 
significantly in the placebo-control group (n=19, 88 ± 40 pre-contrast to 75 ± 32 ml/min/1.72 
m2 post-contrast; p<0.01). In the theophylline group, GFR remained constant (n=18, 75 ± 26 
pre-contrast to 78 ± 33 ml/min/1.72 m2 post-contrast; NS).81 Theophylline was also found to 
be no better than simple hydration using normal saline in preventing ARF in a separate 
study on CABG patients.82  
 
 
1. 2. 6. N-Acetylcysteine (NAC) 
N-acetylcsyteine (NAC), a potent anti-oxidant, may be useful in preventing RCN in 
some patients with pre-existing renal dysfunction undergoing contrast studies such as 
coronary angiography. In one study, Briguori et al studied 183 consecutive patients with pre-
existing renal insufficiency undergoing coronary and/or peripheral angiography and/or 
angioplasty. Patients were randomly assigned treatment with intravenous 0.45% saline and 
oral NAC (600 mg twice daily) (Group A, n=92) or 0.45% saline alone (Group B, n=91) 
before and after administration of non-ionic, low-osmolality radiocontrast. Baseline SeCr 
was similar in both Groups A and B (133 ± 35 umol/L vs. 133 ± 35 umol/L, p=0.37). An 
increase in SeCr after the contrast procedure was seen in 6.5% of Group A patients and 
11% of Group B patients (p=0.22). In a subgroup with low concentration of contrast medium 
administered (< 140 ml), renal function deterioration occurred in 8.5% of Group B and nil in 
Group A patients (p=0.02). This study showed that the amount of contrast given correlated 
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with the subsequent development of RCN. Moreover, NAC + 0.45% saline combination was 
only more effective than 0.45% saline alone for RCN prophylaxis when a small dose of 
contrast was used.83 Tadros et al also found that NAC was useful in a series of patients 
undergoing coronary angiography. However, it was found that NAC was of greater benefit in 
patients with pre-existing chronic renal insufficiency (SeCr > 177 umol/L). However, 
historical controls were used in this study of 55 consecutive patients.84 Durham et al found 
no benefit of NAC in RCN-prevention following contrast studies in a series of 79 patients 
treated with NAC or placebo. In this prospective, randomised, controlled study, patients 
were going for cardiac angiography. All had baseline chronic renal dysfunction (SeCr > 150 
umol/L). Patients were randomised to receive either intravenous hydration + oral NAC (1200 
mg 1 h before and a second dose 3 h after the scan), or intravenous hydration + placebo.85 
Thus, the present role of NAC in RCN prophylaxis is uncertain. Much less is known about its 
usefulness in critically ill patients with ARF and sepsis.  
 
 
1. 2. 7. Growth Factors 
 Insulin-like growth factor-1 (IGF-1) was thought to be useful in ARF treatment in 
early laboratory work. Noguchi et al studied a transient ischaemia rat ARF model in which 
the renal arteries and veins were occluded. These rats were randomly assigned to either 
IGF-1 or saline treatment. It was found that IGF-1 significantly improved both glomerular 
and tubular renal function.86 In another rat model of endotoxin-mediated kidney dysfunction, 
IGF-1 was also beneficial in ameliorating ARF in endotoxin-induced sepsis.87 Clinical 
experience, however, has been disappointing. It was of no benefit in RCN prophylaxis and 





1. 2. 8. Fenoldopam 
A more promising drug of current interest is fenoldopam which is a dopamine agonist 
that augments renal plasma flow (RPF) in both normotensive and hypertensive patients. 
Tumlin et al conducted a prospective, randomised, double-blind, placebo-controlled trial of 
fenoldopam mesylate in patients undergoing contrast angiography. All 45 patients recruited 
for the study had baseline chronic renal insufficiency (SeCr 177 – 442 umol/L). They were 
randomised into two treatment arms: normal saline versus ½ normal saline + fenoldopam 
mesylate at 0.1 mcg/kg/min at least 1 h before the start of contrast infusion. One hour after 
angiography, RPF was found to be 15.8% above baseline in the fenoldopam group 
compared to 33.2% below baseline in the control group (p<0.05). The peak SeCr 72 h after 
contrast exposure was significantly higher in the control group (318 ± 88 umol/L) compared 
to the fenoldopam group (248 ± 31 umol/L) (p<0.05). RPF was significantly reduced in 
patients with RCN compared to those with no RCN following contrast exposure 
(p<0.0001).90 More data are needed from large randomised, controlled trials such as the 
CONTRAST study before the clinical role of fenoldopam mesylate can be confirmed.91 
  
Thus, although several drugs have been tested either for ARF prevention or to 
ameliorate ARF following acute renal injury, none has been shown to be useful in critically ill 
patients, especially in the subpopulation with severe sepsis, multi-organ failure (MOF) and 
ARF. For this group of patients, there are neither drugs to prevent nor accelerate recovery 
from ARF. Ensuring an adequate circulatory volume, cardiac output and systemic perfusion 
pressures, possibly guided by invasive haemodynamic monitoring, remains a fundamentally 
important part of contemporary ICU care and ARF management. To facilitate spontaneous 
renal and patient recovery, it is often necessary to institute acute renal replacement therapy 




Chapter 1.3  
Acute Renal Replacement Therapy 
 Acute renal replacement therapy (ARRT) in critically ill patients with severe renal 
failure refers to multiple modalities of artificial kidney treatment currently available. These 
patients include those with acute renal failure (ARF), acute-on-chronic renal failure (AoCRF) 
and end-stage renal failure (ESRF). The latter group of patients may either be newly-
diagnosed and therefore not on chronic RRT or are already on chronic haemodialysis (HD) 
or peritoneal dialysis (PD). ESRF patients admitted to the ICU with an intercurrent critical 
illness may also include renal allograft recipients on chronic renal transplant 
immunosuppression. Critical illness in chronic dialysis or renal transplant patients may be 
dialysis-related such as vascular catheter infections or arise secondary to opportunistic 
infections in organ transplant patients. In some cases, exacerbation of the underlying 
primary disease such as systemic lupus erythematosus (SLE), may precipitate severe 
critical illness requiring ICU care.  
 
ARRT in all of the above patients does not substitute for the failed or inadequate 
endogenous renal endocrine functions such as erythropoietin (EPO) and vitamin D 
synthesis. The main purpose of any form of ARRT is to optimise the uraemic milieu through 
extracorporeal elimination of blood-borne uraemic toxins. Achieving homeostasis through 
fluid, acid-base, electrolyte and uraemic toxin control in turn optimises conditions for 
eventual spontaneous organ and patient recovery. This is the principal role of “renal-dose” 
ARRT used in those with established severe renal failure. Moreover, certain ARRT-derived 
modalities can be used to modulate hypercytokinaemia in severe sepsis through “sepsis-
dose”, pulsed, high-volume haemofiltration (HVHF), the biological rationale of which is 
further discussed in Chapter 2.2. In contrast to the use of ARRT to treat severe renal failure, 
“sepsis-dose” immunomodulatory techniques such as HVHF aims to prevent the 
development of multiorgan failure (MOF)/ARF due to severe sepsis.  
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The main techniques of ARRT that are to be discussed are as follows: (1) acute 
peritoneal dialysis (acute PD), (2) intermittent haemodialysis (IHD) versus CRRT, (3) slow,  
low-efficiency dialysis (SLED), isolated ultrafiltration (UF) and slow continuous ultrafiltration 
(SCUF), (4) Molecular Adsorbent Recirculating System (MARS).  
 
CRRT is also an ARRT modality and it forms the subject of a Literature Review in 






















1. 3. 1. Acute Peritoneal Dialysis 
This is a simple life-saving technique that is still being used in some places 
with no access to either the equipment or trained manpower to deliver blood-based de-
uraemisation therapies such as HD and CRRT. It is the modality of choice in neonatal and 
paediatric ICU patients with ARF. Lin et al in series of 184 children with post-cardiac surgery 
ARF noted that acute PD was safe and effective in controlling fluid and electrolyte 
derangements.92 In a Brazilian series of 15 infants who developed post-cardiac surgery 
ARF, acute PD was successfully used to treat hypervolaemia. The infant mortality rate was 
very high due to the severity of the underlying cardiac disease. ARF also correlated with a 
poorer infant outcome.93 A separate study observed that low pre-dialysis serum albumin 
concentration correlated with poorer patient outcome.94 Complications in acute PD can 
occur. These include peritonitis, peritoneal dialysate leakage (Figure 3), exacerbation of 
respiratory compromise and even bowel herniation and infarction, according to one case 
report.95 A recent survey suggested that acute PD is becoming less popular in certain 
institutions except in very young infants and paediatric patients who are likely to develop 
ESRF (Figure 4). There is also an associated increase in the use of CRRT in neonatal and 
paediatric ICU patients with ARF.96 In contrast, acute PD in adults remains relevant, albeit 
for limited specific indications. An example is congestive cardiac failure (CCF) which was 
reported to be responsive to acute PD therapy.97 There are also reports of other non-renal 
clinical applications for PD such as core rewarming of patients with severe hypothermia and 
administration of intraperitoneal chemotherapy in oncological patients.98 In the area of critical 
care nephrology, however, a recent Vietnamese series compared the use of continuous 
haemofiltration (CHF) with acute PD in the treatment of ARF in critically ill patients. Phu et al 
reported that CHF-treated patients had a lower mortality rate (15%) compared with acute 
PD-treated ones (47%) (p=0.005). CHF-treated patients also showed a more rapid 
resolution of acidosis and elevated SeCr levels than acute PD-treated ones (p<0.005). RRT 
with CHF was also required for a significantly shorter period of time compared with acute PD 
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patients. It would therefore appear from this open, randomised trial that CRRT is more 
physiological and effective than acute PD if access to the former is not a problem.99  
 
Recent developments in PD for end-stage renal disease (ESRD) patients have 
included the development of more biocompatible dialysate solutions, better PD catheter 
design, newer PD catheter insertion techniques and automated PD (Figure 5). However, the 
use of PD in ICU patients has mainly been in the paediatric population. More needs to be 
































































1. 3. 2. Acute Intermittent Haemodialysis (IHD) versus Continuous Renal Replacement 
Therapy (CRRT) 
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 Acute intermittent haemodialysis (HD) is still widely used in ICUs to treat critically ill 
patients with severe renal failure, including ESRF patients with severe critical illness. 
Although CRRT usage has also become more widespread, it is frequently used in the more 
critically ill and inotrope-dependent hypotensive patients. In contrast, IHD is instituted in 
those with relatively more stable haemodynamic status. IHD can also be used in those with 
intermediate critical illness severity and who are recovering from severe ARF. Such patients 
do not require CRRT.101 However, both IHD and CRRT share a common need for vascular 
access which can either be via arteriovenous fistula (AVF) or graft (AVG) or through central 
venous, dual-lumen dialysis catheters (Figures 6, 7 and 8). Nevertheless, there is concern 
that CRRT is more expensive than IHD and is not as cost-effective. In an analysis by Manns 
et al, it was found that IHD treatment of ARF can indeed result in significant cost savings 
compared with CRRT. However, survivors with renal recovery spend significantly fewer days 
in hospital compared with those with persistent renal failure. CRRT can potentially result in 
cost savings if it can be shown to improve renal recovery compared with IHD (Figures 9 and 
10).102 However, a meta-analysis by Tonelli et al noted that CRRT does not improve survival 
or renal recovery in unselected critically ill patients with ARF.103 The choice of one ARRT 
modality over the other is thus confounded by several factors which are discussed further in 
this chapter.  
 
 
(1) Patient Survival 
Guerin et al conducted a prospective multicentre observational study from March 
1996 to 1997 involving twenty-eight multi-disciplinary ICUs in the Rhone-Alpes region in 
France. A total of 587 dialysis-requiring patients were studied. Among them, 354 subjects 
received CRRT and 233 received IHD as first ARRT modality of choice. CRRT-treated 
patients were found to have a higher number of dysfunctional organs on admission to the 
ICU and higher Simplified Applied Physiology Score II (SAPS II) scores at the time of ARF 
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diagnosis. Mortality was high in both groups (CRRT- vs. IHD-treated groups, 79% vs. 59%, 
NS). Although the modality of ARRT used was not correlated with patient outcome, further 
analysis observed that decreased patient survival was correlated with critical illness severity 
on ICU admission based on SAPS II scores, oliguria, duration between admission and onset 
of ARF, ischaemic aetiology of ARF and concomitant cardiac dysfunction at the time of ARF 
diagnosis.104 One reason why CRRT-treated patients appeared to do worse is that in clinical 
practice, the more severely ill patients tend to have more intractable hypotension and 
therefore more likely to be treated with CRRT than with IHD. Ji et al in a Chinese study of 
193 severe ARF patients between 1978 -1998 corroborated the findings of the French study. 
CRRT treated patients were more critically ill than their IHD-treated counterparts with lower 
mean arterial pressure (MAP), higher critical illness severity APACHE II scores, more 
dysfunctional organs, greater number of patients requiring mechanical ventilation and 
vasopressor support relative to the IHD-treated group.105 In addition, the Chinese study also 
noted that CRRT-treated patients achieved more optimal fluid balance, regulation of 
electrolytes, increased nutritional intake and shorter duration of ARF.105 To resolve the issue 
of which ARRT modality is more optimal and whether modality choice impacts on outcome, 
a prospective, randomised, multi-centre trial was conducted by Mehta et al in California. 
Patients were randomised to be treated with either IHD or continuous haemodiafiltration 
(CHDF). A total of 166 patients were studied. The overall ICU and in-hospital mortality were 
50.6% and 56.6%, respectively. CHDF compared with IHD was associated with increase in 
ICU (59.5% vs. 41.5%, p<0.02) and in-hospital mortality (65.5% vs. 47.6%, p<0.02). There 
were no significant differences between the two groups in terms of median length of ICU 
stay from the time of first nephrological consultation to complete renal recovery. This study 
was however skewed by the fact that despite randomisation, there were significant 
differences in several covariates that were independently associated with mortality, such as 
gender, hepatic failure, critical illness severity APACHE II and APACHE III scores and the 
number of failed organs in favour of the IHD-treatment arm.106 This problem of critical illness 
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severity confounding the therapeutic and clinical efficacy of CRRT vis a vis IHD was partly 
addressed by Swartz et al when they performed a retrospective analysis of 349 adult 
patients with ARF receiving ARRT between 1995 to 1996 at a single medical centre. 
Excluded patients were those who were more critically ill as evidenced by systolic blood 
pressure < 90 mmHg and total bilirubin concentration >15 mg/dl. The remaining 227 
patients were then analysed. Before the exclusion of very sick patients from the analysis, 
initial CVVH-treated patients had a relative risk for death of 2.03 whereas after exclusion, 
these patients had a lower relative risk for death of 1.09 which was comparable with those in 
whom IHD was the initial ARRT modality chosen. This study confirmed that high crude 
mortality associated with initial CVVH treatment was not related to the RRT modality per se 
but to severe associated underlying comorbidities and critical illness severity.107  
 
 
(2) Physiological Parameters 
 In trying to determine whether IHD or CRRT is the more optimal and physiological 
form of treatment in ARF, studies have focussed on certain laboratory and clinical variables 
and outcomes. Brain density changes were studied using serial CT-scans in critically ill 
patients with ARF but no central neurological system (CNS) disease or injury. Patients were 
randomly allocated either IHD or continuous haemofiltration (CHF) treatment and there was 
no cross-over of RRT modality. A total of 12 patients with ARF were studied. They were 
either treated with IHD (one 4 h session and Kt/V  1) or continuous veno-venous 
haemofiltration (CVVH) (one 24 h session and Kt/V  1). CT-scans of the brain were done 
before and after each treatment session in each patient. In the IHD-treatment group, 
significant changes were noted after IHD session in all patients in the gray matter (52.3 ± 
5.2 to 38.9 ± 5.3 Hounsfield units) and white matter (36.7 ± 3.5 to 24.8 ± 3.2 Hounsfield 
units, average delta – 26.7%). No such changes were observed in CVVH-treated patients. 
Given that brain water content can increase with even a single session of HD, it would be 
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preferable to use CVVH to treat severe renal failure in patients with definite signs of raised 
intracranial pressure (ICP) as well as those with obvious brain injury such as in polytrauma 
or head injury. For patients with medical causes of raised ICP such as fulminant hepatic 
failure (FHF) and concomitant severe renal failure, CVVH would appear to be a 
physiological form of treatment in terms of preservation of CNS status quo.108  
 
 
(3) Biochemical Parameters 
 Other workers have examined the relative effects of CRRT versus IHD on specific 
biochemical indices such as uraemic control. Bellomo et al compared critically ill patients 
with ARF treated with IHD and continuous veno-venous haemodiafiltration (CVVHDF) at a 
single centre over two study periods during which IHD was more widely used than CVVHDF 
in the earlier period and the order reversed in the latter period. This retrospective study 
involved consecutive critically ill patients with multi-organ failure (MOF) and ARF (IHD: 
CVVHDF = 47:47). The baseline characteristics of both groups (IHD vs. CVVHDF) of 
patients were comparable (mean age 55 years vs. 60 years of age, NS) and number of 
failing organs prior to ARRT (4.2 vs. 3.7, NS). Patients treated with CVVHDF were 
significantly more ill than their IHD-treated counterparts (APACHE II score 29.4 vs. 25.7, 
respectively, p<0.003). Despite similar SeCr and plasma urea levels at baseline prior to the 
start of ARRT, both biochemical indices were significantly lower in the CVVHDF group than 
in IHD after 24 h of treatment (CVVHDF vs IHD, plasma urea, p<0.0001 and CVVHDF vs. 
IHD, SeCr, p<0.01). Throughout the duration of RRT, more optimal azotaemic control was 
achieved with CVVHDF than with IHD: mean urea levels (IHD vs. CVVHDF = 35.0 mmol/L 
vs. 23.4 mmol/L, p<0.0001) and mean SeCr levels (IHD vs. CVVHDF = 513 umol/L vs. 263 
umol/L, p<0.0001).109 In addition to azotaemic control, the regulation of acid-base and 
electrolytes is equally important when comparing the relative clinical efficacy of IHD and 
CRRT. Uchino et al retrospectively studied 47 IHD-treated and 47 CVVHDF-treated critically 
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ill ARF patients. At baseline prior to the start of ARRT (IHD vs CVVHDF), the frequency of 
abnormal (either high or low) electrolyte values were comparable in the two groups, IHD vs. 
CVVHDF: sodium 42.6% vs. 39.6% (NS), potassium 23.4% vs. 45.8% (NS), and 
bicarbonate 63.2% vs. 54.3% (NS). CVVHDF was more likely to normalise sodium levels 
than IHD (76.2% vs. 47.8%, p=0.0001). The mean serum potassium levels of both groups 
also significantly decreased. However, CVVHDF more frequently reduced the incidence of 
hypokalaemia (1.9% vs. 7.1%, p=0.0006). CVVHDF but not IHD significantly increased 
mean serum bicarbonate levels in the first 48 h (p=0.016) and more frequently normalised 
them (71.5% vs. 59.2%, p=0.0073). CVVHDF thus appears to be a better homeostatic tool 
compared with IHD in the regulation of electrolytes and acid-base status.110 To further 
understand the relative effects of IHD vs. CVVHDF on calcaemic and phosphataemic 
control, two additional studies were performed as detailed in Chapter 3.1.  
 
 
(4) Haemodynamic Status 
Another practical concern with the use of IHD in critically ill patients with hypotension 
is the destabilisation of the haemodynamic status. Tonelli et al attempted to use online 
relative blood volume (RBV) in the ICU setting to determine if impending hypotensive 
episodes could be detected before they actually occurred. It was noted that concordance of 
RBV and hypotension (that is RBV falling prior to hypotensive episodes rather than rising or 
remaining stable) was no greater than chance. Thus, RBV-derived real-time data did not 
predict hypotensive episodes and were not correlated with either mean arterial pressure 
(MAP) or systolic blood pressure (SBP).111 IHD associated hypotension may worsen local 
regional organ hypoperfusion that already exists secondary to systemic hypotension, for 
example in distributive septic shock. Splanchnic regional blood circulation is one such area. 
Perfusion through the splanchnic bed can be indirectly quantitated by measuring the 
following indices: intramucosal pH (pHi) and pCO2 (pCO2i). Thirty septic shock patients with 
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severe ARF were randomised to either CVVH (n=20) or IHD (n=10) treatment. Baseline 
patient characteristics were comparable in terms of critical illness severity (APACHE II) 
scores, haemodynamic status and pHi/PCO2i values. There were no major changes in 
vasopressor support throughout the 24 h study period. CVVH compared with IHD was noted 
to cause decrease in heart rate (HR) (-3 ± 11 vs. +9 ± 8/min, p<0.01) and an increase in 
systolic blood pressure (SBP) (+12 ± 1 vs. –5 ± 17 mmHg, p<0.05) after 2 h of treatment. 
After 24 h, there was an increase in the systemic peripheral vascular resistance in the 
CVVH group compared with the IHD group: +312 ± 755 vs. –29 ± 89 dyne/cm5, p<0.05, and 
this was accompanied by a decrease in the cardiac output: -1.54 ± 1.4 vs. –0.25 ± 0.9 L/min, 
p<0.01. However, pHi values remained constant throughout the 24 h treatment period and 
were not significantly different for CVVH and IHD treated patients: 7.19 ± 0.1 vs. 7.19 ± 0.1, 
NS. There were also no significant differences in the pCO2i values between the two groups. 
Although there were significant changes in the systemic haemodynamic circulation between 
CVVH and IHD treated patients, there were no definite differences in the regional splanchnic 
circulation in critically ill patients with septic shock.112 Data from this German study suggests 
that CVVH can ameliorate the haemodynamic features of distributive shock of severe sepsis 
such as peripheral vasodilatation, hypotension and compensatory tachycardia and 
increased cardiac output when compared with equally ill IHD-treated patients. Nevertheless, 
other workers have attempted to attenuate the hypotensive tendency of IHD in critically ill 
ARF patients through specific dialytic techniques. One such method is sodium and 
ultrafiltration (UF) modelling. Paganini et al explored this in a prospective, randomised, 
stratified cross-over study. In the study, subjects were treated with either fixed dialysate 
sodium concentration (140 mEq/dl) and fixed ultrafiltration (UF) rate (Protocol A) or a 
variable dialysate sodium concentration (ranging from 164 to 140 mEq/dl) and variable UF 
rate (50% UF during the first third of treatment time and 50% UF over the last two-thirds of 
total treatment time) (Protocol B). After three sessions, these patients were crossed over to 
the other protocol and if after a further three sessions, HD were still required, they would be 
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switched back to the original protocol that they were first randomised to be treated with. A 
total of 10 patients with ARF were studied. Haemodynamic stability was greater with 
Protocol B than with Protocol A in all patients. Significantly fewer nursing interventions were 
needed with Protocol B than with A despite the same dialysis delivery time for both groups 
of patients. Thus, sodium and UF modelling during IHD is one possible way by which the 
hypotensive tendency of IHD can be attenuated in critically ill ARF patients without recourse 
to CRRT techniques.113 However, it may be clinically difficult to predict which groups of 
patients would be able to tolerate “modelled” IHD. It may be more prudent to treat those who 
are hypotensive and on high doses of  1 inotrope with CRRT, if resources are available.  
 
 
(5) Dialytic Adequacy 
Early data questioned the dialytic adequacy of IHD compared with CRRT. IHD was 
found to provide inadequate dialysis compared with continuous haemofiltration (CHF). The 
mean serum urea nitrogen (SUN) level was significantly higher in the IHD compared with the 
CHF group: 101 ± 12 mg/dl vs. 79 ± 17 mg/dl, p<0.05. Mathematical simulation suggested 
that daily HD >= five times per week is needed to achieve a comparable degree of 
azotaemia control (evidenced by SUN levels) in CVVH.114 In a retrospective study of 76 ICU 
patients treated with continuous venovenous haemodiafiltration (CVVHDF) matched with 
historical controls of 84 patients treated with either IHD or acute PD (termed conventional 
dialysis or CD group), it was found that CVVHDF patients were more severely critically ill 
based on their APACHE II scores. After adjustment for critical illness severity, it was 
observed that CVVHDF patients had a better survival rate than their CD treated 
counterparts (54.3% vs. 29.3%, p<0.01).115 A similar study involved 234 consecutive 
critically ill patients with severe ARF over a 5 year period and compared continuous 
haemodiafiltration (CHDF, n=150) with conventional dialysis (CD, either IHD or acute PD, 
n=84). Although CHDF patients were significantly older and more severely ill than their CD 
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treated counterparts, they were otherwise similar in the incidence of sepsis and need for 
mechanical ventilation. Mean steady state plasma urea level was lower in the CHDF group 
relative to the CD group (20.1 vs. 31.7 mmol/L, p<0.001). Moreover, hyperphosphataemia 
was also better controlled in CHDF compared with CD treated patients (1.26 vs.1.95 
mmol/L) after 24 h of therapy. CHDF also permitted the administration of full nutritional 
support in significantly greater percentage of patients (91.3% CHDF vs. 64.8% CD patients, 
p<0.001).116 In a separate study, however, van Bommel et al compared ARF patients treated 
with IHD (n=34) versus those treated with continuous arteriovenous haemodiafiltration 
(CAVHDF) (n=60). The CAVHDF patients were more severely ill with higher APACHE II 
scores and greater number of organ system failures. There was no significant difference in 
mortality rate between the two groups (CAVHDF vs. IHD: 43% vs. 59%, NS).117 Other 
studies have examined ARRT modality choice in terms of which treatment permitted more 
intensive nutritional support. Kopple noted that volume control is more flexible and safer 
when CRRT is used in unstable critically ill patients. This can allow more intensive, larger 
volume-based nutritional support to be administered.118 This is in contrast to similar oligo-
anuric ARF patients being treated with IHD in whom fluid restriction is mandatory. This 
restricts both the volume and composition of nutritional support that can be given.119  
 
 
(6) Membrane Biocompatibility 
To further improve the clinical outcome of IHD treated critically ill patients with 
severe ARF, haemodialyser membrane biocompatibility was investigated. The hypothesis 
was that bioincompatible membranes may actually promote and worsen the systemic 
inflammatory state that exists in many critically ill patients, many of whom are also septic. 
This may exacerbate septic organ dysfunction and ultimately worsen patient survival. A 
review by Lang et al based on early dialyser membrane biocompatibility data suggested that 
it did have an impact on clinical outcome in critically ill patients. One study by Schiffl and 
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colleagues compared cuprophane (CUP), regarded as bioincompatible with biocompatible 
polyacrylonitrile (AN69) (Hospal, Lyon, France) membrane in 52 patients with post-cardiac 
surgery ARF. The AN 69 group compared with the CUP group had a lower mortality rate 
(38% vs. 65%, p=0.052), a lower proportion of patients dying from gram-negative sepsis 
(40% vs. 71%, p=0.0162) and improved recovery of renal function. A separate study of 72 
patients with medical ARF compared CUP dialyser membrane with biocompatible 
polymethyl-methacrylate (PMMA) membrane. Patient survival rate was improved with PMMA 
compared with CUP (57% vs. 37%, p=0.11) and recovery of renal function was also better in 
the biocompatible PMMA group (62% vs. 37%, p=0.04). These early studies therefore 
supported the use of biocompatible dialyser membranes for IHD in the treatment of severe 
dialysis-requiring ARF in critically ill patients.120 However, a more recent study by Albright et 
al failed to show any effect of membrane biocompatibility characteristics on patient survival. 
This was a prospective trial of IHD in ARF patients using either only cellulose acetate (CA) 
or polysulphone (PS) haemodialyser membranes. Laboratory markers of biocompatibility 
such as complement, leucocyte count and cytokine concentrations were quantitated at 
initiation and 1 h after initiation of IHD in 10 patients equally assigned to CA and PS dialyser 
groups. The two cohorts were similar in terms of presence of comorbidity such as diabetes 
mellitus, age, critical illness severity APACHE II scores, percetange of cases requiring ICU 
care and their adequacy of dialysis. Patient survival was similar in the two groups (CA 
membrane vs. PS membrane: 76% vs. 73%, NS) and renal recovery at 30 days was also 
comparable (CA membrane vs. PS membrane: 58% vs. 39%, NS). In the ICU subgroup, 
patient survival was also similar in the two groups (CA membrane vs. PS membrane: 73% 
vs. 67%, NS), although there was a suggestion of renal recovery benefit with CA dialyser 
(CA membrane vs. PS membrane: 65% vs. 37%, p=0.04). Laboratory markers of 
biocompatibility between the CA and PS groups were similar. Further studies are needed to 




(7) ARRT Modality Choice 
The choice of RRT modality used to treat critically ill patients with severe renal failure 
ultimately depends on administrative, logistical and resource constraints. While CRRT is 
more optimal for the highly catabolic, septic patient with MOF, it may not always be possible 
to perform it. Moreover, nursing and medical manpower needed for CRRT management is 
dependent on the ICU practice model. In the “closed” ICU system, ICU nurses and 
intensivists manage CRRT exclusively. The availability of newer machines such as the ArRT 
Plus (Fresenius Medical Care AG, Bad Homburg, Germany) has further enabled ICU nurses 
to perform IHD and SLED as well. On the other hand, in the “open” ICU system, dialysis-
trained nephrology nurses undertake CRRT and other forms of ARRT under the supervision 
of nephrologists. Whichever model is adopted, regular in-service maintenance of 
certification may be needed to maintain CRRT nursing competence. Available data suggest 
that earlier initiation of ARRT/CRRT and at adequate dialytic intensities are needed for more 
optimal outcomes. However, what is less clear is the choice of ARRT modality. The 
biological rationale for use of a specific ARRT modality over another is presently not strong 
enough to override logistical and administrative pressures that ultimately dictate the dialytic 
modality used. For less sophisticated medical centres, acute PD may be the only viable form 
of ARRT which is potentially life-saving but associated with a high incidence of 
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1. 3. 3. Isolated Ultrafiltration (UF), Slow Continuous Ultrafiltration (SCUF) and Slow, 
Low-Efficiency Dialysis (SLED) 
Fluid overload or hypervolaemia is a common clinical problem. It is usually  
due to  absolute positive fluid balance and is frequently aggravated by chronic severe 
hypoalbuminaemia. The conventional approach is to restrict fluid intake wherever possible. 
This may be impractical in the critically ill patient who needs high volume crystalloid/colloid 
fluid infusions, blood and blood product transfusions, and intensive nutritional support 
including TPN. The use of diuretics is the standard response to this problem, as alluded to 
earlier in Chapter 1.2. However, some patients may be refractory to high doses of loop 
diuretic infusion or are only partially responsive. In such patients who remain oligo-anuric, 
there is a role for isolated UF and slow continuous ultrafiltration (SCUF) in restoring 
euvolaemia. Wei et al described the technique of SCUF in the treatment of chronic fluid 
overload in congestive cardiac failure (CCF). In this series of 7 patients, all of them had 
chronic renal insufficiency and were resistant to diuretics. A standard Cuprophane dialyser 
was used. SCUF was carried out at a blood flow rate of 175 ± 26 ml/min. The average UF 
achieved was 2189 ± 699 ml per session of SCUF. There were no significant changes in 
either the heart rate or blood pressure pre- and post-SCUF.127 An earlier study by Negovsky 
et al also confirmed the role of sequential UF with haemodialysis, isolated UF and SCUF in 
the management of diuretic-resistant, fluid overloaded patients with severe cardiac 
diseases. UF volume ranged from 1 – 8 L per treatment session at a rate of 17 – 500 ml/min 
at a transmembrane pressure (TMP) of 100 – 400 mmHg.128  
  
Another technique that can be used for ARF patients in the ICU is Slow Low-
Efficiency Dialysis (SLED), also termed Sustained Low-Efficiency Dialysis. It operates at 
blood and dialysate flow rates that are greatly reduced compared to standard IHD and is 
typically carried out over 12 h. Standard IHD equipment can be used and the minimum 
blood and dialysate flow rate settings available on the HD platform are selected. In a first 
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description of the technique by Marshall et al, nine critically ill ARF patients were treated 
with a single session of SLED each. It was found that SLED could be performed in these 
patients and achieved relatively high dialytic doses as quantified by single-pool urea kinetic 
modeling.130 Another study reported a total of 145 SLED treatment sessions in 37 critically ill 
patients in whom IHD had failed or was contraindicated. This study was conducted over 18 
months at a single centre. Each session was over 12 hours nocturnally. Such scheduling 
allowed patient-centered nursing and medical procedures to be carried out during the day 
without the hindrance of ongoing ARRT. The overall mean SLED duration of treatment was 
10.4 h. However, 51 SLED treatments were terminated prematurely. Of these, 11 were for 
intractable hypotension and the majority of the rest were for blood circuit clotting. In those 
with relative haemodynamic stability during SLED, most managed to achieve UF targets with 
an overall mean shortfall of only 240 ml per SLED session. Mild hypophosphataemia and 
hypokalaemia requiring supplementation were observed in 25 treatments. Urea kinetic 
modelling using double-pool analysis showed that SLED dialysis dose delivered per session 
was 1.36 (Kt/V). Observed hospital mortality was 62.2% which was similar to predicted 
mortality based on APACHE II scoring. SLED is thus a relatively safe and effective 
alternative to CRRT in those in whom standard IHD is either contraindicated or not 
tolerated.131 Although more clinical data are needed regarding the safety and clinical efficacy 
of SLED, it appears to be an intermediate intensity alternative to standard IHD and CRRT. 
To illustrate, ICU patients who may benefit from SLED are those who have recovered to the 
extent that CRRT is no longer required yet remain dialysis-dependent. In such patients, the 
trial use of SLED can be a useful transition treatment to ensure dialytic tolerability before 
migrating to conventional IHD. Similarly, SLED can also be used in those who are 
haemodynamically unstable in whom IHD is contraindicated and who may have no access to 
CRRT.  
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1. 3. 4. Molecular Adsorbent Recirculating System (MARS)  
Severe liver dysfunction is frequently observed in critically il patients. It may 
be the primary organ adversely affected with subsequent secondary extra-hepatic 
complications such as sepsis, bleeding and ARF. An example of this may be an acute 
idiosyncratic allergic hepatitis secondary to drugs such as allopurinol or other toxins leading 
to progressive liver damage and ultimately fulminant hepatic failure (FHF). Liver failure can 
also occur in the context of MOF in which it is one of several dysfunctional organs. MOF can 
in turn be due to severe sepsis causing septic shock, primary cardiogenic shock due for 
example to massive acute myocardial infarction, and severe hypotension. Acute liver 
dysfunction can be divided into the following categories: (1) acute liver failure (ALF) 
(including fulminant hepatic failure or FHF, the most severe form of ALF), (2) acute-on-
chronic liver failure (AoCLF) in those with pre-existing chronic liver disease (CLD) in whom 
an acute precipitating event such as sepsis or severe hypotension further depletes 
functional liver reserve, thus inducing AoCLF, and (3) end-stage liver disease (ESLD).132-136 
Artificial liver support can be divided into two different approaches: (1) hepatic excretory-
assist device, and (2) bio-artificial liver. While the former has no biosynthetic function, the 
latter is able to reproduce some of the endogenous hepatic synthetic functions. Albumin liver 
dialysis using the Molecular Adsorbent Recirculating System (MARS) (Teraklin, Rostock, 
Germany) is an example of the former. It can be used in intermittent or continuous mode 
depending on the metabolic demands of the patients, with the MARS monitor coupled to 
either a HD or CRRT machine, respectively. MARS has been shown to be an effective blood 
detoxification tool in severe liver and renal failure, being able to eliminate not only protein-
bound toxins from the blood compartment (Table 1) but also non-protein bound ones as well  
(Figure 11).141-143 Apart from its role as a bridge to liver transplantation, its role in facilitating 
recovery of acute decompensation of chronic liver disease (CLD) is less well-defined.  
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Nevertheless, the application of MARS highlights the central role of CRRT as a core 
blood purification tool for critically ill patients upon which newer blood detoxification 








































Ae: Albumin dialysate exiting Dialyser 1; higher concentration of
liver and uraemic  toxins are found at this point than Aa
Aa: Albumin dialysate re-entering Dialyser 1 after regeneration;
















Substances to be removed 
 
 




• Bile acids 
• Bilirubin 
• Aromatic amino acids 
• Indole-/phenol-metabolites 
• Toxic fatty acids 
• Thiols 


































Continuous Renal Replacement Therapy (CRRT)  
 In Chapter 1.3, the key ARRT options available to treat critically ill patients with 
medically intractable severe renal failure are reviewed. Most of them are intermittent 
therapies. In contrast, continuous renal replacement therapy (CRRT) potentially provides 24 
h, flexible metabolic control provided there are no significant interruptions. However, a 
complementary view asserts that IHD can equally deliver comparable dialytic adequacy if 
performed daily and for long enough duration each time.156  
  
Chapter 2.1 reviews the literature on the clinical effects of CRRT in critically ill 
patients with established severe renal failure, including acid-base and electrolyte control. It 
also provides a brief description of the technical aspects of CRRT. Factors that determine 
extracorporeal blood circuit functional longevity will be reviewed since frequent circuit 
thrombosis undermines its therapeutic potential.  
 
Chapter 2.2 focusses on the emerging use of novel CRRT-based blood purification 
procedures for non-renal indications such as severe sepsis and systemic 
rheumatological/immunological disorders mediated by blood-borne humoral disease 
mediators. Removal of such humoral substances through these blood purification 
procedures may potentially attenuate disease course and severity.  
 
Chapter 2 ends with a summary of what this thesis sets out to achieve with a 
statement of specific objectives against this background of what is known and what is less 






CRRT in Severe Renal Failure  
2. 1. 1. Background 
The first description of CRRT was that of continuous arterio-venous haemofiltration 
(CAVH) by Kramer et al.157 In the early phases of CRRT development during the 1970s/80s, 
CAV- forms of CRRT were commonly used. This was due to the lack of mechanically 
reliable volumetric pumps needed for accurate blood and fluid circulation in the 
extracorporeal circuit (EC).  As such, the force needed to pump blood through the EC was 
dependent on the patients’ own systemic blood pressure. Given that this tended to be low 
and unpredictable in critically ill patients, it was necessary to use blood circuit components 
with low intrinsic blood flow resistivity, including flat-plate haemodialysers and 
haemofilters.157, 158 CAV- modes of CRRT were associated with higher complication rates 
such as haemorrhage, critical lower limb ischaemia and pseudoaneurysm given the need to 
cannulate the femoral artery and vein.159-161 With the advent of modern CRRT machines with 
reliable volumetric roller pumps integrated by microprocessor with other roller pumps 
regulating other fluid pathways on the same machine, CAV- modes of CRRT have largely 
been discontinued. Accordingly, CVV- modes of CRRT have been adopted more widely and 
this has necessitated the use of large bore, dual-lumen central venous dialysis catheters. 
However, the use of such catheters is associated with significant recirculation, especially 
when short ones are used in the femoral vein.126 Thus, the challenges with modern CRRT 
systems are to ensure continuous operational integrity with central venous catheters that are 








2. 1. 2. Technique 
CRRT is an umbrella term to denote three specific technical variants: (1) continuous 
venovenous haemofiltration (CVVH) (Figure 12a), (2) continuous venovenous haemodialysis 
(CVVHD) (Figure 12b), and (3) continuous venovenous haemodiafiltration (CVVHDF) 
(Figure 12c). CVVH is the most commonly performed technical variant.171-173 The principal 
mode of solute elimination with CVVH is convection. It involves bulk flow of plasma water 
(solvent) driven across the haemofilter membrane by transmembrane pressure (TMP) and in 
so doing, shift large amounts of uraemic solutes in aqueous phase into the effluent path, 
producing the ultrafiltrate or “artificial urine”.174-176 Haemofiltration necessitates the 
concomitant infusion of substitution fluids either pre- or post-filter (termed pre- and post-
dilution CVVH, respectively). Such solutions are available in two different forms (Figure 17) 
(chapter 2.1.3). Nevertheless, blood viscosity profile within the haemofilter and relative 
solute clearances differ, depending on whether CVVH is performed in pre- or post-dilution 
mode.177-179 Haemofilters have high hydraulic permeabilities or ultrafiltration coefficients (KUF) 
compared to haemodialysers to permit convection to occur (Figure 16). CVVHD relies on 
diffusive elimination of toxins from the blood compartment. A diffusion gradient is 
established by the flow of dialysate in the inter-capillary potential spaces of a haemodialyser, 
in a direction countercurrent to that of blood. CVVHD has been reported to be useful in liver 
transplant patients with severe renal failure with preservation of blood de-uraemisation 
function despite progressive loss of dialyser-fibre bundle volume with prolonged use.187-188 
CVVHDF combines both convective and diffusive solute elimination from the blood 
compartment. However, the combination of two solute clearance mechanisms in CVVHDF 
(convection + diffusion) from the blood compartment is not necessarily superior to 
convection alone.189 In one study, Reeves et al noted that the mean effluent:plasma (E/P) 
ratio for small molecules such as urea were as follows during CRRT: (1) haemofiltration 
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(0.957 ± 0.038), (2) haemodiafiltration (0.876 ± 0.109), and (3) haemodialysis (0.754 ± 
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with a higher E/P ratio for vancomycin compared to combination of diffusion + convection 
(CVVHDF) and diffusion alone (CVVHD).189  
 
In terms of electrolytes regulation and uraemic toxin elimination from the blood 
compartment, other key differences exist among the three different CRRT modalities. 
Morimatsu et al compared CVVHDF- and CVVH-treated patients with severe ARF. It was 
observed that CVVHDF was more likely than CVVH to achieve normal range serum sodium 
concentrations (74.1% vs. 62.9%, p=0.0026). Both treatments reduced the serum potassium 
levels. Although both forms of CRRT also increased the mean serum bicarbonate levels in 
the first 48 h, CVVH was associated with a lower incidence of metabolic acidosis than 
CVVHDF (13.8% for CVVH vs. 34.5% for CVVHDF; p<0.0001) and a higher incidence of 
metabolic alkalosis (38.9% for CVVH vs. 1.1% for CVVHDF, p<0.0001).190 A separate study 
demonstrated that azotaemic control was better with CVVH than it was with CVVHDF. 
However, the mean serum urea and creatinine levels were significantly lower at baseline in 
the CVVH-treated group than in the CVVHDF-treated ones. Throughout the course of 
treatment, it was shown that mean serum urea and creatinine concentrations were lower in 
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the CVVH than in the CVVHDF group.191 Differences in the handling of calcium, magnesium 
and phosphate ions were also found between CVVHDF and CVVH in ARF patients.192 These 
clinical findings appear to be consistent with those of Reeves et al aluded to earlier, which 
showed that convection alone could achieve better small solute clearance than a 
combination of convection and diffusion as evidenced by a higher E/P ratio for these solutes 
in the former.189 Another aspect of CRRT physiology relates to its acid-base effect. This is 
influenced by the use of lactate- or bicarbonate-buffered fluids during CRRT.193 Part of our 
research was to determine how the choice of buffer affects the acid-base physiology in 
critically ill patients treated with CVVH (Chapter 3.2).  
 
Mosr modern CRRT machines can perform all three forms of CRRT. Irregardless of 
the technique used, a common characteristic is the progressive decay in the permeability of 
membranes used in CRRT, albeit at different rates in different patients. Jenkins et al 
observed that such decay in dialyser/filter membranes occur in a biphasic manner. A large 
exponential decay occurs in the first 1 – 6 h of use followed by a more gradual decay > 6 h. 
Polysulphone filters were the most permeable upon initiation of use but showed the most 
pronounced early and late permeability decay. Both polyamide and polyacrylonitrile 
membranes exhibited minimal permeability degeneration after a brief exponential reduction 
in hydraulic permeability.175  
 
Overall, both the choice of CRRT modality, vascular access catheter and 
haemodialyser/haemofilter membrane is generally empirical based on what is available on-
site rather than what is most appropriate in accordance with patients’ individual medical 
conditions. With greater understanding of the relative blood de-uraemisation and 
homeostatic effects of various forms of CRRT as well as that of other forms of ARRT, it may 




2. 1. 3. Machines and Solutions 
Modern CRRT machines can be divided into two main categories: (1) fluid-bag 
based system (Figure 13) and (2) on-line system. Fluid-bag based systems such as the 
Prisma (Figure 14) use proprietary solutions such as Hemosol BO (Gambro, Stockholm, 
Sweden) for use either as dialysate and/or haemofiltration replacement fluid (Figure 17). 
The purity of these solutions is assured by the manufacturer. However, supplemental 
potassium and/or phosphate ions may need to be added into these fluid bags as clinically 
indicated.165-166 In contrast, on-line systems such as the ArRT plus system (Fresenius 
Medical Care, Bad Homburg, Germany) produce infusion-quality dialysate and/or 
haemofiltration replacement fluids continuously on a real-time basis from tap water. Tap 
water is first converted to reverse osmosis (RO) water first before further processing to yield 
the final solutions containing pre-specified electrolyte concentrations and pH. The on-line 
system is able to support high-intensity RRT without incurring a space penalty whereas the 
fluid-bag based CRRT systems, especially if used in high-intensity RRT protocols, require 
storage space for the bulky fluid bags. On-line systems, however, need regular maintenance 
and tests of water purity in accordance with manufacturer’s machine maintenance 
schedule.167-169 What is common for both systems is the need for roller pumps to effect 
movement of various fluids within their own respective fluid patways of the circuit. However, 
calibration errors in these roller pumps exist.162-163 Another common feature of all modern 
CRRT machines is the reliance on a central microprocessor to integrate and coordinate the 
functions of multiple roller pumps in each machine. The same computerised system 
provides real-time circuit pressure readouts (Figure 15). These multi-point circuit pressure 
measurements displayed real-time may facilitate troubleshooting should circuit dysfunction 
occur while the system is in use.163-164 Machine choice is presently based entirely on what is 
available on-site. More data on the relative therapeutic and adverse effects of both systems 
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may in future encourage greater individualisation of therapy and choice of systems in 





































2. 1. 4. CRRT Circuit Surveillance 
Given that continuous circuit function is central to the dialytic advantage CRRT has 
over IHD, it is imperative to ensure continuous circuit function and patency. Circuit 
monitoring is thus important to allow troubleshooting and intervention to prevent abrupt and 
total circuit thromboses. To this end, most CRRT machines provide real-time readings of 
transmembrane pressures (TMP), arterial and venous pressures as well as effluent fluid 
pathway pressures (Figure 15). Such real-time pressure readings enable catheter 
malfunction to be distinguished from problems arising in the main blood circuit per se.163-164 
However, the diagnostic and predictive value of these multi-point circuit pressure 
measurements are not certain although such information would be of practical importance. It 
is now known that frequent circuit “downtimes” leads to inadequate dialysis with CRRT.170  
 
 
2. 1. 5. Circuit Patency I: Anticoagulatory Factors 
Anticoagulation in CRRT is the principal means of ensuring blood circuit longevity. 
Several pharmacological agents can be used for this purpose. These include low molecular 
weight heparin (LMWH), prostacyclin, citrate and nafamostat mesylate.180-182 Each of these 
is associated with different complications. For example, metabolic alkalosis and 
hypocalcaemia may arise with citrate anticoagulation. Heparin per se may be associated 
with thrombocytopaenia (HITS or heparin-induced thrombocytopaenic syndrome).183 Apart 
from its use in systemic anticoagulation, heparin anticoagulant can also be administered 
regionally.184  Protamine sulphate is used to reverse intra-filter/dialyser heparinisation. Other 
workers have studied heparin-bonded filters in further attempts to minimise complications 
associated with systemic anticoagulation.185 Moreover, the standard laboratory measures of 
anticoagulation such as prothrombin time (PT) and activated partial thromboplastin time 
(aPTT) do not correlate with circuit life. They provide a means of determining the adequacy 
of heparin anticoagulation. However, they offer little prognostic value in terms of predicting 
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impending circuit failure. It was for this reason that thromboelastography (TEG), which 
records the actual process of clot formation, was studied to see if TEG-derived variables 
were more useful in facilitating clinical circuit management (Chapter 5.2).  
 
 
2. 1. 6. Circuit Patency II: Physico-Mechanical Factors 
Another category of factors that determine circuit longevity are physico-
mechanical/non-anticoagulatory in nature. This category includes factors such as circuit 
physical design, haemofilter/haemodialyser geometry and dialysis catheter design, 
configuration and site of placement. Manipulation of these factors has the theoretical 
advantage of not significantly increasing the risk of bleeding systemically. Furthermore, 
circuit life may be potentially prolonged with this approach.186 To test this hypothesis, a 
series of three separate studies were done comparing: two different surface areas of 
haemofilter made of the same membrane material, two different haemofilter geometries 
(flat-plate versus hollow-fibre) and two different approaches to physical administration of 
heparin anticoagulant into the circuit (chapter 4.1). Vascular access dialysis catheters are 
also vital in determining the performance of CRRT circuits. Given the different proprietary 
catheters available, more objective data are needed to guide their selection for use. Blood 
flow resistivity may differ among different catheters. This in turn has a potential bearing on 
catheter and circuit patency and longevity. This formed the rationale for the ex-vivo catheter 
study (Chapter 4.2).  
 
 
2. 1. 7. Other Metabolic Effects of CRRT 
The use of antimicrobials is a common practice in ICU patients. The 
pharmacokinetics and pharmacodynamics of each of these and other drugs in patients 
being treated with CRRT need to be more fully understood. This facilitates more rational 
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drug selection and drug dosing decisions.194 CRRT also has different clearances of 
circulating catecholamines and hormones and these can in turn impact on the course and 
management of critically ill patients.95 Many such ICU patients require intensive nutritional 
support. One of the concerns with such an approach is the potential to exacerbate fluid 
overload and azotaemia in those with concomitant ARF. A study of amino acid clearance 
and nitrogen balance in such patients undergoing CVVHDF was thus carried out to 
determine if there are grounds for such concerns (Chapter 3.4).  
 
 
2. 1. 8. Clinical Impact 
It has been increasingly recognised that CRRT has to be started as soon as possible 
where local resources permit. Gettings et al in a series of trauma patients with severe ARF 
observed that those treated earlier based on lower blood urea nitrogen (BUN) levels at the 
start had better survival rates than those in whom RRT was started later as evidenced by 
higher BUN values at baseline.150 Another view that is supported by a recent prospective 
RCT is that higher intensity RRT or higher ultrafiltration rates in CVVH is associated with 
better patient outcome, all other confounding factors being comparable.151 Thus, the 
consensus is that patients with severe renal failure in the ICU ought to be treated with RRT 
(preferably CRRT such as CVVH) as early as local resources allow and at a high enough 
intensity to make a difference to outcome. Table 2 lists the indications for CRRT in severe 
renal failure based on consensus. A study of ARF in cardiac surgery patients addressed 
both questions of intensity and timing of initiation of CVVH. The results of this study are in 







Potential indications for CRRT in the ICU.  The presence of one of the criteria below 
is sufficient grounds for considering the initiation of CRRT. Two of these make CRRT 
highly desirable.  Combined disorders suggest the need for initiation even before the 
mentioned ‘limits’ of each criterion has been reached.  
 
 
1 Nonobstructive oliguria (urine output < 200 ml/12 h) or anuria 
2 Severe acidaemia (pH < 7.1) due to metabolic acidosis 
3 Azotaemia (blood urea > 30 mmol/L) or (blood urea nitrogen > 100 mg/dl) 
4 Hyperkalaemia (plasma K+ > 6.5 mmol/L or rapidly raising K+)1 
5 Suspected uraemic organ involvement (pericarditis, encephalopathy, neuropathy, 
myopathy) 
6 Progressive severe dysnatraemia (Na+ > 160 or < 115 mmol/L) 
7 Hyperthermia (core temperature > 39.5o C) 
8 Clinically significant organ oedema (especially lung) 
9 Overdose with dialysable drug 
10 Coagulopathy requiring large amounts of blood products in patients with or at risk 




 Intermittent haemodialysis removes potassium more efficiently.  However, if CRRT 
   is started early enough, hyperkalaemia is easily controlled. 
 
2
 For example, a fulminant liver failure patient with ARDS, an INR of 3 and 
  spontaneous epistaxis.  Unless volume is rapidly removed, the patient is likely to 









CRRT-Derived Blood Purification Techniques 
 Basic CRRT technology has been used to derive techniques to treat non-renal 
conditions. This chapter highlights some of these non-renal clinical applications.  
Development in this area has paralleled increasing knowledge about the biology of various 
immune-mediated conditions including severe sepsis and specific multi-organ, inflammatory 
diseases such as systemic lupus erythematosus (SLE) and systemic vasculitis. CRRT-
derived techniques can remove blood-borne humoral disease mediators from the 
intravascular compartment. This is termed “blood purification”. Its aim is to complement 
standard pharmacological treatment to ameliorate the course and intensity of diseases. The 
following three CRRT-based, non-renal blood detoxification techniques will be highlighted to 
illustrate the core utility of CRRT as a base technology: (1) High-volume haemofiltration 















2. 2. 1. High-Volume Haemofiltration (HVHF) 
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 Continuous venovenous haemofiltration (CVVH) can be used for two main 
indications, depending on the ultrafiltration rate (UFR).  Its use to treat established severe 
renal failure refractory to medical treatment has been discussed in Chapter 2.1. This is 
termed “renal-dose” CVVH and usually operates at an UFR of < 6 L/h. It functions as an 
artificial kidney to eliminate uraemic toxins. In contrast, in order to prevent the development 
of MOF/ARF, CVVH can be used in an intermittent, “pulsed” fashion at a “sepsis-dose” of   
6 L/h. This is also termed high-volume haemofiltration (HVHF). The objective is to attenuate 
systemic hypercytokinaemia so that severe sepsis does not evolve into MOF, accompanied 
by ARF (Figures 18 and 19). It can be observed from Figure 19 that synthetic membranes 
used in CRRT in general have pore-size cut-off ranges similar to the molecular weight (MW) 
ranges of cytokines. Thus, CRRT such as CVVH can be used to eliminate cytokines from 
the blood circulation through convection. Early HVHF studies using 6 L/h failed to 
demonstrate a survival benefit although haemodynamic benefits were observed, as reported 
by Bellomo et al. Honore et al in a more recent study showed that short-termed HVHF 
(STHVHF) was beneficial. Isovolaemic STHVHF was carried out over a 4 h period per 
treatment session achieving a total UF of 35 L during each session. A total of 20 patients 
with severe intractable circulatory failure secondary to severe sepsis were studied. Following 
a single session of STHVHF, conventional renal-dose CVVH was continued for the 
treatment of ARF and this was continued for a further 4 days at least. Patients were 
considered to be haemodynamic-responders (n=11) if the following criteria were fulfilled: (1) 
 50% increase in cardiac index after 2 h of HVHF, (2)  25% increase in mixed venous 
oxygen saturation after 2 h of HVHF, (3) increase in arterial pH to > 7.3 after 4 h of HVHF, 
and (4)  50% reduction in adrenaline dose after 4 h of HVHF. The others who did not fulfil 
these 4 criteria were considered haemodynamic non-responders (n=9). APACHE II and 
SAPS II scores at baseline were similar in both groups of patients. The 28-day patient 
survival was better in the STHVHF-responders than in the non-responder group.198 Although 
this study suggests that STHVHF is haemodynamically beneficial and that there is a 
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favourable effect on 28-day patient survival, it remains an experimental therapy for sepsis 
immunomodulation. HVHF is technically demanding and costly. Ultimately, a prospective, 
randomised, controlled trial (RCT) is needed to determine if HVHF is truly disease-modifying 


























































2. 2. 2. Membrane Plasma Filtration (PF) 
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 Another blood purification technique is therapeutic plasma exchange (TPE). Plasma 
contains an array of different humoral disease mediators of varying molecular weight (MW) 
ranges. Some of these belong to the higher MW ranges and include antigen-antibody 
complexes, autoantibodies and large antigen multimers in immunological/rheumatological 
conditions. Plasma can be separated from whole blood in two main ways: (1) centrifugation 
(CF) using apheresis machines and (2) membrane plasma filtration (PF) using standard 
CRRT/HD machines (Figure 20). Whichever method is used, the principle is to discard the 
plasma, thus achieving a reduction in the concentrations of circulating disease mediators. 
However, due to the nondiscriminatory nature of plasma separation, physiological 
substances such as clotting factors and albumin are also removed and thus need to be 
replaced. Plasma substitution fluids such as fresh frozen plasma (FFP) and pooled human 
albumin are used for this. Inherent with TPE, irrespective of technique, is therefore the risk 
of infectious disease transmission and hypersensitivity reactions given the identical need for 
such plasma replacement fluids. Fundamentally, however, PF involves the use of plasma 
filter membranes in contrast to CF. PF membranes have very high MW cut-offs, thus 
allowing extremely large mediators to be filtered. What remains uncertain for individual 
diseases is which mechanism of disease attenuation is more important when TPE is used: 
removing disease mediators through plasma separation and/or the replenishment of 
naturally occurring disease-inhibitors that are found in FFP. Moreover, the immunogenicity 
of plasma filter membranes per se is also uncertain. To illustrate the controversial role of 
TPE as a complementary treatment modality, its place in sepsis treatment was examined in 
a clinical trial by Reeves et al.xxx This Australian study failed to show any significant benefit 
of continuous PF in the treatment of severe sepsis.  However, a more recent series by 
Stegmayr et al showed that centrifugation TPE may be useful.  A total of 76 consecutive 
patients with progressive disseminated intravascular coagulation (DIVC) and MOF, including 
ARF, were treated with centrifugation TPE as rescue therapy, including 66% of them who 
received dialytic therapy for concomitant ARF. Survival rate was 82% of TPE treated 
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patients. This was significantly better than survival in a similar group of historical controls in 










































2. 2. 3. Coupled Plasma Filtration-Adsorption (CPFA) 
 Straight plasma filtration-separation requires large volumes of replacement fluid in 
the form of FFP and albumin, especially if performed at frequent intervals and/or in 
continuous mode. To overcome this inherent limitation, the use of sorbents was explored to 
obviate the need for such plasma substitution fluids and to enhance selectivity of mediator 
removal. Basic CRRT circuitry used for membrane PF was modified to allow interposition of 
a sorbent cartridge post-plasma filter. Filtered plasma is pumped through this sorbent 
canister which is constituted by activated charcoal granules. Post-cartridge plasma is then 
returned back to the main blood circuit post-plasma filter (Figure 21). This technique is 
called coupled plasma filtration-adsorption (CPFA). Some newer CRRT machines have 
already incorporated CPFA into their therapeutic capability. Ronco et al showed its potential 
use in clinical sepsis. In a pilot, prospective, cross-over clinical trial, 10 patients with 
hyperdynamic septic shock were recruited. The patients were randomised to receive either 
10 h of CPFA + haemodialysis (HD) (Treatment A) or CVVHDF (Treatment B). Mean arterial 
pressure (MAP) increased by 11.8 mmHg with Treatment A and by 5.5 mmHg with 
Treatment B (p=0.001). This was associated with an average reduction in noradrenaline 
requirement by 0.08 mcg/kg/min with Treatment A and by 0.0049 mcg/kg/min with 
Treatment B (p=0.003).  Further data showed that spontaneous and lipopolysaccharide 
(LPS)-induced tumour necrosis factor (TNF)-alpha production from the patients’ whole blood 
increased over time with Treatment A suggesting that the immunoparalytic effect of septic 
plasma was attenuated with Treatment A. This observation is most likely due to the 
restoration of leucocyte responsiveness to LPS following treatment with CPFA + HD.200 More 
data are still needed to fully understand both the clinical effects and potential adverse 








P: Pre-plasma filter venous blood entering the blood circuit via central vein 
h: Heparin anticoagulant administration pre-plasma filter 
Pf: Plasma effluent filtered from whole blood as it passages plasma filter 
A: Activated charcoal cartridge through which filtered plasma effluent is pumped 
D: Post-charcoal cartridge plasma is returned back to blood path and dialysed before 
returning back to the same vein 
DI: Dialysate entry into dialyser D 
DO: Dialysate exit from dialyser D 










Aims of CRRT Thesis 
 This is a thesis on CRRT as a therapeutic tool in critically ill patients with severe 
renal failure. The work contained in it spans Chapters 3 to 6. This chapter consolidates the 
hypotheses and objectives of the individual work comprising the thesis.  
 
 Chapter 3 is about the biochemical effects of CRRT. To further understand the 
relative dialytic efficacy of IHD versus CRRT, their calcaemic and phosphataemic effects 
were compared. It was hypothesised that CVVHDF would achieve more optimal control of 
these two electrolytes (Chapter 3.1). To understand and distinguish electrolyte 
derangements due to severe renal failure per se from those due to RRT, a study of whether 
the handling of electrolytes by CVVH was affected by the choice of buffer used in 
haemofiltration (HF) replacement fluids (lactate versus bicarbonate) was performed 
(Chapter 3.3). Metabolic acidosis is a known complication of ARF. Medical and dialytic 
treatment options exist. However, the manner by which CVVH achieves acid-base regulation 
based on the nature of the buffer used in HF substitution fluids, is unknown. We therefore 
conducted a prospective, randomised, double cross-over comparison of lactate- versus 
bicarbonate-buffered replacement fluids used in CVVH and their effects on acid-base 
homeostasis (Chapter 3.2). We hypothesised that lactate-buffered HF substitution fluids 
may induce or exacerbate acidosis but not bicarbonate-based HF fluids. Many ICU patients 
are catabolic and would benefit from intensive nutritional support. However, in those with 
concomitant ARF, there is the concern that such treatment may exacerbate fluid overload 
and/or azotaemia, especially if they are on intermittent RRT. Therefore, a study was 
performed in ICU patients with ARF treated with CVVHDF and intensive nutritional regimen 
to examine if this notion was valid (Chapter 3.4). The hypothesis is that CVVHDF allows 
such a regimen to be implemented without the adverse effects alluded to.  
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 Chapter 4 -- CRRT Technique I is focussed on the physico-mechanical or non-
anticoagulatory factors that determine circuit functional longevity. We have reviewed this 
subject and have noted that frequent circuit disruptions degrade the overall dialytic efficacy 
of CRRT. Moreover, it is potentially advantageous if these factors can be exploited to 
prolong circuit longevity since these do not increase the overall bleeding risk generally. It is 
known that the central venous dialysis catheter is the Achilles heel of EC longevity. 
However, there is paucity of data guiding the selection of proprietary catheters for use in 
patients. One possible dynamic parameter is blood flow resistivity. The hypothesis is that the 
higher this value is, the more easily the catheter potentially clots. Blood flow resistivity was 
thus studied in various brands of catheters under standard experimental conditions (Chapter 
4.2). Apart from the dialysis catheter, the main EC is the other area of concern that may 
potentially be modified to achieve a longer functional lifespan. We thus analysed in three 
separate studies the effect of a larger surface area haemofilter, a different site of heparin 
administration in the EC and a different haemofilter configuration on circuit longevity 
(Chapter 4.1). The hypotheses for these three studies were that a larger surface area 
haemofilter would take a longer time to clot and would therefore last longer, flat-plate 
haemofilters would be expected to last longer given its expected lower intrinsic blood-flow 
resistivity compared to hollow-fibre ones, and finally direct administration of heparin 
anticoagulant into the air-bubble trap would be expected to be associated with a longer 
overall circuit lifespan given that this is the most thrombogenic site in the EC. Apart from 
circuit thromboses, blood abnormalities can occur in the course of CRRT in ARF. Preformed 
cellular elements of circulating blood such as leucocytes, erythrocytes and platelets can 
undergo qualitative and/or quantitative changes. Changes in platelet count are often 
ascribed to the underlying critical illness complex. The effect of CRRT on platelet count is 
less well-defined. We therefore conducted a study to determine if the haemofilter membrane 
used in CVVH has a direct and independent effect on platelet count (Chapter 4.3). Such 
data can help the clinician to interpret derangements in platelet counts in these patients.  
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 Chapter 5 – CRRT Technique II is concerned with the anticoagulatory arm of 
ensuring circuit patency, a mainstay measure. However, rather than study what 
anticoagulants to use and how to use them, we decided to pay attention to alternative issues 
of equal importance. We asked the question whether CRRT could be undertaken in patients 
not receiving any anticoagulants at all (Chapter 5.1). Given that this is done anecdotally in 
practice, we analysed a series of circuits to examine the circumstances under which 
anticoagulantion for CRRT could be omitted. The other issue relates to the monitoring of 
adequacy and intensity of CRRT anticoagulation. We have observed that conventional 
measures of anticoagulation such as PT and aPTT do not predict whether the EC is about 
to clot but merely indicates when anticoagulation is contraindicated especially if the safety 
limit is exceeded. We thus used a non-conventional measure of anticoagulation, 
thromboelastography (TEG), to determine if TEG-derived variables by their direct physical 
measurement of actual clot formation, may provide more accurate correlation between 
degree of anticoagulation and circuit lifespan (Chapter 5.2). Our hypothesis was that TEG 
would indeed be able to do so since it measures the clot formation process directly.  
 
 Chapter 6 deals with the clinical impact of CRRT use. The use of CRRT as with 
other forms of therapeutic tools is often subjugated by other medical, logistical or resource 
constraints that may not necessarily be in the patients’ interest. This chapter therefore 
restores the focus of this work back to the critically ill ICU patient. How soon should CRRT,  
or RRT in general, be used and at what level of intensity should its use be? We analysed 
the observed patient outcome and compared that with predicted values to see if the 
prevailing practice of treating cardiosurgical ARF patients with CVVH was both timely and 
adequate (Chapter 6.1). Having the answers to the twin questions of timing and intensity 




Chapter 3   
Biochemical Effects of CRRT 
 CRRT can be used for both renal and non-renal indications. This thesis is concerned 
with CRRT as a therapeutic tool for severe renal failure. In evaluating its dialytic efficacy 
versus that of IHD and other intermittent forms of RRT, comparisons can be made at 
different levels: biochemical, physiological and clinical. CRRT exerts profound biochemical 
changes in severe renal failure, restoring some parameters back to near normal ranges but 
inducing derangements in others, depending on RRT-related factors as well as patient 
factors such as nutritional support. Specific biochemical indices include acid-base, fluid 
status, and electrolyte concentrations. The aim of this chapter is thus to elaborate the four 
studies that were undertaken to further elucidate the effects of CRRT on acid-base 
regulation, electrolyte control and amino acid/nitrogen balance. Chapter 3.1 attempts to 
define and compare dialytic adequacy in terms of calcaemic and phosphataemic control in 
critically ill patients treated with either IHD or CVVHDF exclusively. Data from this 
comparative study would enable individualisation of RRT depending on patients’ condition 
as well as highlight potential electrolyte disorders that may arise with each of these 
modalities. CVVH performed using fluid-bag based machines utilise proprietary HF 
substitution fluids which are either lactate- or bicarbonate-buffered. The relative effects of 
these two types of fluids on acid-base status were examined and practical implications of its 
findings explained (Chapter 3.2). The two different buffers can also potentially influence the 
kinetics of blood-to-effluent solute movement during CVVH. Such data enables electrolyte 
disorders due to disease to be distinguished from that due to CRRT when it is being 
performed in these patients (Chapter 3.3). Last but not least, given that many critically ill 
patients are also catabolic, nutritional support is an important aspect of therapy. However, 
intensive nutritional support potentially exacerbates fluid overload, electrolyte disorders and 
azotaemia, especially if the patient is on intermittent RRT for ARF. The effect of CVVHDF 
on nitrogen balance and individual amino acid clearances and serum concentrations, are 
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analysed. The notion that intensive nutritional regimens are harmful in ICU ARF patients is 



























Chapter 3.1  
Ionised serum calcium and phosphate levels during acute renal failure: Intermittent 
Haemodialysis versus Continuous Haemodiafiltration  
 
Introduction 
Acute renal failure (ARF) in the critically ill patient is still associated with a poor 
prognosis and, in the absence of randomised controlled trials, there is much controversy 
about which renal replacement therapy should be used.201-204 It has been suggested that 
IHD and CRRT such as CVVHDF can be compared in terms of the  “adequacy of dialysis” 
they deliver.205 The importance of providing such “adequacy of dialysis” is supported by 
recent evidence suggesting that better uraemic control may improve outcome.206 On the 
other hand, the concept of dialytic adequacy does not solely relate to azotaemic control. It 
should logically include other aspects of therapy such as haemodynamic stability, volume 
control, acid-base homeostasis, and the ability to deliver full nutritional support.205 Last but 
not least, it should include the effects of renal replacement therapy (RRT) on serum ionised 
calcium and phosphate concentrations. We hypothesised that IHD and CVVHDF would 
affect ionised serum calcium and phosphate concentrations differently and that CVVHDF 
would be a superior homeostatic tool compared with IHD. Accordingly, we conducted a 
comparative study in consecutive critically ill patients with ARF and now report our findings.  
 
 
Materials and Methods 
 This study is a retrospective cohort study. Forty-four critically ill patients with acute 
renal failure (ARF) treated with intermittent haemodialysis (IHD) in the intensive care unit 
(ICU) were studied. During this period, IHD was used as the only treatment for ARF in the 
ICU. These patients were compared to a further 44 similar consecutive patients treated with 
continuous veno-venous haemodiafiltration (CVVHDF) after a change of unit policy to the 
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exclusive use of CVVHDF as renal support in the ICU. All patient records were reviewed to 
obtain demographic data, details of initial clinical presentation and biochemical data. For all 
patients, APACHE II 207 scores on admission and organ failure scores 208 at the time of 
initiation of renal replacement therapy were obtained. At the same time, daily morning 
biochemical measurements for the first fourteen days of treatment (on morning blood 
samples taken from patients for routine biochemical monitoring in the ICU) were retrieved 
from the computerised records of the Biochemistry Department. The focus of our data 
collection was the morning ionised serum calcium and phosphate concentrations. The 
reference ranges used by the laboratory for ionised calcium was 1.13 to 1.32 mmol/L and 
that for serum phosphate was 0.60 to 1.40 mmol/L. The Institutional Review Board waived 
the need for informed consent for this retrospective anonymous and confidential review of 
medical records.  
 
 
Description of IHD Technique 
 IHD was applied according to the prescription of the attending nephrologist and was 
the only form of treatment available for ARF during the first part of the treatment period 
under study.  The nephrology team reviewed all patients at least once a day. This team 
included a consultant nephrologist, a nephrology fellow, a resident and a dialysis nurse. 
Intermittent haemodialysis was prescribed according to the following principles: 
(1) Prevent hyperkalaemia (K < 6.0 mmol/L) 
(2) Prevent fluid overload 
(3) Avoid severe acidosis (pH < 7.2) 
(4) Maintain plasma urea level at least < 35 mmol/L and, if possible, < 30 mmol/L most 
of the time. 
(5) Avoid haemodynamic side effects of dialysis 
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In general, haemodialysis was performed 3 to 4 times per week for periods of 3 to 4 
hours per treatment session, according to the dialysis prescription. Vascular access was via 
double-lumen catheters or Scribner shunts. Blood flow was maintained between 200-300 
ml/min as allowed by the catheter and dialysate flow rate was kept at 400 ml/min.  Dialyser 
surface area was variable and was adjusted to patient body size. Anticoagulation was 
achieved with heparin and occasionally omitted completely given the high bleeding risk of 
some patients. Most patients (n=32) were dialysed using bicarbonate-based dialysate. 
Acetate was used in close to 30% of patients (n=12). The calcium concentration in the 




Description of CVVHDF Technique 
 CVVHDF was the sole CRRT modality throughout the second part of the study 
period due to a change of unit policy. CVVHDF was initiated and maintained by the 
intensivists and critical care nurses. Vascular access was obtained by insertion of a double 
lumen central venous catheter. Blood flow was maintained at 150 ml/min. Dialysate (Dianeal 
1.5%, Baxter, Sydney, Australia) flow rate was maintained at 1 L/h. Calcium concentration in 
this dialysate is 1.60 mmol/L (Table 5). When clinically indicated, the dialysate flow rate was 
increased to 1.5 to 2 L/h (in the case of one patient) in order to increase azotaemic control. 
Fluid replacement was administered at a rate determined by the spontaneous ultrafiltration 
rate (approximately 700 ml/h on average) and by frequent clinical assessment of the 
patients' fluid status.  
 
In most cases, the extracorporeal circuit required anticoagulation to prolong filter 
lifespan. Typically, this was achieved with low dose pre-filter heparin (500 IU/h) or with 
regional anticoagulation (full-dose pre-filter heparin with protamine reversal post-filter). Filter 
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and patient aPTT were measured every 6-8 hours and adjustments to the anticoagulation 
regime made accordingly. Anticoagulation was omitted altogether in patients at high risk of 
bleeding. Haemofilters were changed if clotting occurred or if the net ultrafiltration rate 




Summary descriptive statistics are presented as means ± SEM (standard error of the 
mean). When data were not normally distributed, comparisons were performed using the 
Mann-Whitney test, when normally distributed, comparisons were performed using Student’s 
t-test.  The Friedman's test (non-parametric analysis of variance) was used to determine if 
there was a significant change in the concentration of ionised calcium and serum 
phosphate, which occurred during the course of renal replacement therapy in each 
treatment group. Post-hoc comparison of such changes, if detected, was performed using 
the Wilcoxon signed-rank test adjusted for multiple comparisons. Finally, Fisher’s exact test 
was applied to determine if there was a significant difference in the incidence of abnormal 
(low or high or both) levels of ionised serum calcium and phosphate in either group. The 
StatView™ (Abacus Concepts Inc, Berkeley, CA) statistical package was used for the above 




 Eighty-eight patients were studied (44 treated with IHD and 44 treated with 
CVVHDF). The individual patient diagnoses are listed in Table 3. The two cohorts were 
similar in age and number of failing organs prior to commencement of renal replacement 
therapy. However, according to APACHE II scores, patients treated with CVVHDF were 
more severely ill than the IHD group (IHD: 24.4 ± 5.1 vs. CVVHDF: 29.2 ± 5.7; p<0.003) 
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(Table 4). The two groups were otherwise similar in terms of treatment with inotropic drugs 
and mechanical ventilation. Both cohorts of patients also had similar incidences of 
bacteraemia and fungaemia.  
 
The changes in morning mean ionised serum calcium concentration during therapy 
are presented in Figure 22.  The serum ionised calcium concentration was frequently 
abnormal before treatment in both groups: 51.6% for IHD and 68% for CRRT (NS). Despite 
treatment, the ionised calcium concentration remained abnormal in 51% of observations 
during IHD and 50.2% of those during CVVHDF. However, abnormal values had a different 
pattern with the different therapies. During IHD, hypercalcaemia was more common (36.1% 
of observations for IHD vs 25.6% for CVVHDF; p<0.019), while during CVVHDF, 
hypocalcaemia was more frequent (24.5% of observations for CVVHDF vs. 14.9% for IHD; 
p<0.011). 
 
Before treatment, both groups had a high incidence of abnormal phosphate 
concentrations: 79.4% for IHD and 64.8% for CVVHDF (NS) with hyperphosphataemia 
being most common (65.1% for IHD vs. 63.2% for CVVHDF) (Figure 23). Compared with 
IHD, however, CVVHDF showed a stronger tendency to lower the mean daily serum 
phosphate concentrations (Friedman’s test for effect over time: p<0.0001 for CVVHDF vs. 
p=0.0104 for IHD; see Figure 23). CVVHDF was also more effective in rapidly reducing the 
mean serum phosphate concentration within the first 48 hours of therapy (p<0.02). In 
addition to lowering the serum phosphate concentration more rapidly, CVVHDF was more 
likely to achieve a serum phosphate within the normal range than IHD (63.8% vs. 54.7%; 
p<0.0001) during the treatment period. However, this beneficial effect of CVVHDF was 





 The dialytic management of ARF over the last decade has been characterised by the 
predominant use of either intermittent haemodialysis (IHD) or continuous renal replacement 
therapies (CRRT) 203,205 and by controversy over their use.209 The effect of these two types 
of RRT on mortality has not yet been compared in a randomised controlled study of suitable 
statistical power, therefore comparisons using surrogate markers have been used. One 
important surrogate marker of dialytic efficiency and safety is “adequacy of dialysis”.205-206 
This concept encompasses the effect of RRT on azotaemia, volume status, acid-base 
homeostasis, nutritional support and haemodynamic stability. Normalisation of serum 
ionised calcium and phosphate concentrations would be another significant component of 
this conceptual framework. However, the differential effect of acute IHD or CRRT on serum 
ionised calcium and phosphate levels has not yet been examined.    
 
 Biologically, calcium has important functions with concentrations regulated within a 
finite range. Abnormalities of serum ionised calcium levels may be associated with subtle 
but important adverse effects in patients with ARF. For example, calcium appears to have a 
central role in the pathogenesis of acute renal failure.210 Experimentally a low-calcium 
environment or the use of calcium channel antagonists protects the tubules from renal 
injury, while a high calcium environment promotes tubular injury.210-211 Such effects of high 
serum calcium on tubular injury may be clinically significant and contribute to the 
aggravation or progression of renal injury.212 Accordingly, the correction of hypercalcaemia 
may be biologically important.  Conversely, hypocalcaemia is known to complicate critical 
illness in general and in ARF. For example, hypocalcaemic tetany induced by 
hyperphosphataemia has been reported in ARF 213 and close to 50% of critically ill patients 
may have hypocalcaemia.214 Correction of such hypocalcaemia results in a significant and 
sustained improvement in blood pressure and left ventricular stroke work index.214    
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Disorders of serum phosphate are also common during ARF because phosphate 
retention is an inevitable consequence of loss of GFR.218-219 Hyperphosphataemia has 
several important adverse effects. If extreme, it can induce renal failure by precipitating the 
deposition of calcium phosphate in the renal parenchyma and other organs 220 or tetany by 
lowering serum calcium 221 or severe anion gap metabolic acidosis.222 Even if mild or 
moderate, it causes resistance to the calcaemic action of PTH and contributes to the 
preservation of hypocalcaemia.223 Furthermore, experimental evidence suggests that it may 
contribute to the development of histological and functional injury in acute renal failure, while 
mild phosphate depletion may be protective to the kidney.224-225 In end-stage renal disease 
(ESRD) patients, hyperphosphataemia may be linked to the calcification of coronary arteries 
and to haemodynamic disturbances.226-228 The significance of these observations for 
patients with ARF is unknown. However, taken in their aggregate these observations 
suggest that correction of hyperphosphataemia may be clinically important. 
 
 Because of the potential adverse effects of disorders of calcaemia, an ideal dialytic 
technique should rapidly and reliably correct such disorders. Unfortunately, as demonstrated 
in this study, both IHD and CVVHDF fall short of such therapeutic goals. However, they do 
so in a different way. They both fail to correct disorders of calcaemia during approximately 
half of the time with IHD being more commonly associated with hypercalcaemia and 
CVVHDF with hypocalcaemia. The full explanation for such differences is unclear but may 
derive, in part, from the use of a relatively high concentration of calcium in the dialysate 
during IHD (dialysate calcium concentration range: 1.50 – 1.75 mmol/L) in our patients, and 
the well-known tendency to lose calcium via convective mechanisms during CVVHDF.215 
This observed difference in incidence of hypercalcaemia and hypocalcaemia in IHD and 
CVVHDF treated patients, respectively, cannot be ascribed completely to the difference in 
dialysate calcium between IHD and CVVHDF (Dianeal ® calcium concentration is fixed at 
1.60 mmol/L). Patient factors such as nature of critical illness may be partly responsible 
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especially given that CVVHDF patients were more critically ill than IHD patients, based on 
their significantly different APACHE II scores. Another weakness of this study is the lack of 
uniformity in dialysate calcium concentration for both IHD and CVVHDF. Having the same 
dialysate calcium concentration for both RRT modalities theoretically and potentially 
removes a confounding factor and renders the subsequent interpretation of the resultant 
differences in serum ionised calcium concentrations more meaningful. 
 
Similarly, hypophosphataemia can also have serious adverse effects, which include 
encephalopathy,229 and decreased myocardial performance.230 In the ICU, 
hypophosphataemia may be aggravated by the institution of nutrition after several days of 
lack of nutritional intake.231 Because of the potential adverse effects of hypophosphataemia, 
its correction appears desirable and can usually be achieved rapidly and safely by the 
administration of intravenous sodium phosphate.232 Similarly, an ideal dialytic technique 
should also rapidly and reliably correct disorders in serum phosphate concentrations. Our 
study demonstrated that hyperphosphataemia is common in untreated ARF patients, 
reaching an incidence above 60% before treatment. As expected, both IHD and CVVHDF 
reduced elevated serum phosphate levels, but the rate of correction differed significantly. 
CVVHDF lowered serum phosphate concentrations within the first 48 hours significantly 
more efficiently than IHD. Furthermore, the greater efficacy of CVVHDF in achieving a 
normal serum phosphate concentration was maintained throughout the duration of 
treatment. These findings suggest that CVVHDF is more effective than IHD at correcting the 
hyperphosphataemia of ARF when applied over a period of time ie it is a more physiological 
homeostatic tool than IHD. It is possible, however, that such greater efficacy of phosphate 
removal may expose patients treated with CVVHDF to a greater risk of hypophosphataemia. 
One reason for this is the absence of phosphate ions in proprietary HF dialysate/HF 
substitution fluids used in CVVHDF, such as Dianeal ®. Accordingly, daily monitoring of 
serum phosphate is important in such patients so that hypophosphataemia can be rapidly 
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treated or prevented by means of prophylactic phosphate supplementation once the serum 
phosphate returns to normal and full nutrition is being provided.  
 
This study is retrospective with all the inherent shortcomings of retrospective studies. 
However, patients in both cohorts were similar in terms of clinical features, need for 
mechanical ventilation, inotropic drug therapy, number of failing organs, and incidence of 
bacteraemia/ fungaemia. They also had similar disorders of serum ionised calcium and 
phosphate concentrations at baseline before treatment.  
 
Therefore, this comparison of the differential effects of IHD and CVVHDF on serum 
ionised calcium and phosphate concentrations are likely to reflect changes in larger 
populations. The morning concentration of serum ionised calcium and phosphate were 
chosen as representative of its serum concentrations during therapy.  Such values are 
objective, numerical and not subject to observer bias. We acknowledge that such 
concentrations are likely to fluctuate greatly. Nonetheless, there were hundreds of 
observations in the two groups, a number likely to ensure that the values used for this study 
were representative of the patterns and differences between the two forms of treatment. 
Indeed such differences emerged, were clear, had a high level of statistical significance, and 
are most unlikely to represent a type I error. Therefore, we believe that the findings of this 
investigation are broadly representative of the prevalent values during treatment. It is 
possible that, if IHD had been applied for longer period of times or more frequently, the 
results of this comparison would have been different. However, second daily dialysis as 
reported in this study remains an accepted standard of practice for ARF in the year 2000, 
even in large world-renown centres.121 Serum phosphate concentrations are influenced by 
nutritional therapy. However, there were no changes in nutritional protocols in the ICU 
during the study period. Moreover, It is also possible that different membranes would affect 
the serum ionised calcium and phosphate concentrations differently so that if biosynthetic 
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membranes had been used, IHD would have achieved different results. On the other hand, 
no clinical data is available to support this view and the choice of membrane for ARF 
patients remains contentious.121  
 
Finally, acetate was used as buffer in a third of our patients. It is argued that 
bicarbonate buffering is preferable to acetate because of evidence of better haemodynamic 
stability in patients on chronic dialysis.216 However, no randomised controlled trials have 
been performed in patients with ARF and the clinical significance of the possible 
haemodynamic benefits of bicarbonate remains unclear.217 In relation to calcaemia and 
phosphataemia, differences in metabolic effects between acetate and bicarbonate dialysate 
have never been documented and appear unlikely.233   
 
CONCLUSIONS 
In conclusion, we have described for the first time the incidence of disorders of 
ionised serum calcium and phosphate in critically ill patients with ARF and their differential 
responses to IHD and CVVHDF. Our findings demonstrate that such disorders are common 
and that they are only partly corrected by artificial renal support. If correction of these 
disorders is sought during renal replacement therapy (RRT), understanding how each form 
of RRT affects ionised calcium and phosphate concentrations should help clinicians plan 














      CVVHDF  IHD 
 
Post partum bleeding    0   2 
Pneumonia     6   4 
Pancreatitis     2   4 
Ruptured abdominal aortic aneurysm 4   4 
Haemolytic-uraemic syndrome  2   1 
Empyema     1   2 
Peritonitis     6   8 
Necrotic gall bladder    1   0 
Cellulitis     1   0 
Vasculitis     3   1 
Infarcted gut     4   4 
Endocarditis     1   2 
Meningitis     1   2 
Myeloma     1   0 
Cholesterol embolism    1   0 
Heroin overdose/rhabdomyolysis  1   0 
Urinary tract infection    3   4 
Candidaemia     2   3 
Trauma     1   3 
Massive operative bleeding   2   0 












      CVVHDF IHD  p  
__________________________________________________________________ 
 
Number of patients    44  44  - 
Mean age     54 ± 14 60 ± 14 NS 
Mean APACHE II score   29.2 ± 5.7 24.4 ± 5.1 0.003 
Number of failing organs pre-treatment 3.5 ± 1.5 4.0 ± 1.4 NS 
Inotrope therapy    35  36  NS 
Mechanical ventilation   33  35  NS 
























Table 5: Composition of commercially available lactate-based and 





* Lactate-based fluid (mmol/L) + Bicarbonate-based fluid (mmol/L) 
_________________________________________________________________________ 
 
Sodium  140     140 
Potassium  1     0 
Calcium  1.6     1.75 
Magnesium  0.8      0.5 
Chloride  100     109.5 
Glucose  10.8     0 
Lactate  46     3 
Bicarbonate  0     32 
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The acid-base effects of continuous haemofiltration with lactate or bicarbonate 




Haemofiltration appears to have a significant and variable impact on acid-base 
balance.257-260 It has been reported to either correct 251-252 or induce metabolic acidosis 100 
according to circumstances. The pathogenesis of these acid-base effects remains poorly 
understood. If commercial lactate-buffered replacement fluid is used during CVVH at 2L/h of 
plasma water exchange, patients will receive the infusion of approximately 90 mmol/h of 
exogenous lactate. This lactate load could overcome endogenous lactate metabolism (60-70 
mmol/h in healthy subjects) 252 and result in hyperlactataemia.100 Such hyperlactataemia 
may become clinically significant. If this happened, then all CVVH at such intensity may be 
best conducted with bicarbonate-buffered replacement fluids instead. Such fluids, however, 
are not widely available and are three times more expensive. Moreover, little is known about 
the specific quantitative buffer-base mass balance of CVVH with bicarbonate versus lactate 
replacement fluids. Accordingly, we conducted a randomised, controlled double-cross over 
study to specifically evaluate, compare and quantify these effects with 2 commercially 
available solutions. 
 
Materials and Methods 
Institutional approval was granted by the hospital Ethics Committee.  Informed consent was 
obtained from each patient’s next of kin. 
 
Study Design  
Eight consecutive patients with established acute renal failure and fulfilling standard criteria 
for the multi-organ dysfunction syndrome 261 were studied. Acute renal failure was defined as anuria 
for > 24 hours and a plasma urea level > 25 mmol/L and need for CVVH.  All patients had to have 
received CVVH for at least 24 hours prior to enrolment. The study patients were randomised to 
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receive either a 2-hour period of lactate-buffered CVVH (treatment A) or bicarbonate-buffered CVVH 
(treatment B). The order in which (A) or (B) was applied was random and concealed (random 
number table and sealed opaque envelopes). The first 2-hour session was followed by cross over to 
the other treatment. On the following day, the same random order cross over was performed with 
the first treatment determined in the same way.  Thus the treatment schedule on the study days for 
each patient was at random in one of the following ways: ABAB, BABA, ABBA, BAAB. Prior to the 
beginning of each 2-hour treatment session, arterial blood was obtained for baseline measurements. 
During each session, arterial blood and UF were obtained at one and two hours of operation. Blood 
and UF were drawn from the circuit using sterile syringes. The replacement fluid was then changed 
and the cycle repeated.  
 
Technique of CVVH  
Isovolaemic CVVH was performed. Vascular access was obtained with 13.5 FG dual lumen 
catheters (Niagara™, Bard, Ontario, Canada). A BMM 10-1 machine or a Prisma machine (Gambro, 
Lund, Sweden) were used with a 1.2 m2 AN69 polyacrylonitrile filter (Filtral 12, Hospal, Lyon, 
France). Blood flow was set at 180-200 ml/min, and ultrafiltrate flow was set at 2 L/h. Lactate-
buffered replacement fluid (Haemofiltration Replacement Fluid, Baxter Healthcare, Sydney, 
Australia) was delivered pre-filter at a rate controlled by either an independent volumetric pump 
(Gemini PC-2, IMED Corporation, San Diego, CA) or by the volumetric pump of the Prisma machine. 
This type of replacement fluid contains the following concentrations of ions: sodium 140 mmol/L, 
potassium 1 mmol/L, chloride 100 mmol/L, calcium 1.6 mmol/L, magnesium 0.8 mmol/L, lactate 46 
mmol/L. It also contains glucose at 10.8 mmol/L. Potassium chloride (13.4 mmol) was added to each 
5-litre bag of replacement fluid (final concentration of 3.7 mmol/L) to prevent hypokalaemia. A 
bicarbonate buffered replacement solution was administered during treatment B (Hemosol BO, 
Gambro Australia, Melbourne, Australia) This type of replacement fluid contains the following 
concentrations of ions: sodium 140 mmol/L, potassium 0 mmol/L, chloride 109.5 mmol/L, calcium 
1.75 mmol/L, magnesium 0.5 mmol/L, lactate 3 mmol/L, bicarbonate 32 mmol/L. Potassium chloride 
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(18.5 mmol) was added to this fluid to prevent hypokalaemia and achieve the same concentration of 
potassium as in the lactate-based fluid. 
 
All replacement fluids were warmed for both techniques. In both techniques, circuit 
anticoagulation was administered according to a previously described protocol.262 All fluid therapy 
not related to haemofiltration was controlled by the attending physician and remained unchanged 
during the brief study period. Nutritional fluids and medications were also continued unchanged 




Arterial blood gases and UF gases were measured (pH, carbon dioxide tension, 
oxygen tension, calculated standard bicarbonate and calculated standard base excess).  
Blood and UF fluid were drawn fresh at timed intervals from the CRRT circuit in sterile 
syringes and immediately analysed for blood gases and lactate using the ABL 30 Blood Gas 
Analyzer (Radiometer, Copenhagen, Denmark).   
 
 
Analysis of Data 
Acid-base variables concentrations were analysed separately for lactate- and 
bicarbonate-CVVH to identify whether changes had occurred over time (Friedman’s 2-way 
analysis of variance with post-hoc Wilcoxon signed rank test adjusted for the number of 
comparisons). Values for each variable at each time point for treatment A and B were 
compared using Wilcoxon signed rank test. First and second treatments (time effect 
assessment) were compared using the same statistics. Results are expressed as medians 





 The clinical and demographic features and time of study of the trial patients are 
presented in Table 6. There were a total of 8 patients (M:F=4:4; age range 39 –72). Mortality 
was 50%. Duration from the start of CVVH to the actual commencement of this study 
ranged from 1 – 9 days. Half of them had significant hyperbilirubinaemia. 
 
Lactate CVVH 
The administration of lactate CVVH induced significant changes in acid-base 
balance. The most striking change was a significant and persistent increase in plasma 
lactate concentration (Figure 24 and Table 7). This change was accompanied by a 
significant decrease in standard Base Excess (Figure 25 and Table 7) and measured serum 
bicarbonate (not standard calculated bicarbonate) (Figure 26 and Table 7) in the absence of 
changes in PaCO2, indicating the onset of a new metabolic acidosis, which resulted only in a 
non-significant trend toward a lower pH.  There were no significant changes in other 
measured variables. 
  
Bicarbonate CVVH  
Bicarbonate CVVH did not induce significant changes in any of the measured  
acid-base variables (Table 8). 
 
 
Comparison between lactate and bicarbonate CVVH 
There were no differences in acid-base variables at baseline for the two treatments. 
After CVVH was started, however, there was a significantly lower mean pH at 60 minutes 
and a lower bicarbonate, base excess and a higher lactate concentration throughout 
treatment, when lactate-based replacement fluids were used.  Bicarbonate (60 min: 
p=0.0038, 120 min: p=0.038) and base excess (60 min: p=0.0019, 120 min: p=0.034) were 
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lower and lactate was higher (60 min: p=0.0011, 120 min: p=0.010) throughout lactate 
CVVH treatment (Figures 24 to 26). There were no differences when first treatment was 
compared to second treatment (time effect).  
 
Differences in UF lactate and bicarbonate losses 
Lactate-CVVH was associated with a significantly higher steady state UF lactate 
concentration compared to bicarbonate-CVVH (10.2 [3.7] vs. 2.9 [1.0] mmol/L; p<0.0001). 
However, the mean UF bicarbonate concentration was significantly lower during lactate-
CVVH (25.6 [4.6] vs. 30.8 [7.3] mmol/L; p<0.0001). Thus, the total hourly mean buffer-base 
loss was 71.7 mEq/L during lactate-CVVH compared to 67.5 mEq/L during bicarbonate-
CVVH (p<0.0001). However, given the buffer-base content of the respective replacement 
fluids, their administration rate and the buffer-base losses in the UF, lactate-CVVH was 
associated with an hourly mean buffer-base balance of + 20.3 mEq/h compared to only + 




Our study showed that CVVH with lactate-buffered replacement fluids induced 
hyperlactataemia with a greater than 60% relative increase in blood lactate levels after 2 
hours of treatment. This is in marked contrast from bicarbonate-CVVH, which did not affect 
plasma lactate levels.  Thus, the presence of lactate in the replacement fluid appeared 
sufficient to overcome the metabolic rate of lactate. This study also found that such 
hyperlactataemia occurred despite significant lactate losses in the UF and was associated 
with a decrease in bicarbonate concentration and in BE (metabolic acidosis), even though 
buffer-base balance was significantly more positive than with bicarbonate CVVH. These 




As described, the exogenous hyperlactataemia induced by lactate-CVVH was 
associated with the development of metabolic acidosis. This observation is supported by a 
decrease in serum bicarbonate concentration in the absence of significant changes in 
PaCO2 and by a simultaneous significant decrease in standard Base Excess.263 
Furthermore, the metabolic acidosis seen in our patients after 2 hours of CVVH was similar 
in magnitude to the change in lactate concentration. These observations suggest that the 
increase in lactate concentration might have been responsible for its development. The 
underlying mechanisms responsible for this “lactic” acidosis are a matter of great 
controversy 264-271 given that lactate was administered as an exogenous “buffer”. Some 
would argue that the acidosis observed in our subjects resulted from the failure of lactate 
transformation into bicarbonate. 271 Another view holds that hyperlactataemia per se can 
induce acidosis by adding an anion (lactate) to plasma, thus increasing the dissociation of 
plasma water and the release of free hydrogen ions, which then lower the pH.264-270 It is not 
yet possible to empirically prove the correctness of any of these theories.  
 
The clinical consequences of the changes described above are unknown. Lactate 
administration is associated with increased gluconeogenesis.272-273 This suggests an effect 
on protein breakdown. In fact, recent evidence indicates that lactate itself, rather than amino 
acids, is the substrate for such gluconeogenesis.272-273 It might be more practical to use 
other poly-carbon anions such as acetate, gluconate or citrate as buffers. However, acetate 
and gluconate can also accumulate in plasma, 237,274 and a direct comparison of lactate to 
acetate-buffered haemofiltration has shown a greater degree of acidosis with acetate-
buffered replacement fluid.274 Citrate has been used as both buffer and anticoagulant during 
CRRT. However, citrate accumulation can also develop, but unlike lactate, citrate levels are 
not easily monitored. Furthermore, while it appears that lactate does not have clinically 
discernible adverse effects, citrate accumulation can lead to hypocalcaemia, decreased 
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coagulability, hypotension, conduction abnormalities, and tetany.272 Finally, Nimmo and 
colleagues reported haemodynamic stability despite hyperlactataemia 250 in a study of 12 
haemofiltered patients with acute renal failure. 
 
The use of bicarbonate-buffered replacement fluid might seem the obvious solution 
to the hyperlactataemia induced by lactate-CVVH. However, the cost of commercially 
available sterile bicarbonate solutions is approximately 3 times higher. Using bicarbonate-
buffered fluid would add approximately $125 to each day of CVVH therapy in our unit. On 
line generation of bicarbonate-buffered replacement fluid is cheaper but it is not widely 
available because it is not part of current haemofiltration machine technology and is not FDA 
approved.  
 
Our findings support the notion that CVVH with lactate-buffered replacement fluids 
induces only limited changes in pH and that the acidosis associated with lactate-CVVH is 
not progressive and is small in magnitude. However, the average baseline lactate was only 
mildly elevated in our patients. Thus, their lactate intolerance was not severe. In individual 
patients with more severe baseline hyperlactataemia (> 5 mmol/L), the changes induced by 
CVVH with lactate-buffered fluids might be more marked and clinically undesirable. For 
example, one of the study patients with a baseline lactate of 3.9 mmol/L developed a lactate 
concentration of 10.1 mmol/L at 2 hours and a change in pH from 7.48 to 7.39. The clinical 
significance of such a fall in pH remains unclear.  However, these observations suggest 
that, in selected patients, great caution should be applied and bicarbonate-buffered 
replacement fluids be used in preference. Bicarbonate use is also warranted in those 
patients with liver failure, because their ability to handle a lactate load may be markedly 
impaired and the degree of hyperlactataemia and acidaemia might, therefore, be much 
greater. Finally, the iatrogenic increases in lactate described in this paper will mask or mimic 
increases in lactate due to endogenous processes (greater level of sepsis, hypovolaemia, 
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poor cardiac output, increasing liver dysfunction) and might lead to confusion in the 
assessment of the patient’s evolving pathophysiological state. Clinicians need to be aware 
of these processes in their interpretation of the biochemical and clinical bedside data. 
 
Our investigation has limitations. It does not deal with clinical outcomes and cannot 
specify the clinical significance of the observations made. However, such observations 
might assist clinicians in understanding the nature of acid-base changes associated with 
CVVH and thereby avoid unnecessary investigations.  This biochemical and physiological 
study only deals with short-term changes. However, we reasoned that the best way to 
specifically isolate the impact of each type of buffer on CVVH-related acid-base changes 
was to conduct a short-term study of this kind. In fact, our study design enabled us to have a 
steady physiological state isolated from confounding variables. Such variables (changes in 
ventilation, clinical condition, administration of intravenous fluid boluses, change in systemic 
haemodynamics, changes in vasopressor administration, need for transport to surgery or 
radiology and the like) can easily and markedly affect the variables under study. To further 
diminish the effect of such confounding variables we performed our study in a double 
crossover manner with random assignment to one of the two forms of CVVH as the starting 
technique. The presence of changes related to the buffer but not to the order of treatment 
strongly supports the view that the type of replacement fluids themselves induced the acid-
base effects described in this study. 
 
In conclusion, we have shown that CVVH with lactate-buffered replacement fluids 
induces hyperlactataemia. Such hyperlactataemia is associated with a mild, non-progressive 
metabolic acidosis. This acidosis occurs despite a positive buffer balance suggesting that 
lactate per se is responsible for its development either as an anion or by failing to generate 
bicarbonate. Although lactate-CVVH only induced mild acid-base changes in general, 
caution should be applied in particular patients who have marked pre-treatment 
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hyperlactataemia (> 5 mmol/L) or liver dysfunction. In such patients, the application of 




























Age Sex Diagnoses SAPS-II INR Bil ALT Study    Outcome 
_____________________________________________________Point____________ 
 
61 F Liver Tx 50  1.5 217 34 2 days   Alive  
72 M VF arrest 82  1.2   20 47 7 days   Alive 
43 M Acute   70  1.1 273 41 3 days   Died 
pancreatitis 
70 F Acute  34  1.1   18 59 1 day   Died 
  pancreatitis 
59 M Liver Tx 71  1.0 297 48 9 days   Alive 
58 F Cellulitis, 35  1.4     7   5 2 days   Died 
  septic shock 
44 F Intra-  38  1.2   19   7 1 day   Died 
  abdominal  
sepsis 
39 M Liver Tx 29  0.9 253 49 9 days   Alive  
___________________________________________________________________ 
 
VF: Ventricular fibrillation; INR: Prothrombin time international normalised ratio; 
Bil: Bilirubin (ug/L); ALT: Alanine aminotransferase (U/L); Study point: Duration from  













Table 7: Acid-base physiological variables during lactate-CVVH 
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Variable Baseline 60 minutes 120 minutes 
Lac (mmol/L) 2.4 (1) 3.9 (1.4)* 3.6 (1.7)* 
PH 7.45 (.06) 7.43 (.04) 7.45 (.07) 
PaCO2 (mmHg) 39.6 (11.9) 40.9 (11.2) 40.1 (12.4) 
HCO3- (mmol/L) 28.1 (5) 26.7 (5.8)* 27.2 (5.7)* 
BE (mEq/L) 3.9 (4.6) 2.3 (4.7)* 2.9 (4.6)* 
 












Variable* Baseline 60 minutes 120 minutes 
Lac (mmol/L) 2.8 (1.7) 2.5 (1.2) 2.5 (1.5) 
PH 7.45 (.07) 7.45 (.07) 7.44 (.06) 
PaCO2 (mmHg) 41.2 (10.7) 40.9 (10.3) 41.9 (8.9) 
HCO3- (mmol/L) 28.3 (7.4) 28.3 (5.8) 28.2 (5.2) 
BE (mEq/L) 4 (7) 4.1 (4.9) 3.7 (5.8) 
 









Table 9:  Buffer Gain and Loss During Lactate and Bicarbonate CVVH 
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60 min 31.4 (4.7)  2.9 (0.6) 68.5 ( 9.0)  1.5 ( 9.0) 
 120 min 30.3 (9.0)  2.9 (1.1) 66.4 (15.9)  3.6 (15.9) 
 Mean 30.8 (7.3)  2.9 (1.0) 67.5 (14.7)  2.5 (14.7) 
 
Lac-CVVH 
60 min 25.2 (5.6) 10.7 (3.2) 71.8 ( 7.5) 20.2 ( 7.6) 
 120 min 26.0 (3.7)  9.8 (4.4) 71.6 (10.5) 20.4 (10.5) 
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Electrolyte mass balance in critically ill patients on continuous veno-venous 




Haemofiltration appears to have a significant and variable impact on the 
concentration of several electrolytes and on acid-base balance.373-378 Some of this effect is 
likely to depend on the composition of the replacement fluid. In Europe and Australia, the 
dominant commercially available replacement fluids are either lactate-buffered or 
bicarbonate-buffered. These fluids are not only likely to have a different effect on acid-base 
physiology, they are also likely to have a different effect on several electrolytes because of 
their different composition. Such differences might affect electrolyte mass balance even 
when renal replacement therapy is isovolaemic (replacement fluid = ultrafiltration). Thus, it is 
possible that, with one type of replacement fluid, the accumulation or loss of a given 
electrolyte might 1) be substantial and 2) differ significantly from that obtained with another 
fluid. Appreciation of such differences might be important for clinicians faced with 
unexplained changes in serum electrolyte concentrations over time during CRRT and might 
help them avoid unnecessary investigations or interventions. Accordingly, we conducted a 
randomised controlled double-cross over study to specifically evaluate, compare and 
quantify these effects with 2 commercially available solutions. 
 
 
Materials and Methods 
Institutional approval was granted by the hospital Ethics Committee.  Informed 




Eight consecutive patients with established acute renal failure and fulfilling standard 
criteria for the multi-organ dysfunction syndrome 379 were studied.  Acute renal failure was 
defined as acute anuria for > 24 hours in the presence of a plasma urea level >25 mmol/L 
and of a serum creatinine > 250 µmol/L. 
 
All patients had to have received CVVH for at least 24 hours prior to enrolment.  The 
study patients were randomised to receive either a 2-hour period of lactate-buffered CVVH 
(treatment A) or bicarbonate-buffered CVVH (treatment B).  The order in which (A) or (B) 
was applied was random and concealed (random number table and sealed opaque 
envelopes).  The first 2-hour session was followed by cross over to the other treatment.  On 
the following day, the same random order cross over was performed with the first treatment 
determined in the same way.  Thus the treatment schedule on the study days for each 
patient was at random order in one of the following ways: ABAB, BABA, ABBA, BAAB.  Prior 
to the beginning of each 2-hour treatment session, arterial blood was obtained for baseline 
measurements.  During each session, arterial blood and UF were obtained at one and two 
hours of operation. Blood and UF samples were drawn fresh from the CRRT circuit into 
sterile syringes and sent to the laboratory for biochemical analysis immediately. The 
replacement fluid was then changed and the cycle repeated. 
 
 
Technique of CVVH 
Isovolaemic CVVH was performed.  Vascular access was obtained with 13.5 FG dual 
lumen catheters (Niagara TM, Bard, Ontario, Canada).  A BMM 10-1 machine or a Prisma 
machine (Gambro, Lund, Sweden) were used with a 1.2 m2 AN69 polyacrylonitrile filter 
(Filtral 12, Hospal, Lyon, France).  Blood flow was set at 180-200 ml/min, and ultrafiltrate 
flow was set at 2 L/h.  Lactate-buffered replacement fluid (Haemofiltration Replacement 
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Fluid, Baxter Healthcare, Sydney, Australia) was delivered pre-filter at a rate controlled by 
either an independent volumetric pump (Gemini PC-2, IMED Corporation, San Diego, CA) or 
by the volumetric pump of the Prisma machine. Potassium chloride (13.4 mmol) was added 
to each 5-litre bag of replacement fluid (final concentration of 3.7 mmol/L) to prevent 
hypokalaemia.  A bicarbonate buffered replacement solution was administered during 
treatment B (Hemosol BO, Gambro Australia, Melbourne, Australia). Potassium chloride 
(18.5 mmol) was added to this fluid to prevent hypokalaemia and achieve the same 
concentration of potassium as in the lactate-based fluid. 
 
All replacement fluids were warmed for both techniques. For both techniques, circuit 
anticoagulation was administered according to a previously described protocol.380 All fluid 
therapy not related to haemofiltration was controlled by the attending physician and 
remained unchanged during the brief study period. Nutritional fluids and medications were 




Samples were drawn into plain tubes off the CRRT machine and sodium, potassium, 
chloride, total magnesium, and phosphate concentrations were measured (Hitachi 747 
Analyser, Hitachi). Haematocrit and albumin concentrations were also measured on the 




Mass balance was simply calculated as the difference between the amount of a given 
electrolyte administered (concentration in the replacement fluid x amount of fluid given over 
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unit of time) and the amount lost in the ultrafiltrate (concentration in the ultrafiltrate x amount 




A commercially available statistical package was used for data analysis (StatView, 
Abacus Inc, Berkeley, CA).  Data are presented as means ± standard deviation.  The 
changes in sieving coefficient and mass transfer with different buffers were compared using 




Eight patients were studied (M:F=4:4; age 56 ± 12 years). All were critically ill with 
mean SAPS II scores of 51 ± 20. There was an average lapse of 4 ± 3 days between the 
start of CVVH and the actual start of this study. Hyperbilirubinaemia (total bilirubin 126 ± 119 
ug/L) was present in this cohort of patients. The rest of the clinical demographic data is in 
Table 6 (Chapter 3.2).  The electrolyte concentrations in the replacement fluids and serum 
are presented in Table 10 and 11, respectively.  
 
Mass transfer calculations showed significant mass gains or losses of some 
electrolytes despite isovolaemic therapy.  The mass transfer values for the various 
electrolytes are shown in Figure 27. They demonstrate a significant gain of sodium with both 
types of replacement fluid (bicarbonate: 23.3 ± 4.9 mmol/h, lactate: 22.7 ± 3.5 mmol/h) but a 
significant gain in chloride with the bicarbonate buffered replacement fluid only  
(12.8 ± 5.3 mmol/h), leading to a significant difference in chloride mass balance compared 
to lactate buffered fluid (-2.5 ± 5.2 mmol/h, p<0.0001).  The same bicarbonate fluid also 
resulted in a significant loss of magnesium of –0.6 ± 0.2 mmol/h, which was significantly 
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different from the magnesium mass balance seen with lactate fluids (-0.1 ± 0.2 mmol/h, 
p<0.0001).  There were no differences in potassium and phosphate mass balance with 
significant losses of phosphate (bicarbonate: -1.7 ± 0.7 mmol/h; lactate : -1.7 ± 0.5 mmol/h) 





Isovolaemic CVVH with two different replacement fluids induced significant 
alterations in patient mass balance for several electrolytes, which differed significantly 
according to the type of fluid. 
 
Sodium and Potassium 
During isovolaemic CVVH, patients gained a significant amount of sodium 
irrespective of replacement fluid.  For example, approximately 23 mmol of sodium were 
gained per hour.  This gain occurred because the 2 L of replacement fluid infused each hour 
had a sodium concentration of 140 mmol/L, while the patients were generally 
hyponatraemic, thus lowering the ultrafiltrate sodium concentration below 140 mmol/L.  The 
clinical effects of a positive sodium balance is close to the sodium gain seen with the 
administration of close to 4 litres of normal saline per day and may be clinically important. 
We added potassium to both replacement fluids to increase the potassium 
concentration from 1 mmol/L to 3.5 mmol/L. This addition seemed sufficient to prevent 
either gains or losses of potassium in our patients. 
 
Chloride 
Bicarbonate buffered fluid was associated with significant mass gains for chloride in 
the range of approximately 13 mmol/h, which would be the equivalent of more than 2 litres 
 146 
of saline being administered to the patient per day.  The most likely explanation for such 
gains is the high chloride concentration present in the bicarbonate buffered replacement 
fluid. It is possible that such continued gain in chloride would induce an increase in serum 
chloride concentration over time, which could affect acid-base variables such as the anion 
gap and might result in a mild hyperchloraemic acidosis.  The more physiological 




There were significant magnesium losses with the bicarbonate-based replacement 
fluid for an approximate daily loss of 14 mmol.  This loss was most likely related to the 
relatively low concentration of magnesium in the replacement fluid and was not seen with 
the lactate buffered fluids, which contain a magnesium concentration of 0.3 mmol/L higher 
than the bicarbonate-buffered fluid.  Given the potential consequences of magnesium 
depletion and the fact that blood levels are poor indicators of total body magnesium stores 




We found that phosphate removal was approximately 1.7 mmol/h.  These 
observations suggest that serum phosphate concentration should be closely monitored 
during isovolaemic CVVH and that phosphate administration is mandatory once 
normophosphataemia is achieved. The replacement dose requirements can be calculated 
from our observations to approximate 40 mmol/day.  
 
This study has some limitations. First, only eight patients were studied.  Some of the 
findings could have been influenced by individual variation, as mass transfer is dependent  
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on the serum concentration of each solute in each patient.  Nonetheless, the concentrations 
of solutes were not markedly abnormal and were representative of the likely values in a 
similar larger population of patients with ARF. Furthermore, the mass transfer of some of 
the electrolytes under investigation was clear and differed appreciably from one type of fluid 
to another, highlighting the clear differential effect of the type of commercial preparation in 
use.  It might be argued that these observations are relatively predictable on the basis of the 
composition of the fluids.  However, more precise empirical quantification appears desirable 
to better appreciate the consequences of such electrolyte shifts as well as plan a rational 
replacement schedule.  It might also be argued that the practical implications of our 
observations are unclear.  However, we would argue that these observations would permit a 
magnesium and phosphate replacement schedule, which is likely to avoid the body stores 
depletion of two important multifunctional electrolytes.  Such a schedule may be clinically 
important.  Our observations also have implications for commercial fluid design and suggest 
that more physiological chloride concentrations might be desirable as might be higher 
magnesium concentrations than those present in the bicarbonate replacement fluid.   
 
In summary, we evaluated the effect of changing the type of replacement fluid on 
electrolyte mass balance. Isovolaemic bicarbonate CVVH can cause significant gains of 
sodium and chloride and losses of magnesium, while lactate-CVVH only induces sodium 
gains.  Addition of potassium to the fluids prevents potassium losses.  Calculation of 
magnesium and phosphate losses allows for a quantitative rational replacement schedule.  








Table 10:  Solute concentrations in bicarbonate and lactate buffers (mmol/L) 
 
Solute Bic-CVVH Lac-CVVH 
Sodium 140 140 
Potassium 3.7 3.7 
Calcium 1.75 1.6 
Magnesium 0.5 0.8 
Chloride 113.2 102.7 
Phosphate 0 0 
Bicarbonate 32 0 
Lactate 3 46 













Table 11:  Electrolyte concentrations in blood pre-and post CVVH (mmol/L) 
 
  Na Cl K Mg Phos 
Bicarbonate Pre 132.9±1.9 102.6±2.8 4.1±1.1 1.04±0.12 0.95±0.37 
 Post 133.1±1.9 102.9±1.8 4.3±1.0 1.06±0.14 0.97±0.36 
Lactate Pre 133.1±2.3 101.8±2.7 4.0±0.3 1.14±0.19 0.91±0.33 




























Graphic representation of electrolyte mass transfer with bicarbonate-
buffered fluids and lactate-buffered fluids
Na=sodium, Cl=chloride, K=potassium, Mg=magnesium, Phos=phosphate. The p value refers to the difference in















High protein intake during continuous hemodiafiltration: Impact on amino acids and 
nitrogen balance. 
Introduction 
Severe ARF is often associated with sepsis and/or multi-organ dysfunction syndrome 
(MODS). It typically requires ICU admission and renal replacement therapy. 275 In this 
setting, adequate nutritional support is important because these patients experience severe 
protein catabolism. The combination of protein catabolism and inadequate nutrition causes a 
markedly negative nitrogen balance.276 A negative nitrogen balance is likely to increase 
morbidity and mortality.277 However, some controlled human evidence 119 suggests that 
protein intake may attenuate protein catabolism and promote recovery from ARF.   
 
In critically ill patients, continuous renal replacement therapies (CRRT) are now 
commonly applied.278 They achieve efficient azotaemic control and facilitate protein 
intake.278 However, a proportion of infused amino acids is lost in the ultrafiltrate or dialysate 
along with other solutes during CVVH/CVVHDF.279-284 In this setting, an aggressive protein 
replacement regimen (2.5 g/kg/day) aimed at improving nitrogen balance could markedly 
worsen such losses. It could also increase costs, exacerbate uraemia, and fail to achieve a 
satisfactory nitrogen balance. Accordingly, we sought to study the metabolic consequences 
of intensive protein supplementation in these patients. We hypothesised that aggressive 
amino acid intake would result in a near neutral nitrogen balance without uncontrolled 




Materials and Methods 
Following institutional approval, we studied seven patients with severe anuric acute 
renal failure (ARF) in the setting of critical illness and multi-organ failure. All patients were 




This technique was applied as previously described.12 We used a polyacrylonitrile 
haemofilter (Hospal AN69, Hospal, Lyons, France) of 0.5 m2 in surface area and a blood 
flow rate of 150 ml/min. Dialysate (1.5% Dianeal, Baxter Australia, Sydney, Australia) flow 
rates of between 1-2 L/h were used. Spontaneous ultrafiltration occurred at a mean rate of 
675 ml/h. Fluid losses were replaced post-filter as clinically indicated, usually to achieve net 
negative fluid balances of 100 to 200 ml/h.  
 
Anticoagulation was achieved either by means of pre-filter heparin (500 IU/h) or by 
regional anticoagulation (full-dose heparin pre-filter with protamine reversal post-filter). 




All patients received 2.5 g/kg/day of amino acids in solution (Synthamin 17, Baxter 
Healthcare, Sydney, Australia) (chemical composition shown in Table 11) through a central 
venous catheter. All patients received 35 kCal/kg/day energy intake excluding amino acids. 
Of these calories, 900 were provided in the form of 500 ml of a 20% lipid solution (Intralipid 
20%, Pharmacia, Sydney, Australia) with the remainder as a 25% dextrose solution 




During treatment, blood was sampled through the pre-filter sampling port of the 
extracorporeal circuit. Simultaneously, paired ultrafiltrate (UF) collection was made over a 
sixty-minute period. Aliquots from these samples were used for urea measurements.  The 
samples of blood and UF were immediately placed in chilled tubes and centrifuged at 40 C 
within 10 minutes of collection. The specimens were then stored at - 200 C until assay. After 
removal of proteins with 4% sulphosalicylic acid, amino acid analysis of blood and 
ultrafiltrate samples was carried out by means of high-performance liquid chromatography 
(HPLC) technology using a Beckman 7300 amino acid analyser (Beckman Instruments, 
Palo Alto, CA). The amino acids that were thus analysed included the following: aspartate, 
glutamate, asparagine, histidine, glutamine, serine, arginine, glycine, threonine, tyrosine, 
alanine, taurine, alpha-aminobutyric acid, beta-aminobutyric acid, methionine, valine, 
tryptophan, phenylalanine, isoleucine, leucine, ornithine and lysine.  
 
 
Calculations and Statistical Analysis 
For each amino acid, the following parameters were calculated:  
1. Descriptive statistics for serum and ultrafiltrate concentration,  
2. Daily losses in the ultrafiltrate (UF concentration of given amino acid x amount of UF 
produced each day),  
3. Percentage lost in the ultrafiltrate (amount of amino acid lost in one day/amount 
given in one day), and  
4. Clearance (concentration of amino acid in UF x UF production rate - in ml/min - 
divided by serum concentration of amino acid).  
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The StatView software package (Abacus Concepts Inc, Berkeley, CA) was used for 
data analysis.  Several equations were then used for the calculation of standard parameters 
of nitrogen metabolism (see below). 
 
The protein catabolic rate (PCR) was calculated according to the following formula: 
PCR (grams/day) = Total Nitrogen Appearance (TNA) x 6.25, where TNA = Urea 
nitrogen losses + creatinine nitrogen losses + amino acid nitrogen losses + {change in 
plasma [urea nitrogen] + change in serum [creatinine nitrogen] + change in [amino acid 
nitrogen]} x Total Body Water + insensible nitrogen losses where TBW = body weight x 0.6 
(males) or body weight x 0.58 (females) and insensible nitrogen losses = 15 mg/kg/day. 
 
Daily nitrogen balance was calculated according to the following equation: 
Nitrogen balance = nitrogen intake – nitrogen losses in UF – change in [urea nitrogen] x 
TBW – insensible nitrogen losses where nitrogen losses in UF = {[UF urea nitrogen] x daily 
UF volume} + {[UF creatinine nitrogen] x daily UF volume} + {[total UF amino acid nitrogen] 
x daily UF volume}. 
 
Because the values for measured and calculated variables were not normally 




All patients were treated with continuous veno-venous haemodiafiltration (CVVHDF). 
Their clinical profiles are summarised in Table 12. A total of 7 patients (M:F=6:1; age 61 ± 
19 years) were studied. They were critically ill as evidenced by mean APACHE II scores of 
32 ± 6. The average duration that these patients were on CVVHDF was 10 ± 5 days. These 
seven patients were studied on twenty different days after at least twenty-four hours of 
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steady state high protein intake, thus obtaining twenty paired serum and ultrafiltrate samples 
for analysis. It has to be noted that although patients in this series were on CRRT for a 
variable number of days (ranging from 3 to 19 days), they were not all on intensive 
nutritional regimen throughout the duration of CRRT. Paired serum and ultrafiltrate samples 
were obtained only when the patient had reached steady state on high protein intake while 
simultaneously being on CVVHDF as well. All subjects received TPN with a continuous 
infusion of 2.5 g/kg/day (median amount of amino acid solution: 1800 ml/day; range: 1500 to 
1920) of a proprietary parenteral solution containing a mixture of essential and non-essential 
amino acids (Synthamin 17, Baxter Healthcare, Sydney, Australia) (Table 13).  
 
Despite a very high median protein catabolic rate of 235 g/day (range:107 to 355) 
and median total nitrogen losses of 24.3 g/day (range: 21.1 to 65.5), the median nitrogen 
balance was only slightly negative at – 1.8g/day (range: - 21 to + 17.9). Furthermore, the 
nitrogen balance was positive during 35% of the study days and the median plasma urea 
concentration was controlled at 26.6 mmol/L (range 16.6 to 36.3). The total median amino 
acid serum concentration was 5.2 mmol/L (range: 3.1 to 7.2), much higher than the 
laboratory reference value (2.8 ± 0.8 mmol/L). The serum profile of individual amino acids, 
however, was quite variable (Table 14).  
 
The median overall quantity of amino acids lost in the UF was 12 g/day, ranging from 
5 to 21% of the administered dose. However, the median loss of amino acids in the 
ultrafiltrate as a percentage of the administered dose was low for histidine (4.47%), arginine 
(2.25%) and methionine (3.01%) but elevated for tyrosine (53.6%), lysine (12.2%) and valine 
(11.58%) (Table 15).  
 
Median amino acid clearances were also variable. They were high for tyrosine (45.5 
mmol/min) but low for taurine (5.4 mmol/min) and tryptophan (7.7 mmol/min) (Table 16). 
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Overall median amino acid clearance was 18.6 ml/min (range: 12 to 29). Glutamine losses 
and clearances could not be accurately assessed because of a co-elutant during HPLC 
analysis, which could not be adequately separated from the glutamine peak.  Glutamine 
clearance was assumed to be similar to the median overall amino acid clearance and such 
approximation was used to calculate the contribution of glutamine losses to overall nitrogen 




Severe ARF usually occurs in patients with sepsis and multiple organ failure. 275 In 
some of these patients, enteral feeding may not be possible and total parenteral nutrition 
(TPN) becomes necessary. Protein catabolism is high in this setting and often leads to a 
negative nitrogen balance, especially if nitrogen intake is restricted.276 A negative nitrogen 
balance may increase morbidity and mortality.277 Some animal and human studies suggest 
286-287
 that protein intake can attenuate such protein catabolism and even promote recovery 
from ARF. CRRT should enable the physician to administer a high protein intake (2.5 
g/kg/day) without the development of fluid overload or uncontrolled azotaemia.205 These 
predictions, however, are tempered by the knowledge that amino acids are lost in the UF 
during CVVH/CVVHDF.279-281 A high protein replacement intake, might simply worsen such 
losses, increase costs, exacerbate uraemia, and result in little improvement in nitrogen 
balance. The aim of our study, therefore, was to describe the consequences of such high 
protein intake on nitrogen balance, uraemic control, serum amino acid concentrations, 
clearances and ultrafiltrate losses.   
 
Several clinically relevant findings emerged from our investigation. First, intensive 
parenteral administration of amino acids is compatible with adequate uraemic control 
(median plasma urea of 26.6 mmol/L), provided that patients are treated with CVVHDF at an 
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adjusted level of intensity. Thus, even in the presence of extreme levels of protein 
catabolism (PCR > 200 g/day), restriction of protein intake because of fear of uncontrolled 
uraemia is not justified.  
 
Second, a near neutral daily nitrogen balance can be achieved with high amino acid 
intake even in extremely catabolic patients.  Our findings, in this regard, should be 
interpreted in combination with data already available from the literature.276, 119, 285 Taken in 
their aggregate, such data demonstrate that increasing nitrogen intake improves nitrogen 
balance. They also show that nitrogen balance is closely related to nitrogen intake in the 
ARF of critical illness (r2=0.906) and a mean nitrogen balance of –11g/day with protein 
restriction. These observations highlight the consequences of such restriction on the 
probability of developing protein malnutrition.  
 
Third, amino acid losses during high intravenous amino acid intake are limited.  
Furthermore, they are quantitatively similar to those reported with intermittent haemodialysis 
or peritoneal dialysis.19,280,283,284,288 They also appear not much greater than those reported 
with a more limited parenteral amino acid intake during CRRT.279,282,284,289 Thus, the fear of a 
high level of “wastage” does not appear justified.  
 
Our study shows significant alterations in serum amino acid concentrations. In fact, 
renal failure per se causes perturbations in the serum aminogram.119,289-291 Druml and co-
workers observed a significant increase in the phenylalanine/tyrosine ratio, a pattern 
consistent with the inhibition of phenylalanine hydroxylase activity.292-294 The same group 
also studied 12 non-hypercatabolic patients with acute renal failure during non-dialysis days 
and performed pharmacokinetic studies of amino acids.289 They found a distinctive serum 
amino acid pattern with high concentrations of phenylalanine and methionine, low levels of 
valine and leucine, and significant alterations in amino acid pharmacokinetics. In keeping 
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with their data, our study also found markedly elevated levels of phenylalanine and 
moderately increased methionine levels. Indeed the changes are those most consistently 
seen in clinical studies of patients with ARF (Table 17).  
 
Once intervention with parenteral administration of amino acids takes place, the 
serum aminogram is further modified 279 and the aminogram appears to reflect the amounts 
of each amino acid infused (Table 17). More recently, Kihara et al 284 used 10-hour diurnal 
slow treatment sessions of CVVHD and amino acid infusions of 40 g/day in 6 critically ill 
patients with acute renal failure. These researchers demonstrated low serum levels of 
taurine, cysteine, cystine and serine. Simultaneously, amino acid losses in the ultrafiltrate 
amounted to 16% of the administered dose. They also reported high serum levels of 
phenylalanine, isoleucine and methionine and low levels of taurine and serine. Recently, 
Frankenfield et al 281 studied 17 trauma patients on CVVHDF.  These patients received 3000 
kcal/day and 2.2 g/kg/day of amino acids. Patients were stratified into two groups based on 
the composition of the amino acid solution administered (either 19% or 45% branched chain 
amino acid content). Losses of amino acids (approximately 6 to 9% of the administered 
quantity) into the UF correlated with serum amino acid levels and intensity of dialytic therapy 
and were higher than in the control group. However, such losses did not correlate with the 
amount of amino acids given. The serum aminogram of these patients differed from a 
similar control group of trauma patients who were not on CVVHDF (Table 17). While the 
pathogenesis of high phenylalanine concentrations in ARF is partly understood, the high 
concentration of methionine cannot be easily explained.289 Importantly, in Frankenfield’s 
study, the composition of the TPN solution administered was a much greater determinant of 
the serum aminogram than renal replacement therapy.  
 
Sepsis, can also induce major changes in the serum aminogram 296-299  including 
above normal levels of phenylalanine (as in ARF) and cysteine, but low levels of most other 
 158 
amino acids.296 When TPN is administered to these patients, the aminogram is markedly 
affected.296,299 Thus, both the patient’s illness and nutritional therapy have a profound effect 
on the aminogram. Furthermore, the administration of large doses of parenteral amino acids 
in septic, critically ill ARF patients appears to overcome the effect of disease on the 
aminogram.296, 299 The high dose amino acid therapy given to our patients induced essential 
amino acid concentrations, which more closely resemble those of normal individuals 
receiving intravenous nutrition. This similarity is particularly true of leucine, valine and 
isoleucine (branched-chain amino acids). Non-essential amino acid concentrations 
(especially glutamine) are also markedly increased compared to those observed in sepsis 
and ARF. High amino acid intake with the preparation used in our study increases the 
concentration of most amino acids to levels higher than those seen in sepsis or ARF, 
suggesting that amino acid intake is a major determinant of amino acid blood levels. The 
clinical significance of these findings is unknown. 
 
This study presents several clinically relevant findings but suffers from several 
limitations. The study sample was small and the data may not apply to all critically ill patients 
with ARF. Unfortunately, such limitations have affected all studies of amino acid intake in 
critically ill ARF patients. They mostly derive from the expense associated with high 
performance liquid chromatography. We did not demonstrate improved patient outcomes. 
Hundreds of patients would have to be studied to answer a clinical question of this kind, an 
undertaking well beyond the scope of this preliminary study.  Our investigation did not 
include a control group. We chose, as a first step, to proceed to a simple prospective cohort 
study (phase I equivalent) to define more clearly the feasibility of an aggressive amino acid 
administration policy before undertaking a controlled comparison. A randomised controlled 
phase II equivalent study using nitrogen balance and degree of uraemic control as 
intermediate outcome measures may now be warranted. Some animal studies show that 
intravenous amino acids may exacerbate renal injury and delay recovery.300-302 The human 
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implications of such studies are difficult to assess, particularly in the light of opposing 
experimental data showing a beneficial effect.287 Furthermore, an earlier controlled human 
study 286 showed that low-dose amino acid supplementation increased survival.  All our 
patients were anuric and measurement of GFR was not possible. An assessment of the 
effect of high protein intake on renal function in septic man could perhaps be undertaken in 
patients with polyuric ARF, although the confounding variables associated with critical illness 
might overwhelm any amino acid-associated effects on renal function and recovery. Finally, 
our investigation does not address the clinical meaning of the reported changes in serum 
amino acid concentrations. However, the beneficial effect on nitrogen metabolism suggests 
that amino acid utilisation increases even at the high intakes administered in our study. 
 
In summary, high dose intravenous amino acid therapy is possible in critically ill 
patients with ARF.  When CVVHDF is used to replace renal function, such amino acid 
administration does not induce uncontrolled uraemia. Amino acid losses through the 
haemofilter are tolerable. Daily nitrogen balance approximates the neutral range instead of 
being strongly negative as previously reported. Finally, the serum aminogram resembles 
that of adequately nutritionally supported critically ill patients without ARF. On these 
physiological grounds, high amino acid intake in critically ill patients with CVVHDF-treated 











Table 12: Clinical characteristics of patients involved in the study 




Failing organs Disease Outcome 
64 Female 7 days 29 Lungs and kidneys Polyarteritis & 
pneumonia 
Survived 








21 Male 19 days 24 Lungs, kidneys, 
Circulation 
Multitrauma Survived 













66 Male 7 days 31 Lungs, kidneys, 





Table 13: Composition of 1000 ml Synthamin 17 
 
 
Amino acids:   
Nitrogen:    
 
Essential amino acids: 
Leucine   
Phenylalanine:   
Methionine:   
Lysine:    
Isoleucine:    
Valine:    
Histidine:    
Threonine:    
Tryptophan:    
 
Non-essential amino acids 
Alanine:    
Aminoacetic acid  
(for glycine) :   
Arginine:    
Proline:    
Tyrosine:    




  16.6 g 
 
 
    7.3 g 
    5.6 g 
    4.0 g 
    5.8 g 
    6.0 g 
    5.8 g 
    4.8 g 
    4.2 g 
    1.8 g 
 
 
  20.7 g 
 
  10.3 g 
  11.5 g 
    6.8 g 
    0.4 g 
    5.0 g  
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Table 14: Serum amino acid concentration in µmol/L. 




Aspartate 30.9 ± 4.4 17 ± 0.5 
Glutamate 296 ± 21.5 47 ± 5.3 
Asparagine 44.5 ± 6.2 59 ± 14 
Histidine 62.1 ± 5.2 78 ± 8 
Glutamine 955.9 ± 103 650 ± 54 
Serine 251.9 ±  13.7 115 ± 15 
Arginine 197.7 ± 11.7 85 ± 7 
Glycine 479.9 ± 31.7 199 ± 23 
Threonine 159.2 ± 9.1 123 ± 22 
Tyrosine 72.1 ± 5.2 61 ± 7 
Alanine 750  ± 50.5 270 ± 45 
Taurine 53.6 ± 8.3 67 ± 6 
Alpha-aminobutyric acid 20.3 ± 2.3 18 ± 4 
Beta-aminobutyric acid 265 ±  5 254 ± 23 
Methionine 65.1± 5.5 20.9 ± 3 
Valine 387 ± 18.1 230 ± 14 
Tryptophan 44.9 ± 4 43 ± 4 
Phenylalanine 231.2 ± 16.4 54 ± 5 
Isoleucine 128.4 ± 6.2 68 ± 4 
Leucine 210.6 ±  7.3 142 ± 23 
Ornithine 156.5 ± 11.4 61 ± 4 

























Table 15:   Daily infusion and losses of individual amino acids 
 




Loss as % of dose 
Aspartate 0 0 0 
Glutamate 0 28.1 (0- -251) N/A 
Asparagine 0 192 (0 – 659) N/A 
Histidine 7,488 (7200– 9216) 334 (0 – 984) 5.3% (0 – 10.6) 
Glutamine 0 N/A N/A 
Serine 7,945 (7500– 9600) 580 (26 – 1518) 7.3 (0.4 – 18.1) 
Arginine 19,205 (17250– 20700) 653 (0 – 2009) 3.4 (0 – 10.4) 
Glycine 0 917 (164 – 3317) N/A 
Threonine 7,087 (6300– 8064) 567 (133 – 1636) 8 (85 – 1244) 
Tyrosine 669 (524– 720) 377 (85 – 1244) 56.3 (11 – 185) 
Alanine 34,769 (31050– 39744) 1808 (390 – 8048) 5.2 (1 – 23.1) 
Taurine 0 93 (0 – 422) N/A 
(α-amino butyrate) 0 63 (0 – 501) N/A 
Methionine 6,550 (6000-7680) 262 (0 – 1294) 4 (0 – 19.3) 
Valine 9,790 (8700-11136) 1263 (269 – 3757) 12.9 (3.1 – 38.6) 
Tryptophan 2,973 (2700-3456) 110 (0 – 370) 3.7 (0 – 12.5) 
Phenylalanine 9,400 (8400-10752) 846 (160 – 2312) 9 (1.9 – 24.6) 
Isoleucine 10,113 (9000-11520) 445 (71 – 1130) 4.4 (0.8 – 11.2) 
Leucine 12,245 (10950-14016) 698 (169 – 1904) 5.7 (1.2 – 15.5) 
Ornithine 0 359 (0 – 770) N/A 
Lysine 9,754 (8700-11136) 1073 (0 – 3078) 11 (0. 31.6) 
Proline 11,475(10240-13100) N/A N/A 
 





Table 16: Clearance of individual amino acids in ml/min 
 
Aspartate   
Glutamate   
Asparagine   
Histidine   
Glutamine   
Serine    
Arginine   
Glycine   
Threonine   
Tyrosine   
Alanine   
Taurine   
α-aminobutyric acid  
Methionine   
Valine    
Tryptophan   
Phenylalanine  
Isoleucine   
Leucine   
Ornithine   




  0 
  0.3 (0 - 2.9) 
24.4 (0 – 82.5) 
17.9 (0 – 54.4) 
N/A 
15.7 (1 – 48.3) 
14.6 (0 – 49) 
17.7 (3.9 – 54.7) 
20.3 (5 – 52.7) 
45.5 (4.2 – 47.7) 
18.1 (4.5 – 57.9) 
  5.5 (0 – 28.3) 
12.3 (0 – 78.5) 
18 (0 – 79.3) 
19.4 (4.4 – 50.5) 
  7.8 (0 – 33.2) 
16.9 (3.9 – 55.9) 
18.5 (4.3 – 48.3) 
17.8 (3.6 – 48.7) 
23.7 (0 – 26.8) 



































Histidine Low Normal Normal Normal Normal Normal Low 
Isoleucine Low Normal Low High Normal High High 
Leucine Low Low Normal High Normal Normal High 
Lysine Low Normal Normal High High High High 
Methionine High High High High High High High 
Phenyl 
Alanine 
High High High High High High High 
Threonine Low Normal Normal High Normal Normal Normal 
Valine Low Low Normal High Normal High Normal 
Alanine Low Normal Normal Normal Normal Normal High 
Arginine Low Normal Normal Normal Normal Normal High 
Aspartate High Normal Normal Low High N/A High 
Glutamate Normal Normal High Normal Normal N/A High 
Asparagine Low Normal Normal Low N/A Normal Normal 
Glutamine Low Normal Low Normal Low Normal High 
Glycine Normal Normal Normal High High Normal High 
Proline N/A Normal N/A High Normal Normal N/A 
Serine  Low Normal Low Normal Normal Normal High 
Ornithine Low Normal N/A High N/A N/A High 
Taurine N/A Normal Low Low Low Normal Normal 
Tyrosine Low Normal Normal Normal Normal Normal Normal 














Chapter 4  
CRRT Technique I: Physico-mechanical factors 
 Much of the clinical efficacy of CRRT depends on the fact that it is continuous as 
opposed to intermittent therapies such as intermittent haemodialysis. In the ideal situation, 
the extracorporeal blood circuit (EC) should remain patent and operational for as long as its 
use is clinically indicated and also without significant membrane performance degradation. 
In reality, due to the contact of circulating whole blood with the plastic surface of the EC, 
including that of the filter/dialyser membrane, blood tends to clot with time. Additionally, 
protein-layering occurs. This causes progressive degradation in the dialytic efficiency of the 
filter/dialyser with prolonged use. Complete clotting of blood in the EC results in total 
cessation of blood flow. This means that a fresh circuit has to be set-up and primed before 
CRRT can be resumed. Such “down-time” reduces the overall time available for blood de-
uraemisation. If frequent and prolonged, such therapy interruptions reduce the overall 
dialytic efficiency of CRRT. Thus, a better understanding of the range of factors that 
determine CRRT circuit longevity is needed in order for its therapeutic potential to be fully 
realised. These factors can be broadly divided into two main categories: (1) Physico-
mechanical or non-anticoagulatory, and (2) Anticoagulatory factors. This chapter details 
three studies performed to increase understanding of the former category of factors 














 The successful operation of continuous renal replacement therapy (CRRT) depends 
on a patent extracorporeal circuit (EC).304 Such patency is typically compromised by circuit 
thrombosis. The common sites of thrombus formation are the membrane, the venous 
bubble-trap chamber on the return limb of the circuit and the double lumen vascular access 
catheter.162 Such circuit thrombosis occurs despite anticoagulation. The typical response to 
circuit clotting is to increase the intensity of circuit anticoagulation. This increase, however, 
carries a risk of haemorrhagic complications.305 Therefore, strategies aimed at prolonging 
circuit life, which do not require increased anticoagulation are theoretically and practically 
attractive. Unfortunately, no randomised controlled studies of any such strategies have yet 
been reported.  Potentially useful strategies to prolong circuit life without increasing 
anticoagulation can be directed at: 
 
(1) rheological factors 306 
(2) membrane protein layering 307 and 
(3) site of delivery of anticoagulant 308  
 
Accordingly, we hypothesised that the life of the CRRT circuit might be prolonged by 
the use of: 
(1) a different membrane configuration (flat plate), which might facilitate less turbulent 
blood flow or 
(2) a different membrane surface area, which would require a longer time to clot or 
(3) a different site of heparin administration to achieve direct anticoagulant 
administration to the air-blood interface of the venous bubble-trap chamber. 
Accordingly, we conducted three consecutive randomised controlled cross- 
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over studies in critically ill patients with acute renal failure treated with continuous veno-
venous haemofiltration (CVVH) and now report our findings. 
 
 
Materials and Methods 
Subjects and Technique Description 
A total of thirty-one critically ill patients with acute renal failure (ARF) requiring CRRT 
were studied.  Continuous veno-venous haemofiltration (CVVH) was performed, as 
previously described.309 It was carried out with the Gambro BMM 10-1 blood module 
(Gambro, Lund, Sweden). Veno-venous access was secured via a double lumen catheter 
(VascathTM, Quinton Instrument Co., Seattle, USA) inserted into one of the central veins 
(femoral, subclavian or internal jugular). The haemofilters were made of polyacrylonitrile (AN 
69 membrane, Hospal, Lyon, France). Ultrafiltrate (UF) generation was volumetrically IV 
pump-controlled at 2000 ml/h. Fluid replacement (Viaflex, Baxter Hemofiltration Solution, 
Baxter Health Care, Sydney, Australia) was delivered by volumetric IV pump at rates 
ranging from 1800 to 1900 ml/h to allow fluid losses as clinically indicated. The rate of fluid 
replacement and UF were controlled with twin-channel intravenous volumetric pumps (IMED 
Gemini, IMED, San Diego, USA). Blood pump speed was maintained at 200 ml/min. 
Anticoagulation was standardised for body weight and in accordance with the results of daily 
coagulation tests: activated partial thromboplastin time (aPTT), international normalised ratio 
(INR) for prothrombin and platelet count. Data from these parameters were then used to 
guide the administration of heparin in accordance with a protocol outlined in Table 18. The 
selected dose of heparin was maintained throughout the day. In accordance with our CVVH 
operational protocol, all patients received 5,000 IU heparin in the final stage of priming 




Study Design:  
Three separate randomised, crossover, controlled studies were conducted over a 
period of 18 months in consecutive patients to address the effects of: 
(1) membrane configuration 
(2) site of heparin administration and 
(3) membrane surface area  
on the EC lifespan. Using the first study as an example, patients were randomised to 
receive either a flat-plate or hollow-fibre filter. Upon clotting of the EC, the next circuit would 
contain the filter configuration that was not used in the first circuit. When clotting occurred in 
the second EC, the next EC would have the membrane configuration used with the first 
circuit once again and so on, as long as CVVH remained clinically indicated. 
 
Study 1: This study compared the duration of circuit life with either a flat plate filter or a 
hollow fibre filter of the same membrane type with the randomised cross over design 
described above.  
 
Study 2: This study compared administration of the same dose of heparin equally divided 
into the venous air-chamber (50%) and into the standard pre-filter port (50%) compared with 
its complete (100%) infusion into the standard pre-filter port alone.  
 
Study 3: The third study compared a filter with a larger membrane surface area (Filtral 12, 
Hospal, Lyon, France; surface area: 1.3 m2) with a smaller one (Filtral 8, Hospal, Lyon, 
France; surface area: 0.75 m2).  
For the purpose of these studies the following standard pre-defined criteria for the 
diagnosis of circuit failure were used: 
1. The UF outflow volumetric pump was unable to deliver UF as prescribed, more than 
three times over a five minute interval. Such failure should occur in the absence of other 
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reasons why sufficient pressure could not be generated to yield the prescribed 2000 ml/h of 
UF. In addition, the pump should continue to fail in delivering UF, despite reducing its flow to 
1.5 L/h. 
2. Presence of visible clot in the venous bubble trap chamber of the EC associated with 
a rise in venous pressure above 150 mmHg and/or a sudden/rapid cessation of blood flow in 
the circuit. 
3. Presence of visible clot in the filter with sudden/rapid cessation of blood flow  
through the EC.  
 
If the haemofilter had to be removed for the purpose of surgery or investigations 
such as CT scanning, such ECs were excluded from the study. The bedside nurse was 
required to closely document the events surrounding filter clotting and the likely source/site 
of such circuit failure. The following data were systematically recorded for the purpose of the 
study: circuit life in hours, perceived cause of circuit failure, cessation of CVVH for any 
elective reason, dose of heparin administered (IU/h), values of routine daily coagulation and 




Statistical analysis was performed using a statistical software package (StatViewR, 
Abacus Concepts Inc, Berkeley, CA). Descriptive statistics were obtained and values 
presented as mean ± standard error of the mean (SEM).  
 
Comparisons between groups within each study were performed using the  
Wilcoxon signed rank test for non-parametric but paired data and the Mann-Whitney test for 
non-paired data. Correlations between coagulation variables and filter life were tested for 





Study 1: A total of 17 circuits were randomised to flat-plate filters and 21 to hollow-fibre 
filters. The mean circuit lifespan was 14.7 ± 4.7 h for flat plate filters and 17.1 ± 2.8 h for 
hollow fibre filters (p=0.109). The two groups were comparable in terms of INR, aPTT and 
platelet count. There was no significant correlation between circuit life and clotting 
parameters except for the platelet count, which was inversely correlated with circuit life 
(p<0.018). Circuit failure was due to reasons other than visible isolated filter clotting in 18 
out of 38 cases (47%). In this regard, venous bubble trap chamber clotting was particularly 
important, accounting for 9 cases (23%) of circuit failure. The distribution of circuit life is 
summarised in Figure 28. 
 
Study 2: The distribution of circuit life for the two approaches to anticoagulation is 
summarised in Figure 29. Once again, circuits were comparable for INR, aPTT and platelet 
count (NS).  The mean filter life for single site of heparin delivery was 17 ± 3.2 h and 18.1 ± 
3.1 h for double delivery site (p=0.756). Venous bubble trap chamber clotting occurred in 
18.5% of circuits and occurred with similar frequency in both groups. 
 
Study 3: The distribution of circuit life in the two groups is presented in Figure 30. The two 
groups were comparable for INR, aPTT and platelet count (NS). There was no significant 
difference in the circuit lifespan between the Filtral 8 (0.75 m2) group compared with the 
larger Filtral 12 (1.3 m2) haemofilters. The mean circuit lifespan was 16.8 ± 13.1 h for the 
former and 15.75 ± 14.3 h for the latter (p=0.972). In all three studies, venous bubble trap 





 Continuous renal replacement therapy can only be successfully performed if the life 
of the extracorporeal circuit (EC) is of acceptable duration. However, contact between blood 
and catheter, tubing and membrane triggers the coagulation cascade.310 Such activation, in 
turn, promotes clotting within the circuit and eventual circuit failure.311 Anticoagulation, 
therefore, is used to prolong circuit life to clinically acceptable levels. Unfortunately, even 
with seemingly adequate levels of anticoagulation, the EC can still fail prematurely.312 The 
typical response to such premature cessation of CRRT function is to increase the intensity 
of anticoagulation.  However, the effectiveness of such an approach, although intuitive, has 
not been tested in a randomised controlled trial. Furthermore, its safety is limited in patient 
at increased risk of bleeding. Because of the dangers associated with increasing 
anticoagulation for the purpose of prolonging circuit life, alternative and safer approaches 
appear desirable. Although several such approaches have been suggested, none have yet 
been proven effective in a randomised controlled trial.313 Such approaches seek to prolong 
filter life by affecting different putative mechanisms of circuit clotting. For example, it has 
been suggested that frequent filter flushes with saline may be effective.314 In addition, the 
infusion of dilute heparin facilitating its admixture with blood has been proposed as a means 
of preventing EC thrombosis. These strategies have not been proven effective. Some 
theoretical considerations suggest other potential strategies for the prevention of circuit 
thrombosis. For instance, turbulence of flow may be a mechanism by which coagulation 
activation is augmented. Such turbulence may be diminished by the use of filters with a 
different configuration such as flat plate filters.315 These filters have been shown to facilitate 
diffusion 315 and may conceivably prolong circuit life.  Another observation prompts a 
possible approach to the prolongation of filter life. It has been frequently noted that the 
bubble-trap in the venous return limb may be particularly thrombogenic because of the 
presence of a blood-air interface or the narrow outlet with plastic mesh filter.316 Indeed the 
air-trap is a frequent site of clot formation and the cause of circuit thrombosis and failure. It 
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would therefore appear potentially useful to deliver some heparin directly into the chamber 
to minimise its thrombogenic potential. Finally, the size of the membrane surface may play a 
role in influencing the duration of filter life. Membrane clotting is mostly a microcirculatory 
phenomenon associated with platelet, red cell and protein deposition on the membrane. The 
membrane becomes progressively “exhausted” and develops a protein/cell layer, which 
leads to a deterioration of filtration capacity, culminating in eventual filter failure. 
Conceivably, a larger membrane surface would take longer to clot or become covered with a 
protein layer, thus resulting in a prolongation of circuit life.   
 
In the light of the above observations, we conducted three consecutive randomised 
cross over controlled trials. We wished to test the hypothesis that, for equivalent 
anticoagulation, a) flat plate filters would increase circuit life b) heparin delivery directly into 
the air chamber would increase circuit life and c) use of a larger membrane surface would 
delay circuit failure. The results of our studies were negative. In study 1, flat-plate 
haemofilters did not have an added advantage over hollow-fibre ones in terms of prolonging 
circuit lifespan. There was, in fact, a non-significant trend in favor of hollow-fibre filters. 
Given that flat-plate AN 69 membrane filters are more expensive than hollow-fibre filters, the 
findings of our study clearly do not justify the use of flat-plate filters for the prolongation of 
circuit life in CVVH. The findings of our first study also suggest that rheological factors are 
not an important pathogenetic factor in the development of circuit clotting.  
 
In study 2, diluted heparin at the same total effective dose was administered either 
entirely through the pre-filter port or administered through the pre-filter port (50%) and 
directly into the venous bubble-trap chamber (50%). This attempt to better protect the 
chamber from clotting by direct heparin delivery, however, was not effective. Not only was 
there no difference in overall circuit life but there was also the same incidence of chamber 
clotting in both groups. A possible explanation for this lack of advantage in administering 
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heparin directly into the venous air-chamber is that the dose delivered may have been 
insufficient to overcome the highly thrombogenic environment of the air-chamber. Another 
explanation is that the admixture of heparin may have been insufficient given the limited 
transit time of blood through the chamber. On the other hand, pre-filter delivery of the dose 
may have more effectively resulted in admixture prior to blood reaching the air-trap. 
Whatever the explanation for this failure, separate anticoagulation of the bubble-trap 
chamber is not justified.  
 
In study 3, a greater membrane surface area failed to prolong circuit life. The 
explanation for this failure may once again lie in the fact that circuit clotting is more strongly 
determined by factors other than the “surface needed to clot”. Factors such as flow 
fluctuations, mechanical obstruction of the circuit, position-related catheter insufficiency and 
the like may be more powerful determinants of circuit clotting, thus offsetting any marginal 
advantage derived from a larger membrane surface area. 
 
All three studies presented achieved negative findings. As for all negative studies, 
issues of statistical power must be considered. Negative results may simply reflect 
insufficient statistical power. Our studies, however, were designed to generate paired data, 
which was sufficiently powered to address relevant clinical questions. Given the standard 
deviation in filter life, the first study had a greater than 80% power of detecting a difference 
in filter life of 7 hours at an alpha of 0.05. The second study had a greater than 80% power 
to detect a difference of 6 hours in filter life at an alpha of 0.05. The third study had a 
greater than 80% power to detect a 3 hour difference between the two groups, also at an 
alpha of 0.05.317 Therefore, if a clinically relevant difference existed between the different 
groups, our study had the ability to detect it. It is, however, possible that small differences in 
circuit life were missed. 
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One of the limitations of our study was that it tested these different strategies using a 
particular technique of CRRT, ie CVVH with volumetric ultrafiltrate control. In such a system, 
the maintenance of blood flow is important to ensure that the filtration fraction (the ratio of 
UF to plasma flow) is not too high. A high filtration fraction would result in 
haemoconcentration and increase the probability of circuit clotting. In addition, filter fatigue 
cannot be detected by a decrease in spontaneous ultrafiltration rate. It can only be detected 
by the inability of the volumetric pump to obtain the 2000 ml/h of ultrafiltrate that it is 
programmed to deliver. Accordingly, the definition of circuit failure would have to take (as it 
did) these operative parameters into account and may not apply to other techniques of 
CRRT. Furthermore, CVVH might be more demanding on the membrane than CVVHD as it 
operates via the generation of transmembrane pressure rather than simple diffusive 
clearance. Such membrane stresses may overcome protective mechanisms directed at 
preventing thrombosis. One other problem, which may be responsible for the failure of the 
protective strategies tested, would be an overall tendency of circuits to clot prematurely. A 
short overall mean circuit life would make it particularly difficult to detect small changes in 
circuit survival. However, the mean filter life reported in our study is a realistic representation 
of the mean circuit life for convective circuits. For example, Lagenecker et al. achieved 
mean circuit lifespans of between 14 to 17 hours operating a CVVH system anticoagulated 
with either heparin or heparin + prostacyclin.318 Our mean filter life was always > 14 hours. 
Accordingly, the system under study was representative of the typical filter operating life for 
CVVH circuits and is relevant to all such systems. 
  
In conclusion, we have conducted suitably powered, randomised, controlled, cross-
over studies of non-anticoagulation-based strategies to prolong filter life and have failed to 
demonstrate their efficacy. We have also demonstrated that the venous bubble-trap 
chamber is a frequent site of thrombus formation and circuit failure.  
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Table 18: Protocol for the Administration of Heparin During CVVH 
INR       aPTT   Plateleta  
___________________________________________________________________ 
 
Bolus Heparin 5000 U followed by 10 U/kg/h <1.5 <40s  >150 
Bolus heparin 5000 U followed by 5 U/kg/h  ≥1.5 >40s  ≥150 
No Bolus      <2.5 >80 
Nil Other      ≥2.5 <60s  <80 
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The successful application of continuous renal replacement therapy (CRRT) 
depends on a patent extracorporeal blood circuit (EC). Adequacy of anticoagulation is 
conventionally considered most important in maintaining EC patency.319 However, 
aggressive anticoagulation is associated with an increased bleeding risk. Another important 
likely determinant of EC life is the adequacy of vascular access.  Adequacy of vascular 
access is likely to depend on the site of insertion, the patient’s body habitus, his/her position 
during treatment, the degree of intravascular filling and the size and length of the catheter. 
Of these factors, the most easily manipulated is the type of catheter used to gain vascular 
access. In fact, different catheters may offer variable resistance to blood flow and thereby 
affect overall EC lifespan. Knowledge of the resistance to blood flow posed by various 
catheters may assist clinicians in their choice and help prevent vascular access dysfunction. 
There are, however, very limited data to compare the resistance to blood flow of 
commercially available catheters under standard conditions 200,320 especially for newer 
haemofiltration catheters. Such data might help clinicians in their choice of device.  
Accordingly, we have performed an ex-vivo evaluation of several commercially available 
catheters and now report our findings. 
     
        
Methods 
This study examined resistance to blood flow in 11 different proprietary vascular 
catheters used in continuous renal replacement therapy (CRRT) in a controlled ex-vivo 
setting. The study catheters were divided into two groups based on length: (a) short (15 cm 
or less, n=5) and (b) long (19 cm or more, n=6).  
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A Prisma CFM pump  (Hospal, Lyon, France) M60 was primed with a mixture of 
expired red cells and a polygeline solution (Haemaccel, Aventis, Sydney, Australia) and 
anticoagulated with 20,000 IU of unfractionated heparin at a constant haematocrit of 32%.  
 
The temperature of the blood was maintained at 37 º C by placing it in a water bath 
incubation and agitation system. Blood was pumped from the blood container through the 
Prisma M60 blood circuit via the outflow limb using the machine roller pump and then 
returned to the container via the inflow limb of the study catheters. The catheters were 
individually tested in turn using a standard procedure. The blood pump speed (QB) was 
increased and then decreased stepwise in the following way in 30 ml/min incremental and 
decremental steps from 30 to 60, 90, 120, 150 and 180 ml/min and back.  
 
The catheter outflow (Po) and inflow (Pi) pressures were recorded at each QB 
following a 1 minute period of blood flow stabilisation. These pressures were read from the 
in-blood-line pressure transducers built into the Prisma machine and M60 circuit. The blood 
line pods interface directly with transducers on the machine to measure outflow, or prefilter 
pressure and, after the filter, inflow or post-filter pressure. These tranducers are zeroed as 
part of the set up machine test before priming. Values for these pressures are displayed on 
the machine data screen continuously.  Pressure-flow relationship lines were then 




Descriptive statistics are presented as medians with range. Comparisons of outflow 
and inflow resistances (paired, non-normally distributed data) were performed with the 
Wilcoxon signed rank test. Comparisons between short and long catheters (non-paired, 
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non-normally distributed data) were performed using the Mann-Whitney test. A p<0.05 was 




The results of the study for the eleven vascular catheters are summarised in Table 
17. The Prisma M60 blood line (Hospal, Lyon, France) accounted for at least forty percent of 
the total overall resistance to blood flow. Different catheters were associated with different 
blood flow resistances over the range of blood flow rates tested at the given haematocrit of 
thirty-two percent. For both groups of catheters with regards to both the outflow and inflow 
luminal pressures, there was a consistent rise in pressures as blood flow rate was increased 
from 30 to 180 ml/min, as expected. (Figures 31 and 32). Among short catheters, the 12 Fr 
Cook catheter was associated with the greatest resistance to outflow while the 11.5 Fr 
Quinton-Mahurkar catheter offered the least resistance (Table 19). Figure 32 illustrates the 
inflow lumen pressures for short catheters. The 12 Fr Cook catheter was associated with the 
highest hydraulic resistance to inflow, while the 14 Fr Medcomp catheter had the lowest 
(Table 19).  
 
Figure 33 summarises the outflow pressures for a given blood flow for catheters > 19 
cm in length. Among them, the 11.5 Fr Medcomp XTP offered the highest resistance to 
outflow, while the 13.5 Fr Niagara catheter offered the least resistance (Table 19).  
 
Figure 34 shows the inflow resistance lines for the same catheters. While the 11.5 Fr 
Gamcath catheter offered the highest resistance to inflow, the 11.5 Fr Medcomp catheter 
was associated with the lowest (Table 19).  
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Hydraulic resistance to outflow (median: 0.8; range: 0.63-0.93) was consistently less 
(p=0.043) than hydraulic resistance to inflow (median: 1.065; range: 0.83-1.08) for short 
catheters. When all catheters were considered as a single group the overall difference in 
resistance between outflow and inflow was statistically strong (p=0.003). No statistically 
significant difference between short and long catheters could be demonstrated, although 
there was a trend in favour of short catheters. 
 
 
Discussion   
 Continuous renal replacement therapy (CRRT) is now an established technique for 
the treatment of acute renal failure in critically ill patients.200 The efficacy of CRRT, however, 
is highly dependent on a continuously patent extracorporeal blood circuit (EC). Frequent EC 
clotting is expensive and erodes the overall adequacy of renal replacement therapy.  
Maintenance of a continuously patent EC is thus of fundamental importance and is typically 
achieved by anticoagulation.310 With this approach, an increase in the amount of 
anticoagulation is a common response to frequent EC clotting. However, such a response 
increases the risk of bleeding and ignores the fact that mechanical problems related to 
inadequate vascular access may be of at least equal importance in the pathogenesis of 
circuit clotting. This is particularly true for double lumen catheters, which generally function 
reasonably well in haemodynamically stable chronic renal failure patients having a 3 to 4-
hour treatment. These same catheters, however, often show their functional limitations in 
critically ill patients on CRRT where they are required to perform 24 hours/day. It would 
therefore be very useful for clinicians to have some standardised assessment of catheter 
performance to guide their catheter selection and, hopefully, decrease operational 
problems. Accordingly, we have conducted an ex-vivo study to examine such catheter 
performance under standard conditions. 
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 Our study demonstrates that, under standard conditions, catheter performance 
measured as hydraulic resistance to blood outflow and inflow varies according to size, 
design profile, and probably length. Using an ex-vivo model, it is not surprising then to note 
that two of the largest gauge catheters (the 14 Fr Medcomp and the 13.5 Fr Vascath 
Niagara) had the lowest resistance to blood flow. However, the 11.5 Fr Quinton-Mahurkar 
design was also found to be one of the least resistive to blood flow, despite its lesser gauge. 
It is also important to note that the circuit per se contributed to almost forty percent of the 
overall resistance to blood flow. Due to catheter design, the resistance to inflow is 
consistently greater than the resistance to outflow. These findings suggest that the inflow 
aspect of the catheter could be improved. 
 
 Our catheter evaluation was performed ex-vivo. Thus, many of the potential 
confounding factors such as choice of central venous access, rheological factors and other 
mechanical factors impacting on catheter integrity and function, were not examined. There 
are clinical data suggesting that such patient factors as size, site of insertion, haematocrit, 
and central venous pressure have an effect on catheter function, including the degree of 
recirculation.322-325 The aim of this study, however, was to illustrate that catheter type per se 
can affect resistance to blood flow. Further studies are needed to assess how these ex-vivo 
findings apply in-vivo.  
 
The values reported for hydraulic resistances are somewhat higher than those 
reported for other dual lumen catheters used for intermittent haemodialysis.320-321,326  Such 
catheters, however, were often of 14 Fr gauge, of split design and the venous pressures 
used for assessment of hydraulic resistance were obtained directly from the machine 
pressure sensors where pressure is read from the blood line via a partly air filled and partly 
blood filled sensing line to a plastic isolator before the machine transducer.  This approach 
tends to dampen the reading in comparison to in-blood line direct transdcuer interfaces used 
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in this study via the Prisma machine and could have yielded artificially lower calculated 
hydraulic resistance values. The measurements reported in this study take into account 
these factors and might better reflect true hydraulic resistance than those so far reported in 
the literature. Conversely the Prisma machine circuit use small bore tubing (3mm) which 
would create more resistance to blood flow for the same pump speed in comparison to 
larger dialysis tubing (usually 6 mm). This factor may have lead to higher readings for all the 
catheters tested and partly account for the circuit resistance reported. 
 
In conclusion, we have shown through in-vitro testing, that several commercially 
available haemofiltration catheters pose markedly different hydraulic resistances to flow. 
Such information, together with other clinical considerations, might assist physicians in their 


















Table 19: Catheter features and performances 
  
Catheter Type, Length and 
Gauge 





Medcomp XTP 13 cm, 14 Fr 0.7 0.78 
Quinton Mahurkar 13 cm, 11.5 Fr 0.56 0.8 
Gamcath 13 cm, 11.5 Fr 0.65 0.93 
Medcomp Softline 13 cm, 14 Fr 0.72 0.93 
Cook 13 cm, 12 Fr 0.82 1.18 
Medcomp 19 cm, 14 Fr 0.8 0.93 
Quinton Mahurkar 19 cm, 11.5 Fr 0.66 0.8 
Gamcath 19 cm, 11.5 Fr 0.88 0.93 
Medcomp XTP 19 cm, 14 Fr 0.93 1.07 
Vas Cath Niagara 24 cm, 13.5 Fr 0.63 0.83 
Single lumen, 19 cm, 10 Fr 0.9 1.06 

















Figure 31  
SHORT CATHETERS - OUTFLOW
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Figure 32  
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SHORT CATHETERS - INFLOW
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Figure 33  
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Figure 34  
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LONG CATHETERS - INFLOW











30 60 90 120 150 180










 Medcomp   11.5F 20cm
 Quinton  Mahurkar
 11.5F  19 cm
-
 Gamcath    11F 20cm
 Medcomp   XTP 11.5F 20cm
 Vascath
   
Niagara 13.5 F 20cm
 10 F single lumen 40 cm
 Circuit only ( Prisma      M60)














Chapter 4.3     




 Thrombocytopaenia is a common finding in patients in the intensive care unit 
receiving CRRT.  These patients have many possible causes for thrombocytopaenia: 
uraemia, sepsis, blood loss, consumptive coagulopathies, heparin and other drugs, and 
marrow suppression.381-382 It is unknown whether haemofiltration itself may also contribute to 
thrombocytopaenia.383 The present study was undertaken to test whether there is a 
decrease in the platelet count across a haemofilter in patients undergoing CRRT. Such 
information may assist clinicians in their assessment and management of 
thrombocytopaenia in patients with multi-organ failure. 
 
 
Materials and Methods 
This study was reviewed and approved by the Human Research Ethics Committee of 
the Hospital.  All patients admitted to the intensive care unit with critical illness and acute 
renal failure requiring continuous haemofiltration were considered eligible for entry to the 
study.  Continuous veno-venous haemofiltration (CVVH) was performed, using one of three 
pump systems: BM 10-1 (Gambro, Lund, Sweden), BM-11/BM-14 (Baxter, Hechingen, 
Germany) and Prisma (Hospal AG, Basel, Switzerland).  The haemofiltration membrane 
used in all cases was a polyacrylonitrile haemofilter (Filtral 12, AN 69, Hospal, Lyon, 
France).  Pump flow was initially set at 200-250 ml/min, and adjusted according to catheter 
flow and machine capabilities.  Ultrafiltration was pump driven and commenced at an 
exchange rate of 2000 ml/h.  The Prisma and Baxter machines used external pumps 
(Gemini Infusion Pumps, Alaris, UK).  Heparin was not used unless there was a short 
haemofilter lifespan (<12 h) due to clot formation.  The haemofiltration circuit was changed 
only when the filter itself clotted.  Intensive care physicians not involved in the study were in 
charge of circuit management. 
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Two blood samples were drawn simultaneously from the circuit, one pre-haemofilter 
and the other post-haemofilter.  The collected samples were analysed for platelet count in 
an automated counter (Sysmex SB 9000, Bayer Diagnositics). In 80% of cases, volume was 
actively being removed (net ultrafiltration) during CVVH to correct fluid balance. Hence the 
post-filter platelet counts were increased by haemoconcentration.  A correction factor was 
therefore calculated using the pump flows and net loss of ultrafiltration fluid at the time of 
sampling (Figure 35). This correction factor was then applied to the measured post-filter 
platelet count, to give a corrected post-filter platelet count which then reflected any true 
change in platelet numbers across the haemofilter. 
 
The main observation end-point was any significant decrease in platelet count across 
the haemofilter.  Secondary end-points were decreases in platelet count in relation to filter 




 The data consist of 48 paired observations from 22 subjects, with between one and 
six observations per subject.  To account for the within subject replication, a mixed model 
approach was used for statistical analysis.  The first step was to examine the autocorrelation 
structure of platelet drop across the six time points.  In fact, only the first three time points 
had enough observations to provide a reliable picture of the structure, since very few 
subjects had more than three measurements. There appeared to be no autocorrelation 
amongst repeated platelet count drops, so this analysis used the simple variance 
components structure.  Red blood cell count, however, did display autocorrelation within 
subjects, and the compound symmetry model appeared to be the most appropriate. In both 
cases, it would have been preferable to use the unstructured model, which makes no 
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assumptions and estimates all autocorrelation parameters, but because of small numbers 
this was not possible.  PROC GENMOD in SAS (SAS Institute Australia Pty Ltd, New South 
Wales, Australia) was used to fit all models. 
 
 The sample size was calculated a priori based on an assumption that we would find 
a small standard deviation in the mean fall of platelet count across the haemofilter. A 
standard deviation of ± 4 x 109/L was estimated, based on our laboratory’s quality control 
figures, which showed a coefficient of variation of 1.5% for platelet 50 -100 x 109/L.  From 
this we calculated that a study population of 48 paired data would give us a 90% power to 




 Forty eight sets of paired data, from 22 patients were collected. Table 20 lists the 
individual patients’ characteristics and reasons for intensive care admission. The average 
patient age was 62 years. The average APACHE II score was 22. The patients had a mean 
creatinine (±SD) of 230 ± 150 µmol/L and mean urea (±SD) of 16.7 ± 9.1 mmol/L.  The 
mean platelet count (±SD) was 91 (± 85) x 109/L, with a range of 16 to 360 x 109/L.  Average 
pump flow at sampling was 216 ml/min, with a range of 100 to 300 ml/min.  The average 
replacement and ultrafiltration volumes were 1804 ml/h and 1909 ml/h, respectively. 
 
 There was a small but significant decrease in the mean platelet count across the 
haemofilter.  The mean platelet count drop was 2.32 x 109/L (se. 1.06, p=0.0487, 95% CI 
[0.01, 4.62]).  Blood flow was strongly related to platelet loss, with a decreased drop of 0.07 
x 109/L platelets for every 1 ml/min increase in blood flow (s.e. 0.02, p=0.0153).  Figure 36 
shows the relationship between blood flow and platelet loss. 
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 There was no association between the age of the haemofilter and changes in platelet 
counts across it.  Seven of the 22 patients received systemic heparin for prevention of circuit 
thrombosis during the study period.  We found no significant difference in the drop in 
platelet count across the haemofilter in patients who received heparin compared to those 
not heparinised. 
 
 There was no statistically significant decrease in red cell counts, taken at 
corresponding times, across the haemofilter.  However, there was a difference in effect 
amongst the machines, with a significant loss of red cells detected during the use of the 





Extracorporeal circuits have become common place in clinical medicine.  A major 
problem with these circuits is their ability to induce changes in the haemostatic system which 
may lead to significant morbidity or mortality.  Thrombocytopaenia is commonly seen in 
clinical situations involving extracorporeal circuits, so it is possible that the circuit may 
contribute to the platelet loss.  In fact, many interactions of platelets with dialysis 
membranes have been observed: platelet adhesion and retention, marked defects in platelet 
aggregation activity, expression of cell-surface proteins, formation of platelet-leucocyte 
aggregates and changes of platelet function such as formation of B-thromboglobulin and 
thromboxane.383, 385-391 However, only a few studies have looked at whether there is actually 
loss of platelets through a dialysis membrane.  Remuzzi et al 385 demonstrated variable 
platelet adhesion and retention on dialysis membranes.  They used a suspension of 
111Indium-labelled platelets and red cells in an in vitro system that allowed quantification of 
platelet deposition.  Their initial results showed considerable platelet deposition on different 
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types of dialysis membrane.  Interestingly, by making the suspensions more physiological, 
such as by the addition of albumin, they observed very low levels of platelet deposition.  
Dialyser thrombogenicity is partly determined by its composition: Docci et al 392 found a 
significant platelet loss during cuprophan dialysis, but not with polyacrylonitrile membranes. 
 
Given the evidence above, we hypothesised that during CVVH, the haemofilter might 
directly contribute to platelet loss.  Our data confirm our hypothesis and demonstrate a small 
but significant drop in the platelet count across a standard polyacrylonitrile haemofilter.  The 
cumulative effect of such a small loss of platelets might contribute significantly to the 
thrombocytopaenia over time.  Assuming that the haemofiltration circuit was able to operate 
continuously, we have calculated the daily platelet loss at 625 x 109 cells (Table 21).  In the 
normal steady state, when platelet production is equal to destruction, platelet turnover has 
been estimated at 120 to 150x109 cells per day.393 The bone marrow has a large reserve 
capacity to increase platelet production, but this could well be suppressed in the setting of 
critical illness.  Hence, a daily loss of the magnitude calculated from our findings could soon 
lead to thrombocytopaenia. 
 
 Alterations in platelet function might also be induced as they pass through the 
haemofilter, leading to further platelet loss in the systemic circulation, but this study was not 
designed to detect such changes.  Boldt et al 383 did find alterations in platelet aggregation in 
patients on CVVH, when compared to matched controls without renal failure and not on 
CVVH, but no significant decline in platelet count in the haemofiltered patients compared to 
controls.  CVVH can also contribute to thrombocytopaenia if there is sudden rapid 




 Increased blood flow was associated with decreased platelet loss across the 
haemofilter.  The mechanisms responsible for this effect are unknown.  However, they might 
include faster transit time, improved rheology, and decreased haemoconcentration.  These 
preliminary findings on the effect of blood need to be confirmed in a study where blood flows 
are independently and randomly altered.  If this beneficial effect of higher blood flows was 
confirmed, this finding would have implications for the choice of blood flow settings in clinical 
practice. 
 
 Although no overall red cell loss across the haemofilter was found, there appeared to 
be a specific machine effect on this variable, such that CVVH with the Prisma machine was 
associated with a significant loss of red cells.  Because these results are based on only 
eight observations, they must be interpreted with caution.  However, they suggest the need 
for a larger study of the effect of different machines on red cells. 
 
 Our findings are dependent on the accuracy of the measurements and of the 
haemoconcentration adjustment factor, which may have been affected by the reliability of 
pump flows and automated platelet counts.  However, we can estimate the importance of 
these potential sources of error by 1) observing the effect of errors in flow measurement on 
calculations, and 2) by looking at concurrent changes in other haematological indices, such 
as red cell count, that would be expected to be altered at the same time and in the same 
way as the platelet count. 
 
 The three haemofiltration units operated in this trial all use roller pumps to facilitate 
blood flow through the circuit.  The pump flows quoted, and hence the measurements we 
have used for blood flow, are calculated figures based on the rotation rate of the roller pump 
and the cross-sectional area of the tubing, rather than direct flow measurements.  Variations 
in the elastance and size of the tubing, and resistance to forward flow of blood, could all 
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produce variations of real flow rate which would be mostly undetectable.  We used the 
correct sized PVC or silastic tubing sets according to the manufacturers’ specification, which 
are supposedly adjusted for the occlusive settings of the roller pumps.  We have actually 
tested the accuracy of these pumps systems using a Doppler flow probe, and found that on 
the whole they are reasonably accurate.  The Gambro BM 10 machine was the least 
accurate, with measured flows varying from sets flows by up to 10%. 
 
 We used only Gemini pumps on the Gambro BM 10 circuits, the Prisma and Baxter 
circuits having their own pumps.  The manufacturers of the Gemini pump claim a flow error 
of ±5% at all pump speeds, a figure which has been validated.  The Prisma manufacturers 
claim a flow error of less than ±1% though this has not been independently validated. 
 
 Automated platelet counts in our laboratory have quality control figures for the co-
efficient of variation as follows: 1.5% for platelet counts above 100 x 109/L, and 2.3% for 
counts between 50-100 x 109/L. 
 
 Table 22 shows some estimations of errors that could occur due to inaccuracies of 
pump flow measurements, and their effect on subsequent calculations.  Overall these errors 
seem to have very little effect on any calculations.  Also as the errors are randomly 
distributed a significant trend should still be evident if there are sufficient samples.  
Furthermore, samples were obtained simultaneously and were unlikely to be associated with 
major fluctuations in pump flows. 
 
 We observed no benefit from the use of heparin in reducing platelet loss across the 
haemofilter itself which has been shown to cause platelet activation and dysfunction.395-396 In 
a recent animal study, Annich et al 397 looked at the effect of heparin and nitric oxide coated 
tubing on platelet consumption in extracorporeal circuits. Using 111In(oxine)-labelled platelets 
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they demonstrated that there was increased platelet adhesion to the circuit in systemically 
heparinised animals compared to non-heparinised controls. 
 
 In summary, thrombocytopaenia is a common finding in critically ill patients receiving 
CVVH, and can be a significant clinical problem.  Our study strongly suggests that the 
haemofilter itself plays a role in the genesis of thrombocytopenia, as a result of immediate 
destruction or retention of platelets as they pass through the filter.  This effect may be 
attenuated by higher blood flows.  Different machines may have different effects on red cell 




TABLE 20: Patient Characteristics 
Patient 
number 










1 71 M 20 24.1 245 316 Cardiac surgery: CABG 
2 69 F 17 8.1 100 254 Sepsis: Faecal peritonitis 
3 74 M 12 19.9 117 59 Sepsis: Psoas abscess 
4 80 M 24 12.8 122 117 Sepsis: Faecal peritonitis 
5 73 F - 3.2 64 66 Cardiac surgery: CABG 
6 65 M - 11.3 222 89 Cardiac surgery: Valve 
replacement 
7 70 F - 14.7 193 72 Cardiac surgery: CABG 
8 68 M 21 11.7 229 41 Multi-organ failure 
9 58 F - 17.3 158 134 Cardiac surgery: Valve 
replacement 
10 76 M 27 28.6 40 95 Gastrointestinal bleeding 
and pulmonary oedema 
11 60 M 19 23.2 156 27 Liver transplant 
12 67 M 28 13.4 358 25 Septic shock 
13 20 F - 5.4 69 116 Cardiac surgery: Valve 
replacement 
14 30 F 32 5.9 137 34 Fulminant liver failure and 
multi-organ failure 
15 29 M 22 14.9 176 26 Liver transplant 
16 67 M 24 14.5 251 23 Multi-organ failure 
17 59 M - 19.1 277 205 Aortic arch repair for 
dissection 
18 34 F 23 18.7 129 35 Liver transplant 
19 78 F 26 16.3 138 211 Cardiac surgery: CABG 
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20 72 M 15 18.9 31 107 Vascular surgery: AAA 
Repair 
21 80 M 24 12.1 162 166 Sepsis: Pneumococcal 
pneumonia 
22 71 M 16 46.7 543 16 Glomerulonephritis and 
sepsis 
 
*Platelet count at entry into study. AAA: Abdominal aortic aneurysm, CABG: Coronary  






















Average pump speed (QF):      219 ml/min 
Average replacement volume (QREP):    1804 ml/hour 
Blood Flow QB = QF  - QREP 
QB =11.3 L/hour, or 271 L/day 
We detected an average platelet loss of 2.3 x 109 cells/L across the haemofilter 
Assuming continuous haemofiltration: 






















Example 1 : A BM – 10 circuit with the following flows dialed in: 
Blood flow   QF   200 ml/min   
Ultrafiltration flow 
  Replacement volume QREP  1900 ml/h  31.7 ml/min  
  Ultrafiltrate volume  QFILT  2000 ml/h  33.3 ml/mm  
Net loss     100 ml/h  1.67 ml/min 
True blood flow (QF - QREP) QB     168.3 ml/min 
The correction factor (CF) calculation is: (blood flow – net loss)/blood flow 
CF1   = (168.3 – 1.67)/168.3 = 0.990 
So, if the post-filter platelet count is 90 x 109/L, this count is then multiplied by 0.990 to yield 
a corrected platelet count of 89.1 x 109/L 
 
 
Error 1: An error of 20 ml/min in the BM-10 blood pump flow (Actual flow is 180 ml/min). 
Now Blood Flow = 180 – 31.7 = 148.3 ml/min 
 CF2  = (148.3 – 1.67)/148.3 =0.988 
So, if the post-filter platelet count is 90 x 109/L, this count is then multipled by 0.988 to yield 
a corrected platelet count of 88.9 x 109/L 
Error 2: A ± 5% error in the Gemini pump for ultrafiltration could produce either of two 
outcomes: 
2100 ml/h ultrafiltrate, or now net loss of 200 ml/h or 3.33 ml/min 
1900 ml/h ultrafiltrate, or now net loss of 0 ml/h 
 
 CF3  = (168.3 – 3.33)/168.3 or CF4  = (168.3-0) / 168.3 
   = 0.98      = 1 
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So, if the post-filter platelet count is 90 x 109/L, this count is then multiplied by either 0.98 or 
1 to yield a corrected platelet count of 88.2 x 109/L or 90 x 109/L, respectively. 
























































Chapter 5   
CRRT Technique II: Anticoagulation 
 Anticoagulation is the mainstay by which CRRT circuits are prevented from clotting 
to achieve reasonable operational circuit lifespans. There are a number of different 
anticoagulants available for use: unfractioned heparin, low molecular weight heparin, 
prostacyclin, nafamostat mesylate and citrate. There are also different routes of 
anticoagulant administration: local or regional versus systemic. Citrate and heparin 
anticoagulation, the latter with post-filter protamine reversal are specific examples of 
regional anticoagulation in which only the intra-haemofilter/haemodialyser blood is 
anticoagulated. Systemic bleeding tendency is thus not or minimally exacerbated with 
regional anticoagulation. The administration of anticoagulant is associated with increased 
bleeding risk and other complications. Yet, a central paradigm to the problem of frequent 
circuit clotting is to increase the dose of anticoagulant. Such a response increases the 
overall bleeding risk substantially given that many ICU patients are already coagulopathic 
and/or thrombocytopaenic. Moreover, increased anticoagulation intensity does not 
automatically translate into improved circuit lifespans. At the other end of the spectrum, 
there have been anecdotal instances in which CRRT has been successfully performed 
without any anticoagulation at all. This forms the subject of an investigaton in Chapter 5.1 
which sets out to elucidate the precise reasons why anticoagulant-free CRRT is indeed 
possible. A related issue to anticoagulation is its monitoring. Standard laboratory markers 
such as prothrombin time (PT), activated partial thromboplastin time (aPTT) and platelet 
count provide an upper threshold limit above which anticoagulation should not be intensified. 
However, having adequate anticoagulation does not consistently ensure continuous circuit 
patency much less predict when the circuit will clot. Circuits have been known to clot despite 
adequate conventional coagulation indices and vice versa. We thus used 
thromboelastography (TEG) to determine if TEG-derived variables are more informative and 
provide closer correlation with circuit clotting. TEG provides a means of directly measuring 
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the actual physical process of clot formation and thus may provide more accurate correlation 

































 Severe acute renal failure (ARF) is a relatively common  complication in critically ill 
patients with multi-organ failure.346-347 Continuous renal replacement therapies (CRRT) such 
as continuous veno-venous haemofiltration (CVVH), are now accepted ways of managing 
such patients.275,348  Successful application of CRRT, however, depends on adequate 
extracorporeal circuit (EC) life. The duration of EC life in turn hinges on anticoagulation.304 
The need for anticoagulation has to be balanced against the increased risk of bleeding in 
high-risk patients. In these patients, performing CVVH without anticoagulation may be an 
acceptable strategy. The practicality of such an approach has, however, been questioned. 
Anticipated recurrent filter clotting and the need for frequent filter replacement would be 
economically undesirable. Furthermore, excessive “down-time” could jeopardise azotaemic 
control. Only limited uncontrolled data exist to guide clinicians with regard to the safety and 
operative efficacy of CRRT without anticoagulation. Thus, in order to understand the clinical 
consequences of a no-anticoagulation approach to CVVH, we studied 40 haemofilters in 12 
critically ill patients at high risk of bleeding. We tested the hypothesis that a “no-
anticoagulation” strategy in high-risk patients yields an acceptable filter life by comparing 
this cohort of patients to a consecutive series of patients treated with low-dose pre-filter 
heparin and now report our findings. 
 
 
Materials and Methods 
A total of 12 critically ill patients with severe ARF requiring CVVH without 
anticoagulation were prospectively identified and studied. ARF was defined by the presence 
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of severe refractory oliguria (urine output < 200 ml/12 h) or anuria, despite adequate fluid 
resuscitation.  Adequate fluid resuscitation was defined as a central venous pressure (CVP) 
above 10 mmHg or a pulmonary artery occlusion pressure (PAOP) above 12 mmHg.  These 
12 patients were compared to 14 consecutive patients who received pre-filter, low-dose 
heparin for circuit anticoagulation.  This study was an audit of current practice in our 
institution and required no specific intervention other than documentation.  Our institutional 
ethics committee waives the need for informed consent under such circumstance. 
 
Continuous veno-venous haemofiltration was performed as previously described.309 
In brief, It was carried out using either the BM-10/BM-11 dual module (Baxter Healthcare, 
Sydney, Australia) or the AK-10 (Gambro, Lund, Sweden) machines. Veno-venous access 
was secured by inserting a 13.5 Fr double-lumen catheter (Niagra™, Vascath Inc, Ontario, 
Canada) into one of the central veins (internal jugular, femoral or subclavian). The 
polyacrylonitrile AN69 (Hospal, Lyon, France) hollow-fiber haemofilter was used in all 
patients. Blood pump speed was between 200 and 300 ml/min. Ultrafiltrate generation was 
volumetrically controlled by a pump at 2000 ml/h. Commercially prepared lactate-buffered 
haemofiltration replacement fluid (Viaflex, Baxter Haemofiltration Solution, Baxter Health 
Care, Sydney, Australia) was delivered pre-filter (pre-dilution mode) by intravenous 
volumetric pump at rates ranging from 1600 to 1900 ml/h, to allow for fluid losses as 
clinically indicated.  
 
A lactate-free bicarbonate-buffered hemofiltration replacement fluid (Hemasol, 
Gambro, Lund, Sweden) was also available for severely acidotic and hyperlactatemic 
patients. Fluid replacement and ultrafiltration rates were controlled by the integrated pumps 
in the dual-module BM-10/ 11 machines while, with the AK-10, these were controlled with 
separate twin-channel intravenous volumetric pumps (Gemini pumps, IMED, San Diego, 
USA).  
 209 
No anticoagulation or saline flushes were used in the study patients. However, in 
accordance with our CVVH operational protocol, all circuits received 5000 IU of heparin 
during the final stages of priming. Before connection of the circuit to the patients, the 
heparin prime was flushed out, thus avoiding anticoagulating these patients. 
 
Patient selection 
The intensivists in charge of the patients care independently decided to perform 
CVVH without anticoagulation based on a clinical assessment of a high risk of bleeding. 
These physicians were not directly involved in the study.  Our unit guidelines suggest that 
patients should receive CVVH without anticoagulation if: 
a) there is ongoing bleeding 
b) there has been a major haemorrhage in the last 48 h 
c) they have had surgery in the last 24 hr or 
d) they have either an international normalised ratio (INR) more than 2 or an activated 
partial thromboplastin time (aPTT) greater than 60 s or a platelet count less than 60 
x 103/mm3.  However, the final decision is left to the treating physician. 
  
The control patients were treated with exactly the same CVVH protocol but, in 
addition, were given low-dose heparin delivered pre-filter at a dose between 5 and 10 IU of 
heparin/kg/h according to clinician judgement.  In our institution, the administration of low-
dose heparin (10 IU/kg/h) constitutes routine CVVH management and is given to the 
majority of patients.  If the aPTT appears to have been prolonged by such a dose, the 
amount of heparin is then adjusted down to 5 IU/kg/h and the aPTT is rechecked.  If the 
aPTT is back to normal values, the patient is continued on that dose of heparin.  The aim of 
low-dose heparin in our institution is to provide a degree of circuit anticoagulation without 
any systemic anticoagulant effects. 
 210 
 For the purpose of this study, the following criteria for diagnosing circuit failure were 
adopted: (1) the ultrafiltrate (UF) volumetric outflow pump was unable to deliver the 
prescribed (dialed-in) UF rate for more than three times over a five minute interval. Such 
failure to yield the prescribed 2000 ml/h of UF should be deemed secondary to loss of 
filtering membrane surface as a result of clotting. In addition, the pump should continue to 
fail in delivering prescribed UF even after reducing the UF effluent flow to 1500 ml/h, (2) 
presence of visible blood clot in the venous air-chamber of the EC associated with a steep 
and sustained rise in the venous pressure above 150 mmHg and a sudden/rapid cessation 
of blood flow in the circuit, and (3) presence of visible blood clot in the haemofilter and a 
sudden/rapid cessation of blood flow in the EC.  
 
Elective CVVH cessation for activities such as surgery and radiological investigations 
were considered non-clotting events for which there were no hemofilter changes. In addition, 
the bedside nurse routinely recorded when the filter, EC lines and venous and arterial 
chambers were changed. Coagulation (aPTT, INR), haematological (platelet count) and 




Statistical analysis was performed using a statistical software package (StatViewR, 
Abacus Concepts Inc, Berkeley, CA). Descriptive statistics were obtained and values 
presented as means with 95% confidence interval. Comparisons between means was 
performed using the Mann-Whitney test for unpaired non-parametric data. Comparisons 
within each group were performed using Wilcoxon’s signed rank test. Correlations between 
coagulation variables, biochemical data and filter life were tested using Spearman's 
correlation test. Comparison of filter life in the study patients and controls was performed 
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 Forty haemofilters and circuits were studied in 12 critically ill patients (M:F=8:4) with 
severe ARF admitted to the intensive care unit (ICU) between July 1998 to July 1999. They 
were compared to 40 consecutive filters in 14 patients treated with low-dose pre-filter 
heparin. A summary of the clinical and demographic data for the two groups is presented in 
Table 23.  
 
In patients receiving no anticoagulation, mean circuit life was 32.0 hours (95% CI: 
20-44.4) compared to 19.5 hours (95% CI:14.2 –23.8) in the controls (p<0.017) (Figure 38). 
Forty-three percent of haemofilters used in the study group lasted more than 30 hours as 
graphically represented in Figure 37. A degree of baseline pre-CVVH coagulopathy (aPTT 
more than 1.5 normal or INR greater than 1.5 normal or platelet count lower than 100 x 
103/mm3) was seen in most of the patients with a mean aPTT of 61 s (95% CI: 45 – 77), a 
mean platelet count of 126 x 103 (95% CI: 119 – 143)/mm3 and a mean INR of 1.9 (95 CI: 
1.7 – 2.1).  
 
Sixty-seven percent of patients were post-operative cases with some degree of 
ongoing blood loss from surgical drains (>50 ml/h) (Table 24). The coagulation findings 
during CVVH in the no-antcoagulation group differed from the control group because of a 
higher INR and a lower platelet count and are presented in (Table 23). Haemofilter lifespan 








Acute renal failure (ARF) is a relatively frequent and major complication of critical 
illness 349 and may require treatment with CRRT.209, 350 The successful application of CRRT, 
however, depends on the maintenance of a patent extracorporeal circuit. Such patency 
depends on the prevention of circuit thrombosis by means of circuit anticoagulation.351  
Several agents and techniques can be used to achieve circuit anticoagulation.314 However, 
heparin remains the most common, cheapest, and simplest.352 Unfortunately, most 
anticoagulation strategies are associated with an increased risk of bleeding. Systemic 
heparinisation is particularly likely to increase the risk of haemorrhage.353 Such an increased 
risk of bleeding may be unacceptable in some patients. Therefore, to decrease the risk of 
bleeding and still maintain a clinically acceptable circuit life, a variety of other strategies 
have been applied.312 One such strategy is to administer pre-filter low-dose (5-10 IU/kg/h) 
heparin.305 Although this approach is likely to decrease the risk of bleeding, it often induces 
a slight prolongation of the aPTT and contributes to the development of 
thrombocytopaenia.354  In patients at very high risk of bleeding (recent haemorrhage, severe 
coagulopathy, liver failure, recent cardiac surgery, or ongoing blood loss) even such effects 
may be clinically unacceptable.355  
 
The use of prostacyclin, low-molecular weight heparin, heparinoids, serine 
proteinase inhibitors, or dextran also exposes patients to an increased risk of bleeding.355  
Regional anticoagulation has been suggested in these cases and can be achieved by 
means of pre-filter heparin administration and post-filter protamine administration.356 This 
approach, however, is often associated with a variable degree of heparin reversal, thus 
exposing the patient to its anticoagulant effects and increasing bleeding risk.356 Further, 
protamine can induce life-threatening hypotension, if given as a bolus, or in allergic patients. 
Because of these problems, regional anticoagulation using pre-filter citrate-based calcium 
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chelation and post filter calcium administration has been proposed.354 This strategy appears 
effective in prolonging filter life although no randomised controlled studies have been 
conducted.354 However, it is associated with a relatively high incidence of metabolic alkalosis 
and requires the preparation of custom-made, calcium-free dialysate/replacement fluid.354-355 
Such preparation is costly, requires dedicated pharmacy personnel, and can be 
cumbersome to set up. Thus, all strategies, which expose patients to an anticoagulant are 
associated with risks, costs, and the potential to induce bleeding. In the light of such 
observations, the safest approach in patients at high risk of bleeding may be to perform 
CRRT without any anticoagulant at all.  
 
CRRT without circuit anticoagulation has rarely and often only anecdotally been 
reported 357 because of the expectation that circuit life would be dramatically shorter by this 
approach. If circuit life were markedly shortened, the cost and labour-intensity of the 
procedure would become excessive, and the “down time” of CRRT would be prolonged. 
Such increases in “down time” may lead to deterioration in azotaemic control.  However, 
there has never been a study to prove that such concerns are justified. We, therefore, 
studied 40 circuits in 12 critically ill patients who were managed with anticoagulant-free 
CVVH and compared their duration to filters in a cohort of patients treated with low-dose 
pre-filter heparin, one of the most common approaches to filter anticoagulation worldwide. 
The aim of our investigation was to describe the safety, efficacy and feasibility of 
anticoagulant-free CVVH in high-risk patients. 
 
 Our patients were severely ill as evidenced by their mean APACHE II and SAPS II.  
Sixty-seven percent of them were post-surgical patients with active bleeding from surgical 
drains. One of the post-cardiac surgery patients developed acute haemorrhagic cardiac 
tamponade in the immediate post-operative period and required emergency evacuation of 
blood clot and surgical haemostasis. Another patient with acute fulminant hepatic failure, 
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coagulopathy and severe secondary cerebral edema had developed an acute but small 
iatrogenic subdural haematoma following elective insertion of an intracranial pressure probe. 
Before commencement of CVVH, most patients were thrombocytopaenic and had a 
significant degree of coagulopathy, as evidenced by prolonged aPTT and INR values. In all 
of these patients, therefore, it was felt that any further increase in the risk of bleeding was 
unacceptable and that anticoagulation-free haemofiltration should be applied. 
 
Despite the lack of any circuit anticoagulation, the mean circuit lifespan achieved in 
our study was 32 hours. In addition, forty-three percent of circuits lasted more than 30 
hours. These data are all the more significant when one takes into account the results of 
other studies of filter/circuit life during CVVH. Langenecker et al, 318 for instance, using pre-
filter heparin at a dose of 6 IU/kg/h recently reported mean filter life was 14.3 h during 
CVVH. When prostacyclin at 6 ng/kg/min was used, mean filter life increased to 17.8 h and 
when a combination of heparin and prostacyclin was used, it increased further to 22 h. In 
another study of CVVH, 358 mean haemofilter life was 69 h. In this study however, 
ultrafiltration was not pump-controlled and heparin was administered to achieve levels just 
below systemic heparinisarion. Ponikvar et al 359 studied the anticoagulant effects of 
prostacyclin at a dose of 5 ng/kg/min during CVVH. Mean haemofilter life was 19.7 hours. 
Thus the mean circuit life in our control patients is well within that reported in the literature 
for CVVH in patients receiving different forms of circuit anticoagulation. However, when 
compared to the control group our high-risk patients achieved a longer duration of filter life. 
Both our study patients and those in the control group are from the same intensive care unit 
and would have been managed in accordance with the unit’s CRRT protocol. There were no 
reasons to suspect that the management of the various aspects of CRRT in terms of 
vascular access, intensity of anticoagulation, choice of anticoagulant and indications for 
CRRT, would have been significantly different in both groups of patients. The only 
discernible difference would have been the omission of heparin anticoagulant in our study 
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population and the use of low dose heparin in the control group as per departmental 
guidelines in the control arm. Thus, apart from this key difference, both groups could be 
considered to be effectively comparable in all other CRRT-related and medical aspects. A 
possible explanation why the non-anticoagulated filters lasted longer than those on 
conventional anticoagulation could have been that “auto-anticoagulation” achieved as a 
spontaneous consequence of their critical illnesses is superior to exogenous 
pharmacological anticoagulation in maintaining a patent circuit for longer. This point, 
however, warrants further investigation.  
 
There are several possible explanations for the circuit duration achieved in our study 
patients.  Firstly, they suffered from coagulopathy and/or thrombocytopaenia and thus 
experienced a degree of “auto-anticoagulation”. In most of our patients, such 
coagulopathies required ongoing active treatment with repeated infusions of platelets and 
fresh frozen plasma. Secondly, CVVH was performed in the “pre-dilution” mode. Such pre-
filter replacement fluid administration reduces the haemoconcentration associated with the 
removal of plasma water, thus decreasing the likelihood of circuit clotting.308, 316 Thirdly, we 
routinely used blood flows equal to or greater than 200 ml/min. Such relatively high blood 
flows may increase shear forces on the capillary fibers, diminish protein layering and retard 
membrane clotting. In order to achieve and maintain such blood flows, we perform CVVH 
with large bore (size 13.5 Fr) double lumen catheters. Catheters of this size may minimise 
post-filter pressures, diminish the risk of mechanical problems, and reduce the number and 
intensity of flow fluctuations within the circuit during CVVH. These effects are likely to retard 
circuit thrombosis. Whatever, the mechanisms at work, mean filter life > 30 hours is clinically 
satisfactory. In fact, it remains controversial whether a filter life > 24 hours should be 
aggressively pursued. Several studies indicate that high flux membranes adsorb 
immunologically active molecules which participate in the pathogenesis of the pro-
inflammatory response to sepsis.360 Membrane saturation occurs over a period of time and 
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is usually complete before 24 hours.360 Maintaining filter life beyond such time, exposes the 
patient to the release of such pro-inflammatory molecules back into the circulation and 
decreases the potential anti-inflammatory effect of CRRT.360-361 
 
There was no correlation between filter lifespan and measured laboratory indices of 
coagulation such as aPTT, platelet count and INR. These parameters are normally taken at 
the start of CRRT and at regular time intervals ranging from 8 – 12 h thereafter as CRRT is 
in progress. Such interval check of the coagulation parameters would have been carried out 
for both the study and control groups since this was conventional practice in the unit. This 
lack of correlation between standard clinical measures of anticoagulation and circuit lifespan 
has been a common finding in patients receiving therapeutic anticoagulation during 
CRRT.306, 310 Such data suggest that factors other than the coagulation system, such as 
physical factors (for example, the blood-air interface in the venous air-chamber) and 
rheological components of the system may be more important in determining the lifespan of 
extracorporeal circuits.162 There were no bleeding complications during CVVH in our 
patients.  
 
It is worth mentioning that the coagulation profile and risk of bleeding in these 
patients is highly dynamic.  The administration of clotting factors often occurs when the risk 
of bleeding is considered very high, removal of fluid by means of CVVH affects the platelet 
count and haemoglobin concentration with a secondary effect on bleeding time, and the 
correction of uraemia improves platelet function.  All these factors may affect filter life 
independently and require consideration by the clinician, especially with regard to the 
decision to switch from CVVH without anticoagulation to CVVH with low-dose heparin.  In 
our unit, this decision is currently not subject to specific guidelines due to the lack of data.  




A mean serum urea of 16 mmol/L and mean serum creatinine of 198 µmol/L were 
achieved during the course of anticoagulant-free CVVH confirming adequate azotaemic 
control. In fact, anticoagulation-free CVVH allowed clinicians to start therapy under any 
circumstances and very early in the course of a patient’s illness. Thus anticoagulation-free 
CVVH has no adverse effect on uraemic control and facilitates the early start of therapy. 
 
Other strategies aimed at minimising bleeding risk while maintaining circuit life might 
have been equally safe and effective. It is hard, however, to conceive of any therapy that 
would be safer than giving no anticoagulant at all. Nonetheless, interval circuit saline 
flushing has been proposed as an inexpensive, albeit time-consuming, method of 
overcoming build-up of cellular and macromolecular constituents, thereby prolonging circuit 
lifespan. No data have been published using this method in patients receiving CRRT.  
 
Our study suffers from several limitations. It is not randomised. However, the control 
group is representative of typical ICU patients receiving CRRT and, in our opinion, sufficient 
for meaningful comparison. Due to the episodic nature of bleeding complications, a very 
large population of patients would have to be studied to demonstrate a significant reduction 
in bleeding episodes with anticoagulant-free CVVH. Finally, we cannot provide a strict 
definition of which patients should receive anticoagulation-free CRRT. However, we have 
described the patients’ clinical circumstances and coagulation profile and thus hope that this 
information conveyed a useful impression of which patients may benefit from this approach.  
Furthermore, we have reported the guidelines for circuit anticoagulation under which 
clinicians operated during the study period.  The data provided should enable other 
clinicians to reproduce our approach. 
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In summary, we have described a cohort of patients at high risk of bleeding in whom 
we have conducted CVVH without the use of anticoagulants and have compared it to a 
control group treated with low-dose heparin. Anticoagulant-free CVVH was associated with a 
satisfactory circuit life, no bleeding complications, and excellent uraemic control. Our 
findings suggest that anticoagulation-free CRRT should be strongly considered in patients at 
























Clinical diagnoses, source of bleeding risk and hospital outcome for patients 
receiving continuous veno-venous haemofiltration without anticoagulation   
 
 





64 Male CAD Post-CABG 10 U platelets, 
10 U cryopr 
Survived 




10 U FFP, 
15 U platelets 
Survived 
60 Male FHF Post liver 
Transplant 
12 U FFP, 
15 U platelets 
Survived 
44 Female FHF Subdural 
haematoma 
15 U FFP, 
20 U platelets 
Died 




8 U FFP, 
25 U platelets 
Died 




15 U platelets, 
15 U FFP 
Died 
67 Female FHF Haemorrhagic 
gastritis 
5 U FFP Died 





2 U FFP, 
5 U platelets 
Survived 
66 Male CAD Post-CABG 5 U platelets Survived 
55 Female CAD Post-CABG 7 U platelets Survived 
79 Male Biliary sepsis Post-biliary 
surgery 
- Survived 




35 U platelets, 
10 U FFP 
Died 
 
CAD: coronary artery disease; FHF: fulminant hepatic failure; CABG: coronary artery  













Clinical characteristics of study and control patients. 
 No anticoagulation 
        (n=12) 
Low-dose heparin 
         (n=14) 
Age (years) 57.7 (50.9 - 64.5) 61.1 (57.1 – 64.1) 
Gender 8 Male; 4 Female 9 Male; 6 Female 
APACHE II score 28.1 (23.1 – 33.1) 26.7 (23.2 – 30.2) 
SAPS II score 60.3 (54.1 – 66.5) 56.2 (50.9 – 61.5) 
Duration of CVVH (days) 8.2 (4.1 – 12.3) 7.6 (5.4 – 9.8) 
Mechanical ventilation 7 (58%) 9 (64.2%) 
Inotropic drugs 9 (75%) 11 (78.6%) 
Pre-CVVH urea (mmol/L) 19.6 (13.5 – 25.7) 22.3 (18.2 – 26.4) 
Pre-CVVH creatinine (umol/L) 264 (168 – 360) 354 (290 – 418) 
Urea on CVVH (mmol/L) 16 (11.8 – 20.2)b 16.9 (12.3 – 21.5)b 
Creatinine on CVVH (umol/L) 198 (166 – 230)b 235 (192 – 278)b 
aPTT (seconds) 48 (42 – 54) 56 (43 – 69) 
INR 1.81 (1.58–2.04)a 1.24 (1.15 – 1.33) 
Platelets (x 103/mm3) 72 (56 – 88)a 187 (154 – 220) 
Liver failure 6 1 
Ongoing blood loss 4 0 
Coagulopathy 2 1 
Survival 5 (42%) 8 (57%)  
 
NB: Numerical values indicate means with 95% confidence intervals in brackets; 
a significant difference from controls at a p<0.0001; b different from baseline value at a p<0.01.  
APACHE II: Acute Physiology and Chronic Health Evaluation II critical illness severity score;  
SAPS II: Simplified Acute Physiology Score II; CVVH: Continuous venovenous  







































Cumulative circuit survival plot of non-anticoagulated circuits (triangles) and control 















Chapter 5.2  
A prospective study of thromboelastography (TEG) and filter life during continuous 
veno-venous haemofiltration (CVVH) 
 
Introduction 
 Anticoagulation is commonly used in continuous renal replacement therapies 
(CRRT) to maintain circuit patency and function.311,357 The adequacy of such anticoagulation 
is typically monitored by means of routine measurements of blood coagulability (INR, aPTT, 
activated clotting time or ACT and platelet count).311 Despite this clinical approach, there is 
little evidence of a correlation between the intensity of conventional heparin-based 
anticoagulation and circuit life. Also, there is no evidence of a correlation between the 
values of routinely monitored tests of coagulability and filter life.  
 
Thromboelastography (TEG) is a global measure of clot formation.363 While standard 
clotting indices such as ACT, aPTT, INR and platelet count measure discrete components of 
the haemostatic system, TEG provides data on the dynamic interplay of these factors.363-364 
Its major clinical applications have been in the monitoring of coagulation during liver 
transplantation 364 and cardiac surgery/cardiopulmonary bypass (CPB).365-367 Such 
usefulness during CPB suggests that TEG may be useful in predicting the duration of 
function and adequacy of anticoagulation in other extracorporeal circuits such as  CRRT. 
TEG-derived variables, therefore, may correlate with circuit life and prove clinically useful in 
predicting which filters are likely to clot prematurely. Accordingly, we conducted a 
prospective pilot study of the correlation between TEG-derived variables, routinely 





Materials and Methods 
We studied twenty-one filters in six critically ill patients receiving CRRT. In all patients, 
CRRT was provided in the form of continuous veno-venous haemofiltration (CVVH). The 
BMM10-1 blood monitor (Gambro, Lund, Sweden) was used to maintain blood flow at 200 
ml/min through the filter using an AN69 haemofilter (Hospal, Lyon, France) and pump-
controlled ultrafiltration (UF) at 33 ml/min. Fluid replacement was delivered in the pre-
dilution mode. CVVH was otherwise performed in accordance with a previously described 
protocol.329,368 Circuit anticoagulation was achieved using a standardised approach with 
dilute heparin (10,000 U/L saline) with dosage selected according to clinical judgement or by 
means of continuous prostacyclin infusion with dose selection on the basis of clinical 
judgement. 
 
Cessation of filter life was defined as the inability to further operate the circuit due to 
the presence of clot in the filter or in the air-trap or elsewhere in the circuit. 
 
The apparatus for performing TEG is made of two mechanical parts: a heated (37 ° 
C) cuvette, which is oscillated and a pin suspended freely from a torsion wire. Freshly drawn 
blood (0.35 ml) is placed in the cuvette. While the sample remains in the liquid phase, the 
motion of the cuvette does not affect the pin. Once the clot starts to form however, the fibrin 
strands “couple” the motion of the cuvette to that of the pin, thus transmitting the shear 
modulus and elasticity of the clot through the pin. Such shear effect is then amplified to yield 
the TEG trace.  This trace is simultaneously recorded on heat sensitive paper (moving at a 
rate of 2 mm/min). Various TEG parameters (r, K, ANG, MA, Clot lysis at 30 minutes and 60 
minutes were measured and studied. TEG blood sampling was performed randomly on 20 





The following TEG variables were used for the purpose of the study:  
r ( reaction time ) : This is the time elapsed from the point when the sample is placed in 
the cuvette until TEG tracing amplitude reaches 2 mm. It represents 
the rate of initial fibrin formation, which is dependent on plasma 
clotting factors and circulating inhibitor activity. Prolongation of the r 
time suggests coagulation factor deficiencies, anticoagulation or 
severe hypofibrinogenaemia. In contrast, a small r value may 
represent a hypercoagulable state. The normal range is 6 to 8 
minutes (15 to 30 mm). 
K (clot formation  This variable is measured from r time to when the TEG 
time)  : amplitude tracing reaches 20 mm. It is the time for a fixed 
degree of viscoelasticity to be achieved by the forming clot resulting 
from fibrin build up and cross-linkage. This is affected by the activity 
of clotting factors, platelets and fibrinogen. The normal range is 3 to 6 
minutes (6 to 12 mm).  
Alpha angle (ANG) : This is the angle formed by the slope of the TEG tracing from 
the r to the K value. It denotes the speed of clot formation. Decreased 
values may indicate hypofibrinogenaemia or thrombocytopaenia. The 
normal range is 50 to 60°.  
MA (maximum  This is the greatest amplitude on the TEG trace and is a 
Amplitude   :  reflection of the absolute strength of the fibrin clot. It is a direct 
function of the maximum dynamic properties of fibrin and platelets. 
Both quantitative and qualitative platelet defects affect the value of the 
MA. The normal range is 50 to 60 mm.
  
A60  : This is the amplitude of the TEG tracing 60 minutes after MA is 
achieved. It measures clot lysis or retraction. The normal range is MA-
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5 mm.  CLI (Clot Lysis Index): It is derived from theformula [A60/MA x 
100]%.  It is a measure of the amplitude as a function of time and 
reflects loss of clot integrity through lysis.  The normal range is > 
85%. 
Clot Lys 30 and 60: This is a measure of clot breakdown at 30 and 60 minutes. This 
variable is also a measurement of thrombolytic activity. 
Routine tests of coagulability were also performed including (INR, 
aPTT and platelet count).  The duration of filter life was recorded. 
 
Statistical Analysis 
Summary descriptive statistics of all measured variables were derived and analysis 
was performed with a proprietary statistical software package StatViewTM (Abacus Concepts 
Inc, Berkeley, CA). Correlations were tested for using Spearman’s correlation test due to the 
non-parametric nature of data. A p value < 0.05 was considered statistically significant. 
 
Results 
 A total of 21 circuits were studied in six consecutive critically ill patients. The 
distribution of circuit life in these patients is presented in Figure 39. The degree of 
anticoagulation applied to maintain filter patency was variable and dictated by clinical 
concerns regarding the risk of bleeding.  The type and dose of anticoagulants used is 
summarised in Table 25.  Mean haemofilter lifespan was 20.7 ± 4.0 hours. The mean aPTT 
was 67.7 ± 12.8 seconds achieved with a mean heparin dose of 472.5 ± 96.2 U / h. 
However the aPTT value had no correlation with filter life (p=0.463).  The mean INR was 1.4 
± 0.1 and also had no correlation with circuit life. Patients were anemic with a mean 
hemoglobin of 96 ± 3 g /L and relatively thrombocytopaenic, with a mean platelet count of 
118 ± 15.8 x 103/mm3.  In fact, of the 21 circuits studied, 11 were used in patients with a 
platelet count <100 000/mm3. The platelet count, however, did not correlate with circuit life 
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(p=0.249). On the other hand, when circuits with a clinically acceptable life span (arbitrarily 
taken to be equal to or more than 15 hours were compared to those that failed prematurely, 
there was a difference in platelet counts with the count being lower for filters with an 
acceptable life span (p=0.046) 
 
None of the TEG derived parameters (TEG index, r, K, r+K, MA, alpha angle and clot 
lysis) were significantly correlated with circuit life. On the other hand, the dose of heparin 
was significantly correlated with several of the TEG parameters (alpha angle: p=0.013, K: 
p=0.06, r: 0.03, MA: 0.002) (Table 26) as a reflection of its anticoagulant activity and the 




 Anticoagulation during CVVH can be achieved through the use of heparins, 
heparinoids, prostacyclin, citrate and nafamostat mesilate.304-305 In the clinical environment, 
the adequacy of such anticoagulation is usually monitored by means of routinely available 
tests of blood coagulability. Such tests typically include aPTT, INR and platelet count. 
Clinical experience, however, has shown that these tests are poor predictors of circuit 
life.308,314 In particular, there has never been a demonstration that their prolongation results 
in an increased duration of circuit function. Furthermore, when heparin is used, little data 
support a correlation between the dose of heparin and the duration of circuit function. The 
lack of correlation between routinely performed tests of blood coagulability and circuit life 
has a number of potential explanations. One of them is that these tests are inaccurate 
descriptors of in vivo coagulability. If this explanation accounted for their inability to predict 
circuit life, a test or tests that more closely approximated in vivo coagulation may prove 
superior in predicting and correlating with the duration of circuit function during CRRT. One 
such test is Thromboelastography (TEG). It has the theoretical advantage of being a global 
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and dynamic measure of clot formation.369 In fact, while standard clotting indices such as 
ACT, aPTT, INR and platelet count measure single aspects of the clotting cascade, TEG 
provides data on the way different components of the cascade interact to produce clot 
formation and subsequent clot lysis.370 Furthermore, TEG has proven useful in other fields 
of medicine involving extracorporeal circulations such as cardiopulmonary bypass (CPB).371 
Such application during CPB suggests that TEG may also be useful in assessing adequacy 
of anticoagulation during CRRT. TEG-derived variables, therefore, may correlate with circuit 
life and prove clinically useful in predicting which filters are likely to clot prematurely. Such 
information would then allow early intervention to prevent unexpected circuit clotting and 
loss of patient blood due to inability to return it electively. To test whether TEG would 
provide a clinically relevant advantage over other routinely performed coagulation tests, we 
conducted a prospective pilot study of the correlation between TEG-derived variables, 
routinely measured coagulation tests and filter life in a cohort of critically ill patients requiring 
CRRT. 
 
We studied twenty-one filters in six critically ill patients receiving CRRT. In all 
patients, CRRT was provided in a standard way in the form of continuous veno-venous 
haemofiltration (CVVH). Circuit anticoagulation was achieved using a standardised 
approach and cessation of circuit life was also defined in a standard way so that 
confounding variables would not affect our findings.  Blood was randomly sampled from the 
21 circuits during steady state anticoagulation to determine the standard indices as well as 
the TEG parameters.  This form of sampling sought to ensure that findings would be 
representative of the level of anticoagulation for a given circuit.  Despite these precautions, 
commonly used coagulation tests aPTT, platelet count and INR as well as TEG-derived 
parameters (TEG Index, r, k, MA, ANG and clot lysis at 30 and 60 minutes) could not be 
correlated with circuit life.  The only significant finding was obtained comparing platelet 
counts for circuits with an arbitrarily defined clinically acceptable lifespan (>15 hours) to 
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circuits with a shorter (<15 hours) during of function.  The filters with a longer duration of 
function were operated during periods of significantly lower platelet counts. 
 
Therefore TEG, like other routine tests of anticoagulation adequacy failed to provide 
useful information regarding filter life. Only the presence of a low platelet count (<100 x 
103/mm3) may be seen as a weak marker of greater filter longevity. Our findings are in 
keeping with existing literature.306 They highlight the very limited usefulness of monitoring of 
routine coagulation tests as a measure of adequacy of anticoagulation for the prevention of 
filter clotting. They also support the view that TEG provides no additional clinically useful 
information. The findings of our study, in conjunction with previous literature, support the 
view that monitoring of anticoagulation adequacy by either aPTT, INR or TEG can not 
provide the clinician with an accurate measure of the adequacy of circuit anticoagulation and 
is, therefore, not indicated for such purposes.  Such monitoring, however, may be useful to 
ensure the safety of a given anticoagulation regimen. 
 
There are several possible explanations for this failure of anticoagulation monitoring 
to provide clinically useful information regarding expected CRRT circuit life. One possible 
explanation is that such tests are all inaccurate representations of the complex 
extracorporeal circuit-haemostatic pathways interaction.306 Another explanation may derive 
from the fact that the above tests only partly assess the fibrinolytic system.310 It is likely that 
this system is operative at variable levels in these critically ill patients and that its activation 
or dysfunction participate in the pathogenesis of circuit failure.310 Platelet counts provide no 
information on platelet function. In critically ill patients there are variable levels of platelet 
activation or dysfunction, which may also affect filter life. Other proteins involved in the 
regulation of coagulation such as activated protein C are also deficient in critical illness 310 
making the laboratory assessment of in vivo coagulability even more difficult. Furthermore, 
many patients with multi-organ failure have deficiencies of antithrombin III, the co-factor for 
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heparin.372 In these patients, therefore, the dose of heparin is unlikely to provide a guide to 
the likelihood of filter clotting. 
 
Another explanation may be due to the fact that circuit lifespan is dependent on more 
than just the interplay of the membrane and tubing with the coagulation and fibrinolytic 
systems. Hydraulic, rheological and other physicochemical factors 315 within the haemofilter 
fibres could be equally important. Also vascular access dysfunction with fluctuations in the 
actual blood flow delivered to the filter,162 inducing stasis within the circuit or filter may be 
extremely important in the pathogenesis of circuit clotting.  Such mechanical factors may 
overwhelm even the most effective circuit anticoagulation. The interface between air and 
blood in the venous bubble trap of the circuit may be extremely thrombogenic and also 
overcome the effect of heparin on the coagulation cascade. Close to 20% of our circuits fail 
because of clot in the venous chamber. 
 
This pilot study has several limitations. Firstly, the sample size was small. However, 
consecutive filters were studied giving us the opportunity to detect even a moderate 
correlation between the tests perfomed and circuit life. Secondly, there was no control group 
to demonstrate whether, in the absence of any monitoring of coagulation, circuit life would 
be affected. Thirdly, more sophisticated tests of coagulation or fibrinolysis were not 
performed to study the link between in vitro and in vivo clotting. However, the goal of our 
investigation was to establish whether routine tests or TEG had any predictive ability or 
clinical usefulness in the monitoring of adequacy of anticoagulation during CRRT. Finally, 
we could not make any statements about the usefulness of monitoring of coagulation tests 
in predicting the risk of bleeding because of the small sample of patients and because this 




 In conclusion, this study showed that standard coagulation indices do not correlate 
with circuit lifespan. Heparin dose per se also does not correlate with circuit life. The 
additional use of TEG confers no advantage to the clinician seeking to monitor the 
adequacy of anticoagulation during CRRT. Filter clotting remains an unpredictable event 
and the adequacy of prophylactic anticoagulation cannot be established by readily available 
tests of coagulation. Accordingly, measurement of aPTT, INR and TEG derived variables, 
although potentially useful in determining the safety of a given regimen of anticoagulation, 
does not appear useful in determining its efficacy as antithrombotic prophylaxis during 



























Values of standard anticoagulation parameters, type and dose of  
anticoagulants 
 
Patient/Circuit INR    aPTT Platelet Haematocrit  Heparin 
   (seconds) (x103/mm3)       ( % )  (IU/h) 
 
1 1.3    83     76  27  700 
2 1.1    45   226  29  700 
3 1.3    60     86  27  700 
4 1.3    66   160  26  700 
5 1.2    76     60  28  700 
6 1.1    68   107  28  700 
7 1    46   230  23  600 
8 1.3    38     40  28  nil 
9 2.2    58     48  31  nil 
10 39  204     27  nil  nil 
11 1.7    58   141  26  nil 
12 1.4    40     48  29  250 
13 2.2  105     71  28     Prostacyclin 
14 2    58     64  29     Prostacyclin 
15 1.1    35     47  27  700 
16 1    44     53  30  1500 
17 1.1    43     92  27  800 
18 1.2    47   130  32  800 
19 1.1    44   106  29  1000 
20 1.1    76   277  31  300  

















Correlation between heparin dose and TEG or coagulation variables 
 
Correlation      p value 
___________________________________________________________________ 
 
Heparin dose & Circuit Life    0.02 
Clot Lysis Time @ 30 min & Circuit Life  0.05 
Clot Lysis Time @ 30 min & Heparin Dose  0.001 ± inverse 
Clot Lysis Time @ 30 min & aPTT   0.35 
Clot Lysis Time @ 60 min & INR   0.019 
Clot Lysis Time @ 60 min & Platelet Count  0.016 ± inverse 
Clot Lysis Time @ 60 min & Heparin Dose  0.022 ± inverse 
ANG & Heparin Dose     0.013 
K & Heparin Dose     0.006 
R & Heparin Dose     0.03 
MA & Platelet Count     0.002 
















































Clinical Impact of CRRT 
 While it is important to understand the mechanical basis underpinning the function of 
CRRT as well as its biochemical and physiological effects, the ultimate test of therapeutic 
usefulness of any drug, device or procedure lies in its clinical end-points. In the case of 
CRRT, renal recovery and patient survival are specific examples of such outcome 
measures. Overall, the three pertinent questions are: (1) ARRT modality choice: intermittent 
or continuous, (2) Timing of initiation: to start early or late and on the basis of what 
parameter, and (3) Intensity and adequacy of renal replacement therapy: in terms of actual 
delivered dialytic dose. The controversies surrounding the choice of ARRT modality has 
been discussed in Chapter 1.3. Chapter 6.1 describes the outcome in a group of 
cardiosurgical patients with CVVH-treated ARF. The hypothesis is that earlier initiation of 
CVVH as well as adequate blood de-uraemisation achieved with CVVH is associated with a 
better actual patient outcome compared to predicted outcome based on critical illness 
severity scoring/predictive models. This chapter restores the focus of this thesis back to the 
critically ill ARF patient with emphasis on when and how CRRT should be used in such 




















Severe acute renal failure (ARF) (defined as renal failure requiring renal replacement 
therapy) is a major complication of cardiac surgery and is associated with a very high 
mortality (60% to 100%) when treated with standard intermittent haemodialysis.327-328  More 
recently, continuous renal replacement techniques have been introduced, which circumvent 
the haemodynamic instability associated with intermittent haemodialysis and its limited 
ability to control the patient’s volume state.275 One  such form of continuous renal 
replacement therapy is continuous venovenous haemofiltration (CVVH).329 The early and 
intensive application of this therapy has the potential to substantially facilitate the care of 
patients with severe ARF after cardiac operation.330 
 
 However, its application has been called into question because of the perception that 
CVVH is costly, resource intensive, and ultimately still unable to improve the short-term 
outcome of these patients.331 In addition, there is a need to predict which patients will benefit 
from such intensive therapy to use it more rationally.332-333 Thus, outcome prediction, choice 
and effect of renal replacement therapy after cardiac operation remain poorly defined and 
yet these remain important issues in the post-operative management of patients undergoing 
cardiac operations.  
 
 Accordingly, we conducted this study to address two questions: (1) whether the early 
and intensive use of CVVH resulted in a better than predicted outcome, and (2) whether a 
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simple and yet accurate model could be developed to predict the outcome of these patients 
before renal replacement therapy was applied. 
Material and Methods 
 
 Patients treated with CVVH for severe ARF after cardiac operation were identified 
using a prospectively collected intensive care unit database.  The medical records of these 
patients were obtained and data were retrospectively recorded with focus on demographic 
features, surgical characteristics, haemodynamic and clinical features at the time of initiation 
of CVVH, duration of intensive care unit (ICU) stay, survival to ICU discharge, and survival 
to hospital discharge.  Such information was collected to achieve the following goals: 
(1) perform meaningful comparisons with recent series of similar patients;  
(2) calculate a predicted risk of death using a recently validated formula; 332 
(3) Develop a simple and yet reasonably accurate outcome prediction model specific to 
these patients. 
 
The technique of CVVH consists of a double lumen catheter that is used to pump 
blood through a module (AK 10, Gambro, Lund, Sweden) containing pressure alarms and 
an air bubble trap. The blood flow rate is kept at 200 to 250 ml/min. Ultrafiltration is pump 
controlled at 2 L/h.  Replacement fluid is administered prefilter at a dynamically adjusted 
rate chosen to achieve the desired fluid therapy goals for any time period.  Polyacrylonitrile 
filters (AN69, Hospal, Lyon, France) are used in all patients.  Anticoagulation of the circuit is 
carried out according to clinical judgement and circuit duration.  In this study, some patients 
received no anticoagulation, others received only low-dose (300 to 500 IU/h) prefilter 
heparin therapy, and others received either full heparinisation or regional heparinisation 




 Univariate analysis, using hospital mortality as the outcome, was used to determine 
significant prognostic variables.  The Student’s paired t test was used for continuous 
variables, and the x2 test for categorical variables.  Variables were considered significant if 
the p value was less than 0.05. 
 
 Two predictive models were then developed.  The first model was obtained using 
multivariate linear regression analysis (Microsoft Excel 97 SR-1; Microsoft, Seattle, WA), 
whereas the second used a back propagation, feed-forward neural network (Neurosolutions 
1998; Neuro Dimension, Gainesville, FL).  Both models were developed using the whole 
data set of 65 patients, and then tested on the same 65 patients.  In addition, the data set 
was randomly divided into two sets: one set of 35 patients (a training set) and a second set 
of 30 patients (a test set), to develop a second set of models that could be tested on a new 
set of patients. 
 
 Variables were eliminated in a stepwise manner from the regression model if they 
did not increase performance (measured by the R2 value and receiver operating 
characteristic [ROC] value). 
 
 The four remaining variables left the simplest model that did not significantly affect 
performance (ie, difference in R2. Value was <0.02 and ROC <0.01 when compared with a 
model that incorporated all variables).  For the basis of comparison, the neural network was 
developed using the same four variables as the statistical model.  Continuous variables 
were converted to binary variables by graphing and arbitrary selection of the best cut-off 
point.  This was performed for the purpose of simplicity of the model. 
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 The four final variables were hypotension, repeat operation, base deficit (<-2) and 
Glasgow coma score (<11). Discrimination of the two models, and the Liano score, was 
tested using the ROC curve method, using the Wilcoxon statistic to generate standard 




 Cardiac operation was performed on 3,154 patients during the 5-year period.  Sixty-
five patients (2.1%) developed severe ARF.  Their demographic and clinical characteristics 
are presented in Table 27. 
 
 The mean time between operation and the initiation of CVVH was 2.38 days (95% 
confidence interval [CI] 1.62 to 3.15) with a mean duration of CVVH of 3.98 days (95% CI 
3.00 to 4.97).  With ultrafiltrate flow at 2 L/h, the mean peak urea level was kept at 25.8 
mmol/L (95% CI 23.8 to 27.7) and the mean peak creatinine at 333 umol/L (95% CI 305 to 
362).  Mean duration of ICU stay was 9.6 days (95% CI 7.5 to 11.7) and mean duration of 
hospital stay was 24.5 days (95% CI 18.2 to 30.8). 
 
 Using Liano’s predictive model, the mean predicted risk of death for this group of 
patients was 66% (95% CI 60% to 72%).  However, the ICU mortality was 36.9% and the 
actual in-hospital mortality was 40% CI 28% to 52%).  This difference was significant 
(p=0.003).  The standardised mortality ratio (actual/predicted mortality) was 0.61 (95% CI 
0.38 to 0.84). 
 
 Using readily available clinical and biochemical variables univariate analysis was 
performed to identify which factors were most clearly associated with poor outcome  
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(Table 28).  Subsequent multivariate regression analysis allowed for the development of a 
simple predictive equation to calculate the risk of death (ROD) in a given patient: ROD= 
0.072 + (0.711 x Hypotension) + (0.169 X Repeat Surgery) + (0.187 X Glasgow coma score 
< 11) + (0.026 X Base Excess Score < -2). 
 
This model compared favourably with Liano’s equation in its ability to predict 
outcome with a ROC of 0.89 to 0.92 depending on the development and testing approach.  
However, the neural network-based approach, appeared to more closely approximate the 
ideal predictive model with an ROC of 0.90 to 0.98 depending on the development and 




Caridac surgery is routinely performed in many tertiary institutions.  Despite major 
advances in surgical techniques, anaesthesia and cardiopulmonary bypass, serious 
complications can still develop.334 Among these complications, ARF is one of the most 
serious.  The incidence of post-bypass ARF varies from study to study depending on its 
definition.335-337 However, in all studies, ARF is associated with an increased mortality.335-337 
 
In fact, patients with mild to moderate ARF are usually responsive to medical therapy 
and eventually remit spontaneously. Those with severe ARF (ARF requiring renal 
replacement therapy), however, are different. They usually continue to deteriorate, require 
ICU care, and need acute artificial renal support.337 Many of these patients have multiorgan 
failure, require mechanical ventilation, intraaortic balloon counterpulsation, the continuous 
administration of inotropic/vasopressor drugs, and, at times, the use of extracorporeal life 
support.  In these patients, even in this decade, mortality has remained high (>60%) despite 
the aggressive use of intermittent haemodialysis.337 
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There are several potential explanations for such a high mortality.  Case mix has 
changed over time to include older and sicker patients.334 Irreversible postoperative 
cardiogenic shock may develop, and dialysis is more aggressively applied. All of the above 
explanations may account for the persistently high mortality rate associated with severe ARF 
after cardiac operations.  However, in our opinion, an additional explanation may lie in the 
choice, timing, and intensity of renal support. 
 
Early case series from large North American academic centres in the 1970s used 
intermittent haemodialysis and reported 100% mortality.334 Although a recent report shows a 
mortality of 63% 337 using standard haemodialysis, fluid control and the removal of uraemic 
toxins may be suboptimal in critically ill patients when this technique is used 278 and 
bioincompatible membranes may aggravate inflammation.338 Furthermore, intermittent 
haemodialysis causes serious haemodynamic instability.338 Because of the limitations of 
intermittent haemodialysis in haemodynamically compromised patients, continuous renal 
replacement therapies have been developed.278 
 
Continuous renal replacement techniques offer continuous and steady fluid removal 
and uraemic toxin clearance.  Their intensity can be easily titrated to prevent or rapidly treat 
volume overload.  Continuous removal of waste products also ensures the minimisation of 
the adverse immunological and pro-inflammatory effects of uraemia.  Myocardial depressant 
factors may be removed, 339 myocardial performance improve, 332 and nutrition optimised.119 
 
Given the physiologic advantages of continuous renal replacement techniques, it 
may appear surprising that several clinical studies have so far failed to demonstrate 
evidence of a survival advantage.340-342 There are, in our opinion, some potential 
explanations for such failure.  First, CVVH has often been applied too late in the 
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postoperative course, 340 leading to prolonged and poorly controlled uraemia, restricted 
nutrition, and volume overload.  Second, CVVH has often been of limited intensity leading to 
inferior uraemic control with its attendant sequelae.206, 343  
 
In the light of the above considerations, we hypothesised that earlier and more 
intensive CVVH would lead to a better than predicted outcome.  To test this hypothesis we 
analysed the results of such a policy in our cardiothoracic ICU during the past 5 years.  The 
outcomes achieved are consistent with our hypothesis. 
 
It is possible that we achieved encouraging results simply because our patients were 
only moderately ill. Our findings, however, suggest the opposite with many requiring 
intraaortic balloon pump, prolonged mechanical ventilation, and the administration of 
inotropic or vasopressor durgs.  Yet, in-hospital mortality was only 40%, the lowest reported 
in the literature so far.  For example, Alarabi and colleagues 344 reported an overall mortality 
of 52.3% in patients with severe ARF after cardiac operation treated with continuous 
arteriovenous haemodialysis and continuous haemofiltration.  Their patients appeared 
similar to our group in illness severity and age, but the intensity of treatment was much less.  
A French study by Levy and associates,342 of 16 patients who had undergone operation with 
cardiopulmonary bypass, reported a mortality rate of 87.5% despite the use of CVVH.  
These investigators treated patients similar to ours in illness severity; however, they only 
achieved ultrafiltration rates of 0.5 to 1 L/h, half of that applied to our patients.  No 
information on the timing of treatment is provided. 
 
Baudouin and colleagues 340 reported a more than 80% mortality in similar patients.  
In this series, however, CVVH was initiated much later (> 8 days postoperatively) and delay 
in initiating CVVH identified patients more likely to die.  Furthermore, the ultrafiltration rate 
was also approximately 50% of that achieved in our patients.  Finally, Tsang and colleagues 
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331 recently reported 48 cardiac patients treated with either continuous arteriovenous 
haemodialysis/haemofiltration or CVVH.  Their patients were younger than our group and 
appeared to have a similar degree of illness severity.  However, once again, the intensity of 
filtration was approximately 50% of that used in our patients.  The duration of ICU stay was 
longer than in our cohort and in-hospital mortality was 52%. No information was available on 
the timing of intervention. 
 
To further test our hypothesis, we compared the outcome of our patients to that 
predicted using a previously validated, ARF-specific predictive model.332 The results suggest 
a reduction in mortality from 66% to 40%.  The predictive model might not operate 
accurately in this very specific group of patients and only a randomised controlled trial could 
address this question with full scientific methodology.  However, this model performed well 
in our patients (discussed later) and the difference is striking and highly significant.  The 
difficulties associated with conducting a randomised controlled trial of sufficient power and 
quality have been previously highlighted.345 
 
The second aim of our study was to develop a specific predictive model that could be 
applied before haemofiltration to decide whether its use was warranted.  We found that the 
following risk factors were important predictors of outcome: sustained hypotension, use of 
intraaortic balloon pump for haemodynamic support, neurologic dysfunction, metabolic 
acidosis, reoperation and the need for prolonged mechanical ventilation.  Multivariate logistic 
regression analysis further narrowed the significant prognostic variables to hypotension, 
second cardiac operation (re-operation), the presence of a base deficit and neurological 
dysfunction as reflected by the Glasgow coma scale at the time of starting CVVH. 
 
Increasing the ability to predict patient outcome can assist clinicians to select 
patients most likely to benefit from CVVH.  Several attempts have been made to develop, 
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ARF-specific prognostic tools.  Among such scores, Liano’s is the one best sustained by 
statistical evidence.  It was derived from a community-based ARF database.  Thus, it may 
not strictly apply to the critically ill patient who has undergone a cardiac operation.  We, 
therefore, used readily available clinical data to develop a predictive scoring system for this 
selected group of patients and compared its performance to that Liano’s equation.  Although 
Liano’s score yielded a ROC value of 0.86, the ROC values in our regression models 
ranged from 0.89 to 0.92, depending on the developmental approach.  In addition, a neural 
network analysis model was associated with a higher ROC value ranging from 0.9 to 0.98.  
Clearly it is possible to predict outcome with reasonable accuracy either using our predictive 
equation or neural network software.  We believe such information can assist clinicians in 
making difficult therapeutic decisions and allocating resources wisely. 
 
In conclusion, we report the largest series of patients with severe ARF after cardiac 
operation treated with CVVH.  Early and intensive application of CVVH was associated with 
a better than predicted outcome, which is the best reported so far in the literature.  These 
results are encouraging and support our approach.  Furthermore, we have developed a 
simple predictive equation to estimate mortality before the start of CVVH.  We have also 
shown that, using neural network software, an accurate prognosis can be achieved.  We 











Clinical and Demographic Characteristics of Patients 
 
Demographics   Mean ± SD (Median, Range) 
___________________________________________________________________ 
Age    70.5 ± 6.8 (71.6, 48.8 – 84.7)    
Gender    75.4% Male 
Tu score   5.6 ± 2.9 (5.0, 1.0 – 13.0) 
Liano score   0.66 ± 0.24 (0.61, 0.29 – 1.14) 
ICU stay   9.6 ± 8.8 (6, 1 – 40) 
Hospital stay   24.5 ± 25.6 (16, 2 – 155) 
Hospital mortality   40.0%a 
SMR (Liano)      0.61%b 
 
Type of Surgery 
CAGS     56.9% 
Single valve    16.9% 
Complex    26.2% 
Emergency    20.0% 
Elective    70.8% 
Urgent       9.2% 
 
Clinical and Biochemical 
Oliguria    78.5% 
Mechanical ventilation  58.5%  
Duration vent (days)  4.9 ± 6.2 (3, 0 – 30) 
Hypotentension   40.0% 
IABP     32.3% 
CRF     44.6% 
Peak urea (mmol/L)  25.8 ± 8.0 (26.0, 9.6 – 52) 
Creatinine (mmol/L)  0.333 ± 0.118 (0.333, 0.141 – 0.758) 
Base deficit   -4.5 ± 6.0 (-4.3, -22.6 – 6.5) 
Cardiac index   3.0 ± 0.8 (3.0, 1.4 – 5.0) 
a
 95% CI, 28.0 – 52.0  b 95% CI, 28.0 – 52.0 
CAGS = coronary artery graft surgery 
IABP   = intra-aortic balloon pulsation 
SMR   = standardized mortality ratio 
CRF   = chronic renal failure 




Variables Associated With Increased Mortality Using Univariate Analysis 
 
 
Variable   Died  Survived p Value 
 
Age    72.4  69.2  0.057 
Sex (male)   73.1%  76.9%  0.724   
Tu score     6.7    4.9  0.016 
Liano score     0.84    0.53  <0.0001 
CRF   38.5%  48.7%  0.415 
Hypotension   80.8%  12.8%  <0.0001 
Bilirubin   36.5  26.5  0.204 
Creatinine            329            336  0.825  
GCS   10.7  13.8  0.003 
Base deficit     8.2    2.0  <0.0001 
IABP    61.5%  12.8%  <0.0001 
Cardiac index      2.8    3.1  0.098 
Nephrotoxic     3.8%    7.7%  0.53 
Mechanical ventilation 88.5%  38.5%  <0.0001 
Mech. Vent, time    5.3    4.5  0.607 
CWH duration     2.6    4.9  0.018 
Peak urea   24.6  26.6  0.380 
ICU stay     5.7  12.2  0.002 
Hospital stay     8.8  34.9  <0.001 
Surgery to CWH time    1.7    2.8  0.11 
Oliguria   80.8%  76.9%  0.712 
Repeat surgery  19.2%    7.7  0.165 
Complex surgery  34.6%  20.5%  0.205 
Emergency surgery  34.6%  10.3%  0.016 
Sepsis   19.2%  10.3%  0.305 
 
CRF = chronic renal failure;  CVVI = continuous veno-venous hemofiltration; 
GCS = Glasgow coma score;  IAPB = intraaortic balloon pulsation; 





Comparison of the Performance of Different Predictive Models 
 
 
   Evaluated on all 65 Patients 
Model      ROC Value (95% CI) 
Liano      0.86 (0.77 – 0.96) 
Regression     0.92 (0.85 – 0.99) 
Neural network    0.98 (0.93 – 1) 
   Evaluated on the 30 Patient ‘Test Set’ 
Model      ROC Value (95% CI) 
Liano      0.74 (0.51 – 0.97) 
Regressiona     0.89 (0.78 – 1)    
Neural networka     0.90 (0.73 – 1) 
a Developed on a separate 35 patient ‘training set’ 







Visual comparison of the receiver operating characteristic (ROC) achieved with  
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